Covista Stock

Greetings, and welcome to the Covista Fiscal First Quarter 2027 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce Jeremy Cohen, Vice President of Investor Relations.

Good afternoon, and welcome to Covista's earnings call for the first quarter of fiscal year 2027. On the call with me today are Steve Beard, Chairman and Chief Executive Officer of Covista; and Bob Phelan, Chief Financial Officer.

Before I hand you over to Steve, I will take you through the legal safe harbor and cautionary declarations.

Certain statements and projections of future results made in this presentation constitute forward-looking statements that are based on our current market, competitive and regulatory expectations and are subject to risks and uncertainties that could cause actual results to vary materially. We undertake no obligation to update publicly any forward-looking statement after this presentation, whether because of new information, future events, changes in assumptions or otherwise. Please see our latest Form 10-K for a discussion of risk factors as they relate to forward-looking statements.

In today's presentation, we will use certain non-GAAP financial measures, and we refer you to the appendix in the presentation materials available on our Investor Relations website for reconciliations to the most directly comparable GAAP financial measures and related information.

You will find a link to the webcast on our Investor Relations website at investors.covista.com. After this call, the presentation and webcast will be archived on the website for 30 days. I will now hand you over to Steve.

Thanks, Jeremy. Good afternoon, everyone, and thank you for joining us. Four weeks ago, in my letter to shareholders, I said we'd explain our economics plainly, so I'll start there. We're running ahead of the fiscal 2027 guidance we set, and that bodes well for our Purpose at Scale growth strategy. Today, we serve nearly 105,000 students, up 7.6% from a year ago and our 13th consecutive quarter of total enrollment growth. In the first quarter, revenue grew 10.7% to $512 million. Adjusted EBITDA grew 17.1% to $131 million and adjusted earnings per share grew 25.1% to $2.19 per share.

Our role for capital is simple. $1 stays in the business only if it earns more there than it would in your hands. This quarter, we repurchased $84 million of stock and funded new campuses, programs and technology from operating cash. That performance ran ahead of our plan, and we're raising our fiscal 2027 guidance for both revenue and adjusted earnings per share. We're taking a prudent view of the remaining quarters, and we'll update you as the year progresses.

The demand backdrop underpinning Purpose at Scale is durable. We see no reduction in demand for health care workers, from employers or from the talent who wants to choose these purposeful careers. Recent analysis shows that health care accounted for about 3 out of every 4 U.S. jobs created over the past year. That dynamic is highly encouraging for our business model, but what deserves more attention is the human toll of health care jobs going unfilled.

Recently, we published the Covista Healthcare Workforce Index. The analysis projects that without action, the health care workforce shortage is on track to nearly double by 2040. Yet the data also shows that investment in attracting, developing and retaining talent could close over half of that gap by 2040. In our view, talent isn't scarce. American nursing schools turned away roughly 93,000 qualified applications last year, and about 30,000 more applicants were turned away from U.S. medical schools. They weren't turned away for a lack of ability, but for a lack of faculty, clinical site availability and lack of space from caps written into state and accreditor policy. The binding constraint here is capacity, not interest.

Through Purpose at Scale, we're attracting and developing more future clinicians and partnering with leading health systems to keep them. Three things make this franchise durable. About 90% of our students study health care where the demand is driven by licensure and patient need. The constraint in our market is capacity, and we fund ours from operating cash at 0.5x net leverage. And a significant portion of our students now arrive through employers who help pay for their education.

Now let me turn to the segments, starting with Chamberlain. Total enrollment grew 1.3%, our third straight quarter of growth, and revenue grew 7.4%. The difference between the 2 is threefold: better mix, more credit hours per student and pricing. Total enrollment growth was led by pre-licensure BSN and application growth remains strong heading into our November session. As you know, no university confers more nursing degrees than Chamberlain, and we're building on that. That means adding seats, partnerships and investing in the support that helps students get from enrollment all the way through to graduation.

Chamberlain is also expanding into new markets with new programs, delivering on its platform extension strategy. The Cincinnati campus opened in August. Salt Lake City started classes this week, and Nashville is expected to open in January. We also opened our second physician assistant program in Phoenix at full capacity with a third location already in the works.

Chamberlain entered fiscal 2027 on an improved foundation. And while its path isn't perfectly linear, we're executing on several growth levers at once, and each of them is gaining traction. We're adding seats, we're deepening our health system partnerships, and we're investing more in student success, all of which puts Chamberlain on a sustainable growth trajectory.

Turning to Walden. We achieved double-digit total enrollment growth for the tenth straight quarter and set another enrollment record. Sustaining that over multiple years takes execution across every part of the portfolio and the team keeps delivering. It also means stronger comparables ahead, which we've already contemplated into our long-range planning. The strength remains broad-based at Walden across all degree levels with doctoral and undergraduate programs leading the way and strong persistence continues to compound that new enrollment growth.

Our new marketing campaign at Walden is "Your Career, Our Job", and it's working. It shows undergraduates that Walden delivers on its promise with support from choosing a career through coaching and personalized tools that map coursework to specific jobs. Undergraduate enrollment, a priority we called out at Investor Day, grew by more than 20% in the first quarter.

Turning to our Medical and Veterinary segment, it had another strong quarter. Total enrollment grew 3.5% with both medical and veterinary contributing. Disciplined operations continue to turn enrollment growth into healthy revenue and profit. As we flagged last quarter, some students used our multiple intake cycles to start a term early ahead of changes to federal loan programs. That shift lifted the May cycle and made the September class a bit smaller. So the right way to read the business is May and September combined. On that blended basis, we delivered very strong results.

Interest in medicine and veterinary medicine remain durable, and we don't expect the loan changes to affect long-term demand. There are more than 2 applicants for every U.S. MD seat, while first year U.S. class sizes have grown less than 2% a year for 2 decades. In that pool of prospective students, U.S. medical schools overlook a group who have proven they can succeed with us. We're leveraging the evolving landscape as an opportunity to enhance our prospective student journey, reducing friction and driving engagement throughout the process. Students are enrolling and performing and our class mix has improved as a result, in line with our core customer strategy.

Let's bring this concept to life. Among students who sat for USMLE Step 1, recent data shows that Ross Med and AUC students passed on their first attempt at rates comparable to or higher than U.S. MD students with similar MCAT scores in most score ranges. On the vet side, we continue to operate near capacity. Leading indicators for the veterinary licensing exam continue to strengthen, underscoring that we're serving our students well and driving student success.

Turning to employer integration. Our collaboration with Advocate Health, the third largest nonprofit integrated health system in the country, started in Wisconsin last month. We'll expand that relationship to all 3 of our Chicagoland campuses. Chicago is one of the largest markets for both Advocate and Chamberlain, and the plan has always been to expand over our overlapping geographies. In addition, our partnership with SSM Health has outperformed, and we've raised enrollment targets with them.

The model we continue to advance makes sense for health systems, for Covista and for our students. Health systems get a differentiated and proprietary pipeline. We get more durable enrollment at a lower cost of acquisition and students get financial support on their way into the profession.

Turning to technology. Our enterprise technology investments continue to advance. The AI-powered classroom has moved beyond the prototype stage and is now in full development and testing, bringing together all of our capabilities along with those of our leading technology partners. We're designing it specifically around the needs of our students and faculty. At our scale, we believe this creates an opportunity to deliver a more personalized learning journey and a differentiated student experience from first inquiry all the way through to licensure.

On the shift to LLM search, as we said, this is a real dynamic for any company that serves consumers. Fortunately, our institutions start from a position of strength. We have strong brands, great student outcomes and prepare students for careers in health care fields where there are real shortages of workers. As a result, our institutions continue to compete strong in visibility, share of voice and sentiment, and our data shows continued improvement in leadership where it matters.

We're building on this foundation by further improving discoverability and positive sentiment of our institutions. We analyze tens of thousands of answers to measure how our institutions appear and how they're described and whether they're recommended all the way down to the program level. From there, we develop new content to ensure that the LLMs have the latest and greatest information about the quality and value of our programs.

So to summarize, Purpose at Scale starts from a position of strength. Over the next 3 years, we'll continuously layer in the 4 priorities we presented at Investor Day that enhance our trajectory and widen our competitive moat. That means operational excellence in everything we do, platform extension through new campuses and programs, employer integration through more and deeper health system partnerships and a technology focus that brings education powered by AI. Just as importantly, we generate the cash to fund these priorities and still return capital to shareholders at the same time.

We are America's largest health care educator, and that scale is a real advantage. But scale isn't the point. What you should leave with from this call is that we're deploying capital to extend our lead and build the company in our sector in a way that compounds intrinsic value per share the longest and most attractively.

I want to thank you all for your continued support. And with that, I'll turn it over to Bob to walk through the financials in more detail.

Thank you, Steve, and hello, everyone. We began our next strategic chapter, Purpose at Scale, with strong results that demonstrate the durability of our operating model. I'll now review our first quarter results and key drivers. Later in my remarks, I'll discuss our updated expectations for fiscal 2027.

Starting with the top line. First quarter revenue increased 10.7% to $511.5 million with strong growth from all 3 segments. Total company enrollment was up 7.6%, with all 3 segments contributing, and that growth carried through to the bottom line. Adjusted EBITDA was $131.2 million, up 17.1% compared with the prior year. Growth was led by Walden and Med & Vet with Chamberlain contributing even as that segment invests in new campuses. Adjusted EBITDA margin of 25.6% expanded 140 basis points from the prior year as revenue growth and efficiencies across our platform generated operating leverage, partially offset by investments in our strategic growth initiatives.

Adjusted net income increased 16.8% to $75.8 million and adjusted earnings per share was $2.19, up 25.1% compared with the prior year. Our earnings per share growth continues to benefit from a lower share count and lower interest expense. Diluted shares outstanding averaged 34.6 million in the quarter, about 2.5 million lower than the prior year, reflecting our share repurchase activity. Interest expense declined to $9.9 million from $11.1 million, reflecting our actions to reduce debt and lower our borrowing costs.

Next, I'll discuss the first quarter financial highlights by segment. Chamberlain reported first quarter revenue of $192.4 million, an increase of 7.4% compared with the prior year, driven by enrollment growth in pre-licensure nursing along with higher credit hours per student and pricing optimization. Total student enrollment increased 1.3% to over 40,000 students. Chamberlain's third consecutive quarter of growth and pre-licensure BSN total enrollment grew for the 17th consecutive quarter. Chamberlain adjusted EBITDA increased 7.1% to $37.6 million and adjusted EBITDA margin of 19.5% was essentially in line with the prior year. Chamberlain's first quarter results include approximately $3 million of costs related to new campuses as we invest ahead of any significant enrollment. Excluding these additional costs, Chamberlain adjusted EBITDA would have increased nearly 16% to $40.6 million.

Turning to Walden. First quarter revenue increased 14.1% to $216.7 million, driven by strong enrollment growth. Total student enrollment grew 12.8% to nearly 59,000 students, the highest total enrollment in university history. Walden has now grown enrollment for 13 consecutive quarters, including 10 straight quarters of double-digit growth. The strength remains broad-based across health care and non-health care programs. Adjusted EBITDA increased 16.1% to $71.9 million, and adjusted EBITDA margin expanded 60 basis points to 33.2% as operating leverage from the enrollment growth more than offset continued investments in marketing.

For the Medical and Veterinary segment, first quarter revenue increased 10% to $102.5 million. Total student enrollment increased 3.5% with growth at both our medical and veterinary schools. Adjusted EBITDA increased 27.9% to $27.4 million, and adjusted EBITDA margin expanded 370 basis points to 26.7%, which reflects the high operating leverage inherent to this segment as we grow enrollments.

Shifting to cash flow and the balance sheet. Free cash flow over the trailing 12 months was $355 million, up 11.4% from the comparable prior year period, reflecting strong operating performance and high cash conversion. That growth came even as capital expenditures over the same period rose to $99 million from $56 million as we invest in new campus capacity and technology. We ended the quarter with $222 million of cash and cash equivalents and net leverage of 0.5x. During the quarter, we repriced our $510 million Term Loan B, reducing the interest rate spread by 25 basis points to SOFR plus 2%.

We also returned $84 million to shareholders through share repurchases in the quarter, buying back approximately 660,000 shares at an average price of $127.63. We have $578 million remaining under our $750 million repurchase authorization. We will continue to take a disciplined returns-focused approach to capital allocation, prioritizing reinvestment in our institutions and being opportunistic about returning excess cash to shareholders.

Turning to our outlook. Based on the strength of our first quarter performance and our expectations for the balance of the year, we are raising both our revenue and adjusted earnings per share guidance for fiscal 2027. The increase reflects first quarter results ahead of our plan. We're taking a prudent view of the remaining 3 quarters. We now expect revenue in the range of $2.06 billion to $2.095 billion or approximately 5.5% to 7% growth year-over-year, up from our prior range of $2.05 billion to $2.09 billion. At the midpoint, that's an increase of $7.5 million. We now expect adjusted earnings per share in the range of $9 to $9.20 or approximately 9% to 11.5% growth year-over-year, up from our prior range of $8.90 to $9.15. At the midpoint, that's an increase of $0.07.

A few assumptions frame the updated guidance. First, we continue to invest in new campuses ahead of enrollment. We will continue to keep you apprised of the expenses before those campuses carry meaningful enrollment. Second, on a quarterly phasing, as a reminder, Walden returns this fiscal year to a normalized academic calendar. That means this year for Walden, we will have 1 less week in the second quarter and 1 additional week in the third quarter compared with fiscal 2026. Last year, that shifted $18 million of revenue and adjusted EBITDA from the third quarter into the second quarter. As a result of that changing back, it will have a pronounced impact for the year-over-year comparison in the second quarter and benefit the third quarter with no net impact on the full year. That means second quarter growth will be well below our full year rate and third quarter growth well above it.

We continue to expect 0 to 50 basis points of adjusted EBITDA margin expansion for the full year, and that includes our continued investment in new campus capacity. That compares with 140 basis points in the first quarter. We continue to expect capital expenditures to be above fiscal 2026 levels as we bring new capacity to market and invest in technology with higher spending weighted towards the first half of the year. We also continue to expect a higher adjusted effective tax rate in fiscal 2027 than in fiscal 2026.

Overall, the first quarter demonstrated our operating model working at scale. Enrollment growth is flowing through to profit, converting to cash and that cash is funding the new campuses and technology behind Purpose at Scale, while we continue to return capital to shareholders.

And before I turn the call back to Steve, I want to share a personal update, something I don't normally include in our earnings calls. After nearly 7 years at Covista and 5 as our CFO, I have decided to retire from Covista. Serving this company and leading this team has been one of the great privileges of my career. Together, we navigated one of the most consequential periods in Covista's transformation, completed Growth with Purpose ahead of our fiscal 2026 and long-term targets and now enter Purpose at Scale from a position of strength. We've accomplished a lot in the last 5 years, but at this inflection point, the timing is right for a transition, and I'm ready for my next challenge. I will remain in my role until a successor has been named, and I'm fully committed to a smooth transition. To our Board, investors and analysts, thank you for your trust, your thoughtful questions and your partnership over the years.

With that, I will turn it back to Steve.

Thanks, Bob. Before we open the call to Q&A, I just want to take a moment to thank Bob for his service at Covista. Bob has been an exceptional and trusted partner to me, the company and the Board of Directors. And he's done so through one of the most important periods in the history of the company. Covista finished Growth with Purpose ahead of both our fiscal 2026 and long-term targets and enters Purpose at Scale with a robust balance sheet and real financial strength. More importantly, Bob built a finance organization with the depth to carry us forward, and we're deeply grateful for his leadership and the excellence he brought to the team and to the function. As Bob mentioned, he'll continue in his role until a successor has been named. We have an active search underway. I'm confident in the continuity of our financial operations and reporting through this transition. And with that, we'll open the call to Q&A.

[Operator Instructions] And our first question comes from the line of Jeff Silber with BMO Capital Markets.

First of all, Bob, I just wanted to thank you for all your help over the years and wish you best of luck.

Thank you. Appreciate it.

Yes, of course. Moving back to, I guess, the quarterly results. I know in your prepared remarks, you addressed the loan caps. You didn't think there was an issue in the Med & Vet business. But I know there was some confusion early on, on nursing, whether it was going to be considered graduate or professional. And I know it ended up being in the professional bucket. But do you think there was any impact on enrollment because of that confusion?

No, I don't think so, Jeff. What we've referred to previously was primarily related to the Medical and Veterinary segment, where we did see 2 dynamics play out at once. First, we saw some pull forward in enrollments where students sought to get ahead of the loan changes. And we talked about that a couple of quarters ago and what that meant for enrollment. The other thing that we've cited is a bit of hesitancy on the part of students and families to make the leap until they fully understand all of their options to finance the entirety of the 4-year student journey in medical school. And so we believe there is still an opportunity on the consumer education side of things to ensure that students and their families are as well versed in all of the options they have for financing their journey, and we hope to overcome any remaining hesitancy through that consumer education over the next few enrollment cycles.

Okay. Great. That's very helpful. And then just moving back to the quarterly results. I know you don't give specific quarter-to-quarter guidance, but the adjusted EPS beat was pretty sizable versus consensus. Were there any expenses that might have been shifted into the second quarter or future quarters? And if so, which of the 3 segments did that occur?

Sure. I can take that. And I would say, no, there were not any expenses shifted. If anything, we made some additional investments in the first quarter. So really the outperformance largely driven by the revenue overperformance that we had.

The next question comes from the line of Alex Paris with Barrington Research.

Congrats on the beat and raise. And Bob, I'll echo Jeff's thoughts. Appreciate all your help and wish you nothing but luck going forward.

Thank you.

So my questions are likely related, I think. First off, I wanted to talk about Chamberlain enrollment up 1.3%. I was expecting a little bit more of a step function from Q4 to Q1. I guess the first question is, can we get a little additional color there? And what drove enrollment in Q1?

Yes. So Chamberlain grew total enrollment by 1.3%, and I think that was incrementally short of what we expected. It's important to note, though, that new student enrollment grew at a very healthy rate, led by pre-licensure BSN, which we believe is the critical growth area of the program mix at Chamberlain. The shortfall was really twofold. A bit of it was in continuing students. We had fewer of them return in September than we forecast. And then we had some lingering softness in post-licensure RN to BSN. On the first count, we expect that's easily corrected with some additional persistence efforts across certain of our students. And then on RN to BSN, we've got strategies and tactics in place to position that product more competitively from a pricing perspective. So as we go through the balance of the fiscal year, we expect to pick up incremental additional lift for the total enrollment story from those 2 areas. And we remain confident in the total enrollment story for Chamberlain over the course of the fiscal year.

Okay. Great. I was going to ask. I expected a step function, but I also expect a continued accelerating growth, maybe not as much of a step function in Q1, but the balance of the year. So we're starting off at up 1.3%. We would expect that to improve in terms of year-over-year growth rate in subsequent quarters. Is that accurate?

That's correct. And we still expect our most significant products to lead the way. Pre-licensure BSN total enrollment was up 13.2%, which was the 17th straight quarter of growth in that category. That will continue to be the growth engine for us, but we do expect improvement in post-licensure programs, RN to BSN in particular, and we do expect to address any issues around persistence and continuing students. So we are very, very confident about Chamberlain's trajectory over the next several quarters.

Okay. And then the related question is guidance. You beat on revenue versus consensus by $20 million in the first quarter. The revenue guidance midpoint to midpoint is $8 million. Likewise, on adjusted EPS, you beat by $0.36 versus consensus, but the increase is $0.07 midpoint to midpoint. I think Bob said that you're taking a prudent view on the balance of the quarters. What does that mean? And what is leading to your prudence on the subsequent 3 quarters?

Yes. So by way of a headline, we guide to the full year, not to the quarters. We set a range that we had a high degree of confidence in, and we raised it after 1 quarter. And obviously, as we've done every year that this team has been in place, we'll continue to revisit that as we get better visibility into the year. We come in with 7.5% more students than we had a year ago. That base drives revenue. And so as we progress through the year, as we look at what the art of the possible is, we will adjust the guide accordingly.

As for how we think about it in this particular instance, while we had a really strong beat and we're proud of that, as you know, we're monitoring a couple of dynamics that are puts and takes across the reported financials. You know about the Walden calendar shift, no full year impact, but there is a quarter-over-quarter impact with that $18 million of revenue and EBITDA that moves from Q2 to Q3.

We're investing ahead of revenue at Chamberlain with our campus expansion, and we expect those start-up costs to rise over the course of the year. Nashville opens in January, and we've got more sites that we're working on. So we're monitoring that and the implications for the full year as well.

Bob has talked about this. We've got a slightly higher tax rate for FY '27 that we're navigating as we think about full year results. And Q1 carried more of the year's earnings in our plan anyway. So again, we're pleased with the additional momentum in Q1. We're pleased to be able to raise the full year guide in Q1. It bodes well for the rest of the year. And again, if we think the opportunity is north of where we've got it now, we'll adjust accordingly next quarter.

The next question comes from the line of Jack Slevin with Jefferies.

Congrats on the really strong quarter, and I'll echo everyone's thank you to Bob. I appreciate all of the work over the time covering. If I just want to jump back in and maybe I'll take it a little more broadly on the margin front. I guess thinking about how that paces in the guidance and as you think about investments in the business, I guess I'd love to just dig in on -- is there a cadence that we should be thinking about acceleration in some of those Chamberlain investments that might weigh down on margin a little later? Or is the trajectory from 1Q a pretty decent way to think about that? Or any other specific call-outs around how you'll be managing the cost base and investments over the next couple of quarters would be great.

Yes. I'm going to let Bob answer that question, but before he does, just point out that one of the things we really like about our model is the inherent operating leverage and the really robust free cash flow that allows us lots of optionality around how to deploy that cash, including making investments in new campus expansion. But Bob, do you want to talk about how that investment flows over the course of the year?

Yes. So one of the things that you mentioned is should you be taking the first quarter and kind of extrapolating that? I would say, no. The way I would look at it is more of a -- we are sticking with the -- up to 50 basis points of improvement for the full year. And as we've said before, there's always going to be some fluctuations quarter-to-quarter. And in particular, what I would just point out is that for Walden, given the shift that we've talked about, that you would expect to have some lower margin rates year-over-year in the second quarter because of the shift. Third quarter, you would then recover that and you would expect to have higher margin rates. But for the full year, we do expect to still be within that range of up to 50 basis points of improvement.

Okay. Understood. That's helpful. And then if I look -- not a perfect metric, but revenue per student was quite strong in both Chamberlain and in Med & Vet in the quarter. Is there anything you can speak to on sort of what's driving that? I'm not sure if it's mix or core price or across the business, maybe how you're approaching price through this year would be helpful.

Yes. It's a combination of things. I'll start and Bob will keep me honest. We've got mix that's driving some of that revenue delta. We've got pricing driving some of it, and we've got credit loads, which were up in the quarter, which drives some of that revenue spread as well.

No, that's exactly it. Nothing else to add on that.

The next question comes from the line of Jasper Bibb with Truist Securities.

First, I'll add my congrats on the retirement, Bob. It's been a pleasure working with you.

Thank you.

And then just for my first question, I know we kind of talked about this a little bit in the prepared remarks, but this week, kind of the big topic around a lot of consumer businesses has been this search versus AI kind of debate. Can you just provide, like, a little bit more detail on what you're seeing in student acquisition costs and kind of how you're adapting in the current environment?

Yes. So as we've said before, the shift to AI search is real, and we believe it changes the way in which students find every school, including ours. We had, for a variety of reasons, an opportunity to get out ahead of this, particularly as a result of some of the rebranding work we did and moving from Adtalem to Covista. And while there's lots more work to be done, we feel pretty good about how we've navigated it thus far. It hasn't really resulted in any real headwinds from an inquiry, application, or new enrollment perspective. We've read, obviously, the commentary from other peers who have had to make increased investments in paid search to offset what they think they may have lost from the LLMs. But as we sit here today, we feel pretty good about the work we've done to navigate this dynamic.

We've invested heavily in monitoring systems that allow us to test where our brands and programs show up in LLM search and also to be able to test whether they show up in a positive light. So where our brands are most authoritative, and we have obviously the most brand equity at Chamberlain, descriptions are about 90% positive for that institution in most LLM search, slightly below that for Walden, which is more of a fighter brand, but we view that as an incredible opportunity for upside at Walden given how well that institution performs on its own.

So no implications for total enrollment for us. We continue to monitor the behavior of the LLMs, and we continue to work hard to get the right kind of content into the marketplace that is tailor-made for where those LLMs go to search for their data and ultimately make their recommendations.

That's super helpful. And another really nice quarter for Walden. You've had a great run there. I know you don't give segment guidance, but just any color on how you're thinking about the next 3 quarters of Walden in the context of, kind of, your updated guidance would be helpful.

Yes. So we remain pleased with the performance at Walden. The team continues to do an excellent job. Record enrollment this quarter, up almost 13%. We feel really good about that. We also feel really good about some of the strength they're seeing in the relatively small portion of the portfolio that's not health care. Education, in particular, doing really quite well, which we think is an important dynamic because Chamberlain's status as a comprehensive university, we believe, is a real source of strength for it.

Walden also continues to enjoy really, really strong persistence, which creates a flywheel effect for the strong new enrollment. And so even though that institution faces ever increasingly challenging comps cycle over cycle, we remain impressed with their ability to meet that challenge and to lap them in a very impressive way. So we can't do anything but be highly complimentary about the work at Walden.

Got it. Just last one for me. I just had a working capital question. The receivables balance picked up a little bit sequentially. Is there anything that kind of specific that drove that? Or is it more of a timing thing?

Yes. I think if you're referring to what's in the Q and sequentially, I mean, when you look from June 30 to September 30, it's not really comparable. What you really should take a look at is last year's number. And you'll still see an increase. But if you look at last year compared to this year at September 30, what you'll see is a smaller increase. So again, sequentially, it's different because of the timing of when the sessions, the academic sessions are. But we did have an increase in the receivables, largely speaking, commensurate with the revenue increase we had, but a little bit higher than that percentage.

This concludes the question-and-answer session. And I'd like to turn the call back over to Steve Beard for closing remarks.

I'd just like to thank everyone for participating in the call and listening in. One thing I want to highlight, on Monday, our first student started classes at Salt Lake City and shortly afterwards, the first Advocate students in Chicago began their journey with us. It's really gratifying to see the Purpose at Scale strategy in action, and none of it happens without the incredible work of our faculty advisers and staff who show up for our students every day. I want to close out, again, expressing my appreciation for Bob Phelan, his partnership, his steady stewardship of the financial operation and the company and being an incredible thought partner for me over the course of the last 5 years. And with that, we'll close for the evening, and we look forward to talking to you next quarter.

Thank you. This does conclude today's conference. You may disconnect your lines at this time, and we thank you for your participation.

Greetings, and welcome to the Covista Fourth Quarter 2026 Earnings. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce Jeremy Cohen, Vice President, Investor Relations. Thank you. You may begin.

Good afternoon, and welcome to Covista's Earnings Call for the Fiscal Year 2026 Fourth Quarter and Full Year. On the call with me today are Steve Beard, Chairman and Chief Executive Officer of Covista; and Bob Phelan, Chief Financial Officer.

Before I hand you over to Steve, I will take you through the legal safe harbor and cautionary declarations. Certain statements and projections of future results made in this presentation constitute forward-looking statements that are based on our current market, competitive and regulatory expectations and are subject to risks and uncertainties that could cause actual results to vary materially. We undertake no obligation to update publicly any forward-looking statement after this presentation, whether as a result of new information, future events, changes in assumptions or otherwise. Please see our latest Form 10-K for a discussion of risk factors as they relate to forward-looking statements.

In today's presentation, we will use certain non-GAAP financial measures, and we refer you to the appendix in the presentation materials available on our Investor Relations website for reconciliations to the most directly comparable GAAP financial measures and related information. You will find a link to the webcast on our Investor Relations website at investors.covista.com. After this call, the presentation and webcast will be archived on the website for 30 days.

I will now hand you over to Steve.

Thanks, Jeremy. Good afternoon, everyone, and thank you for joining us. Fiscal 2026 closed out Growth with Purpose. Three years ago, we set out to prove that closing the health care workforce gap and delivering for shareholders could be the same thing. We were right, and we exceeded not just this year's guidance, but the long-term targets we set at the outset of the strategy. This strategy changed how we operate and where we stand in the market. It built the infrastructure for durable, profitable growth while holding our focus on student outcomes. The results are worth stating plainly.

On the operational side, we delivered 12 consecutive quarters of total enrollment growth across the company. Record enrollments at Walden and Chamberlain during fiscal '26, 100,000 enrolled students, up from 76,000, joining a community of 400,000 alumni, delivering care in nearly every community in the country. Those gains converted into revenue, margin and free cash flow. Over the last 3 years, we grew revenue from less than $1.5 billion to $1.95 billion, expanded EBITDA margins by 300 basis points, nearly doubled adjusted earnings per share and more than doubled free cash flow, which let us invest in high-return opportunities and return capital to shareholders at the same time.

Now we begin Purpose at Scale, our next 3-year strategy. It carries forward the operating discipline that produced those results and adds 3 pillars across our 5 institutions: platform extension, employer integration and technology. I want to spend my time on those 3 pillars and how they show up in our fiscal 2027 outlook.

From a macro perspective, behind our strategy and our guidance sits a demand backdrop that has not changed. The population is aging, care demand is rising and the existing workforce is under real strain. This is a secular story, not a cyclical one. In our Covista Care Capacity Monitor, more than 70% of clinicians and health care executives told us that staffing shortages are affecting their ability to deliver quality care. Staffing is the constraint, patient care pays the cost, and that's the problem we were built to solve.

Turning to 2026 results. All 3 segments finished fiscal 2026 strong. Walden and Medical and Veterinary each delivered their strongest total enrollment growth of the year in the fourth quarter, and Chamberlain accelerated again. We exceeded our annual financial guidance, delivering revenue growth of 9.3% to $1.95 billion and adjusted earnings per share growth of 23.7% to $8.25 per share, both finished above the high end of our raised ranges. We're also initiating fiscal 2027 guidance today, but we're pacing ahead of the long-term targets we set at the start of Investor Day, and we continue to build momentum towards them. Bob will take you through those details in a few minutes.

Turning to the platform extension. Let me start with Chamberlain. Platform extension means putting our programs in more places, more formats and more markets. At Chamberlain, the team continues to execute the marketing and conversion initiatives we committed to, taking friction out of the funnel and improving marketing efficiencies. That includes a new campaign built on the compassion, camaraderie and calling that define nursing as a profession. We're also extending existing campuses with broader course offerings and evening and weekend access in large urban markets. That supports persistence. It expands the addressable student population in markets where we already carry fixed costs.

On new capacity, 6 campuses are in active development and 3 have full regulatory approval. Cincinnati and Salt Lake open in the first half of fiscal '27 and the attractive economics are why we are moving at this pace, roughly $9 million to $12 million of capital per campus, EBITDA breakeven in 24 months and steady-state margins accretive to our existing campus base. Underneath it all sits the structural demand tied to a national nursing shortage. Together, these initiatives should drive growth in both new and total enrollment, and we expect Chamberlain's total enrollment growth rate to accelerate again in the first quarter, consistent with the sequential improvement we saw from the third to the fourth quarter in fiscal '26.

Turning to Walden. That institution delivered its strongest quarter of the year, and Bob will give you the enrollment and revenue detail in a moment. What matters strategically is the breadth of that growth. It was broad-based with every degree level contributing. Doctoral accelerated on better program alignment to professional needs. Master's added the most students in absolute terms and undergraduate grew fastest, up more than 20%, which we're supporting by our new Your Career is Our Job campaign, which positions Walden as a career outcome partner and not just an education provider.

Investment in student persistence continues to pay off. Increasingly sophisticated analytics let us support at-risk students before they fall behind. And as you know, persistence is one of the critical drivers of both financial and operational performance, and Walden compounds that year after year. New programs launched into the 2026 academic year added roughly 1,700 students, 4 more launched last month and 2 behavioral sciences programs are in regulatory review. Our ability to launch quickly in high-demand fields is a durable competitive advantage.

Turning to Medical and Veterinary. The segment delivered strong top line performance with disciplined execution and fiscal 2026 was its strongest year in several years. Two important drivers. First, we built an on-the-ground recruitment team that lifted our high-yield prospective student pipeline, and we've upgraded tech-enabled admissions to support that yield. Some of this quarter's enrollments reflect students moving ahead of the OB3 loan changes. That's a consumer behavior dynamic rather than a shift in underlying demand, and it doesn't change how we see the segment's full year trajectory, which is embedded in our fiscal 2027 guide.

We have also been more methodical about the core student profile that fits our class mix. That leads me to expanding our employer partnerships. First, early results with SSM are strong enough that we're expanding our target enrollment there. Second, we announced a new collaboration with Advocate Health, the third largest nonprofit integrated health system in the country. In Covista, they found a partner with the scale and the infrastructure to support them in building a sustainable nursing workforce. Delivered through Chamberlain, the program funds nursing education, builds clinical readiness inside Advocate's care setting and creates a financially supported pathway into the profession. The first cohort starts in September.

And given the geographic overlap between us, we expect it to serve hundreds of students a year. Employer participation changes the economics for everyone at the table. When an employer commits, whether through tuition support, hiring commitments or clinical integration, we expect students to roll at higher rates, persist longer and be more likely to complete their education. Health systems get a differentiated pipeline, and we get a more durable enrollment model at a lower cost of acquisition. Our care capacity monitor shows why the runway is long. Nearly 70% of health care executives say talent partnerships work, but only 22% are meaningfully investing in them. That gap is the opportunity we're stepping into.

Let me now touch on our enterprise technology investments. We launched AI credentials with Google Cloud in the third quarter and added 9 more certifications in the fourth quarter. More than 9,000 learners have enrolled. We're also testing prototypes of an AI-powered classroom with students now. The first live deployments are expected in the second half of fiscal 2027. The shift from search optimization to AI answer optimization is changing how prospects find their options. Three things position us well: trusted brands in a category with durable demand, strong student outcomes and marketing teams that moved early and are optimizing for both AI and traditional search.

We expect that institutions with trusted brands, authoritative content, relevant programs and strong conversions will be the ones prospects find and trust. We're watching this shift closely, and we'll keep you updated on what we see. I also want to take a moment on recent leadership additions. We announced 2 new Board members, Emily Chiu and Leslie Storms, who bring operating experience and judgment in sectors central to our next phase of growth. In addition, Rick Sinkfield joins as Vice President of Expansion, overseeing the enterprise-wide expansion, including Chamberlain's campus growth. He brings 2 decades of experience in complex regulated markets from Laureate to ETS, plus his service on Chamberlain's Board of Trustees. In addition, Scott Liles becomes Chief Strategy and Performance Officer, adding corporate strategy and a new performance acceleration office to his leadership of the Medical and Veterinary segment.

So in closing, let me attempt to bring this all together. We enter Purpose at Scale with the foundation to go after a much bigger opportunity, a proven operating model, a balance sheet that can fund the plan and momentum already in place across all 3 segments. The demand opportunity is structural. The returns on the capital we are deploying are attractive. We hold the leading position in health care workforce education, and we intend to extend it. Our best work remains ahead of us. As always, thank you for your continued support.

And now I'll turn it over to Bob for a deeper dive into our operational and financial outcomes.

Thank you, Steve, and hello, everyone. Fiscal year 2026 was a milestone year for Covista. We completed our 3-year growth with purpose strategy, and we did so in a position of real financial strength, exceeding both our 2026 targets and the long-term financial targets that we set at the start of that journey.

Our results demonstrate the durability of the operating model we have built, sustained enrollment growth, expanding margins, robust cash generation and a balance sheet that gives us significant flexibility as we begin our next chapter, Purpose at Scale. That cash generation and robust balance sheet allowed us to return meaningful capital to shareholders over the course of Growth with Purpose, reducing shares outstanding by 20%, all while continuing to invest in the business. We enter fiscal 2027 with momentum and with the financial capacity to further invest in significant and expanding opportunity ahead while continuing to deliver strong returns for shareholders.

I will now review our fourth quarter and full year results and key drivers, and then I will discuss our expectations and assumptions for fiscal 2027. Starting with the top line. Fourth quarter revenue increased 9.7% to $501.4 million, driven by all 3 segments and led by Walden and Med/Vet. For the full year, revenue was $1,954 million, up 9.3% and which exceeded the high end of our raised guidance range. Adjusted EBITDA in the fourth quarter was $126.9 million, up 15.2% compared to the prior year. Growth was led by Walden with Med/Vet and Chamberlain contributing.

Fourth quarter adjusted EBITDA margin of 25.3% expanded 120 basis points from prior year. For the full year, adjusted EBITDA was $521.7 million, an increase of 13.5%. Adjusted EBITDA margin was 26.7%, up 100 basis points versus prior year and in line with the approximately 100 basis points we committed to at the start of the year. This reflects the operational leverage and efficiencies embedded across our platform, partially offset by an elevated level of investment in our strategic growth initiatives.

Fourth quarter adjusted net income increased 16.6% to $72.8 million. Adjusted earnings per share was $2.09, up 25.9% versus the prior year. For the full year, adjusted net income increased 15.3% to $294.7 million and adjusted earnings per share was $8.25, up 23.7% and which exceeded the high end of our raised guidance range.

Our EPS growth continues to benefit from lower interest expense and a lower share count. Full year interest expense declined to $45.4 million from $52.3 million, reflecting our actions to reduce and refinance debt and lower our borrowing costs. Average diluted shares outstanding were approximately 2.6 million lower for the full year at 35.7 million, reflecting our fiscal 2026 share repurchases. These benefits were partially offset by a higher effective tax rate, consistent with what we communicated throughout the year.

Next, I'll discuss our fourth quarter financial highlights by segment. Chamberlain reported fourth quarter revenue of $190.2 million, an increase of 3.2% compared with the prior year, driven by pre-licensure nursing and masters program enrollment growth, along with pricing optimization. Importantly, Chamberlain delivered its second consecutive quarter of positive total enrollment growth, up 1.6% and its 16th consecutive quarter of pre-licensure BSN total enrollment growth. Fourth quarter adjusted EBITDA increased 3.8% to $46.8 million, with adjusted EBITDA margin of 24.6%, up 20 basis points versus the prior year.

Turning to Walden. Fourth quarter revenue increased 15.7% to $210.8 million, driven by strong enrollment growth. Total student enrollment was up 14% to nearly 55,000 students, our 12th consecutive quarter of growth and the highest total enrollment in Walden's history with strength across health care and non-health care programs. This also represents the ninth straight quarter of double-digit enrollment growth.

Fourth quarter adjusted EBITDA increased 32.3% to $69.7 million and adjusted EBITDA margin expanded 410 basis points to 33%, driven by our strong revenue growth and operational excellence that generated efficiencies and leverage. For the Med/Vet segment, fourth quarter revenue was $100.3 million, an increase of 10.7% versus the prior year. Total student enrollment was up 7.3% to over 5,100 students, led by medical with new enrollment accelerating at both Med and Vet. Fourth quarter adjusted EBITDA increased 12.3% to $22.5 million with adjusted EBITDA margin of 22.4%, up 30 basis points versus the prior year.

Shifting to cash flow and the balance sheet. We continue to enhance our financial strength through robust cash generation and disciplined capital deployment. Full year operating cash flow of $471 million was up 41% over the prior year, while free cash flow of $393 million was up 39%, reflecting our high cash conversion and strong operating performance. Net leverage improved to 0.5x, down from 0.8x at the end of fiscal 2025.

During the year, we also refinanced our debt at attractive rates and extended our maturities, further solidifying our financial position. Taken together, these actions give us the financial flexibility under purpose at scale to invest in the growth ahead and at the same time, return capital to shareholders. And on that front, during fiscal 2026, we returned $238 million to shareholders through share repurchases at an average cost of $98.35. We have $662 million remaining under our $750 million repurchase program, which was authorized in late 2025, and we will continue to take a disciplined returns-focused approach to capital allocation.

Turning to our outlook. Today, we are initiating fiscal 2027 guidance, the first year of our Purpose at Scale strategy. Importantly, we are pacing ahead of plan toward our long-term targets, aided by our strong performance in the back half of fiscal 2026. This is a testament to our business model and the execution against the strategic plan we have put in place. For fiscal 2027, we expect revenue in the range of $2,050 million to $2,090 million or approximately 5% to 7% growth year-over-year. We expect adjusted earnings per share in the range of $8.90 to $9.15 or approximately 8% to 11% growth year-over-year.

A few underlying assumptions to frame the guidance. We continue to expect a positive step change in Chamberlain's total enrollment. For the first quarter, we expect the total enrollment growth rate to accelerate again, consistent with the sequential improvement we saw from the third quarter to the fourth in fiscal 2026. We expect additional growth throughout the balance of the year. Walden and Med/Vet are facing stronger comparables, which was already contemplated in our long-term targets. Related to the quarterly phasing, our fiscal 2027 assumptions contemplate Walden returning to an academic calendar that will have 1 less week in Q2 and 1 additional week in Q3 compared to fiscal 2026, thereby impacting the year-over-year comparisons in those 2 quarters. As a reminder, in fiscal 2026, the shift resulted in $18 million of revenue and profitability being recognized in the second quarter rather than in the third quarter. And to be clear, there is no net impact for the full year comparison of fiscal 2027 to fiscal 2026.

With respect to adjusted EBITDA margins, we expect approximately 0 to 50 basis points of adjusted EBITDA margin expansion for the full year fiscal 2027. Our growth reflects the impact of our Purpose at Scale strategy and is in spite of investments we are making in campus expansion. We also anticipate more of our improvement in adjusted EBITDA margin expansion to be in the back half of the year due to the Walden academic calendar shift and relatively higher investment levels anticipated in the first half of the year.

We anticipate a capital expenditure run rate slightly higher than the annualized fourth quarter fiscal 2026 spend as we bring new capacity to market, and we will continue to invest in new technology as one of our pillars of the Purpose at Scale strategy. And finally, we expect our effective tax rate to be higher in fiscal 2027 than in fiscal 2026.

Overall, we conclude growth with purpose, having exceeded our commitments, and we enter Purpose at Scale with strong momentum, including a proven operating model, a strong balance sheet and a clear path to converting durable health care demand into sustainable, profitable growth. We expect to continue to execute on expanding access and delivering positive student outcomes, deploying capital to meet the health care education market's growing demand and ultimately generating high returns for all stakeholders.

And with that, I will now turn the call over to the operator for Q&A.

[Operator Instructions] And our first question comes from Jack Slevin with Jefferies.

Congrats on another strong quarter, guys. To kick off, I know this is going to be a point that is important for a lot of investors, so I'll just address it head on. I heard a little bit of the commentary on some pull-forward activity in the second quarter related to OB3. I'd just love to get your take on having past that sort of 7/1 drop-dead date on Grad PLUS, what you've seen before it across the business and what you've seen post that date in the last month or so here?

Yes. So let me start by reiterating what we said before, which is that we don't anticipate any headwinds for any of our programs or any challenges for any of our students persisting to our programs resulting from the OB3 changes. Obviously, we continue to monitor that closely. With respect to Med/Vet, we have seen some pull forward in the quarter with folks attempting to front run the changes from the legislation. We view that as a consumer behavior dynamic, not a shift in underlying demand.

And the way we encourage investors to think about it is that a portion of the incremental growth coming in the fourth quarter as a shift between 2 periods, right? We'll get some of those enrollments now. Maybe we'll get some of those enrollments in the next enrollment cycle. But over the 2 enrollment cycles together, we expect total enrollment to trend consistent with our forecast for the year. So our view of the world is that it has shortened the sales cycle for some students who have decided to jump into our programs earlier. That's fantastic. And that just means that we have more capacity for the additional demand that we expect to show up in the fall enrollment cycle. So we view it as a net positive, and we're prepared to serve those students who decided they wanted to jump into enrollment.

Awesome. I appreciate the color there, Steve. And for my follow-up, just looking a little bit forward here to the September enrollment cycle and lapping some of the headwinds or misexecution you saw last year. Just wanted to check in on any leading KPIs you have for Chamberlain specifically and sort of how post-licensure and the broader Chamberlain portfolio might be shaping up as we head towards September enrollment?

Yes. So we continue to be very encouraged with the trajectory for total enrollment at Chamberlain. As you know, we're accelerating beyond where we were at the time we announced Q3 earnings. We feel good about the places that enrollment momentum is coming from, particularly in pre-licensure BSN, but also recovery and stability in post-licensure BSN and in the other graduate programs. So we're really bullish on Chamberlain's performance into fiscal '27 and all the leading indicators we monitor, including search data, inquiries, applications are all trending as favorably as we close out Q4 as they were at the close of Q3, which bodes well for the all-important fall intake cycle.

And your next question comes from Jeff Silber with BMO Capital Markets.

This is Ryan on for Jeff. Just congratulations on the Advocate Health partnership. I was wondering how we should think about the scaling of that and over time and then just the magnitude of the P&L impact for Chamberlain.

So I think we're encouraged to have the endorsement of the third largest not-for-profit health system in the country and their willingness to work with us to think creatively about how to meet their nursing pipeline needs. The program will start out relatively modestly tailored, focused primarily in North Carolina, but we expect it to expand in due course as we prove it out much as has been the case with SSM, where we started out with a narrowly defined program and the demand performance of that program has been sufficiently robust we've actually raised the enrollment targets in St. Louis.

So we're encouraged with the partnership. We're looking forward to delivering the folks at Advocate and then taking that success across the various markets in which they're prepared to deploy this kind of innovative approach to talent acquisitions.

And then I know the definition of professional programs changed a bit at the end of the quarter, inclusive of nursing now. I was wondering if you're feeling any better about some of your programs now?

We think that's a positive development. It wasn't one that we factored into the way we thought about the market opportunity for those programs. We were highly confident that even with the old definition that we'd be able to support our students in financing their academic journeys with us. As you know, we serve a not insignificant number of working adults for whom they're providing inputs to the pay. But net-net, we think it's a very positive development, and we're encouraged to see it. And we know that the nursing profession is quite [indiscernible] with that outcome as well. So it's a positive all around.

And your next question comes from Jasper Bibb with Truist Securities.

I guess I'll start on what's kind of been the topic of this earnings season so far. Curious what you're seeing with the increased consumer adoption of agentic search. Has that had any impact on the volume or the quality of leads you're seeing or maybe the conversion rates further down the funnel?

We're monitoring this dynamic closely. I'm pleased to say that it hasn't had any headwind impact on our funnel, particularly the top of the funnel. That said, we believe the dynamic is real, and it's one that I think all consumer discretionary brands will have to adjust to. As we said in prior calls, I think we got an early start on that, particularly from the content development perspective because we were rebranding the enterprise as Covista.

And we're going to point now that we actively track how our brands are represented across all the major AI platforms and answer engines, including tracking visibility, share of voice, competitive positioning. Obviously, this is going to continue to evolve. It's a bit of a moving target. But as we sit here today, we feel pretty good about the handle that we have on it. And we've been able to continue to drive robust top of the funnel activity for our programs despite [indiscernible]

Good to hear. I guess on Chamberlain, helpful comments on the Chamberlain sequencing. I guess I'm wondering if you could give us any additional detail on how much of an acceleration in enrollment growth you're anticipating in the '27 guidance? And then thinking back the last couple of quarters, you've given us some pretty good detail on application growth as the leading indicator in the past 2 quarters, I think. So if you have that number, I'm curious how that's trending.

We don't guide to enrollment growth by institution or program. We provide directional commentary from time to time. What I would tell you is that we do feel that the issue that we were remediating a little over a year ago at Chamberlain is one that has been fully addressed. We feel really, really good about the performance of our marketing and enrollment teams at Chamberlain. We feel really good about the trajectory of new enrollment across particularly pre-licensure nursing and the stabilization in post-licensure. So I think we expect keeping aside the year-over-year comparisons for a moment, I think on a sequential basis, we're expecting to see really attractive gains in total enrollment in Chamberlain over the course of fiscal '27.

And that's all the questions we have for today. So I'll now hand it back to Chairman and CEO, Steve Beard, for closing remarks.

Thank you. I think what I'd love to do as we close is really extend my sincere gratitude to the Covista family and all of our faculty and student advisers who'll stick by our students throughout the year. The results that we enjoyed over the course of this fiscal year is really the product of the incredible work that they do. So I want to express my gratitude for that.

And then the final idea, I think I want to leave the investment community with is that as we turn the page from fiscal '26 to '27, the structural demand environment for the programs we take to market is broad, it's robust and it's durable, but demand alone is an advantage. The advantage is really converting that demand into qualified, licensed clinician. That depends on improving the student journey, clinical placement capacity, strong licensure outcomes and regulatory standing built through years of consistent execution. These capabilities we enjoy at scale and difficult to replicate and can't be assembled quickly.

So we're going to continue to invest behind those capabilities and those advantages while thoughtfully returning excess capital to shareholders. And our owners can rest assured that we're not managing for the next quarter or the next year. We're building the capacity America needs in 2035 and durable earnings that results from that.

So thank you for your support. We look forward to seeing you next quarter.

Thank you. And that concludes today's conference. All parties may disconnect. Have a good day.

Greetings, and welcome to the Covista Third Quarter 2026 Earnings Conference Call.

[Operator Instructions]

Please note that this conference is being recorded. I will now turn the conference over to Jeremy Cohen, Vice President, Investor Relations. Thank you. You may go ahead.

Good afternoon, and welcome to Covista's Earnings Call for the Fiscal Year 2026 Third Quarter Results. On the call with me today are Steve Beard, Chairman and Chief Executive Officer of Covista; and Bob Phelan, Chief Financial Officer.

Before I hand you over to Steve, I will take you through the legal safe harbor and cautionary declarations.

Certain statements and projections of future results made in this presentation constitute forward-looking statements that are based on our current market, competitive and regulatory expectations and are subject to risks and uncertainties that could cause actual results to vary materially.

We undertake no obligation to update publicly any forward-looking statement after this presentation, whether as a result of new information, future events, changes in assumptions or otherwise.

Please see our latest Form 10-K and Form 10-Q for a discussion of risk factors as they relate to forward-looking statements. In today's presentation, we will use certain non-GAAP financial measures. And we refer you to the appendix in the presentation materials available on our Investor Relations website for reconciliations to the most directly comparable GAAP financial measures and related information.

You will find a link to the webcast on our Investor Relations website at investors.covista.com. After this call, the presentation and webcast will be archived on the website for 30 days. I will now hand you over to Steve.

Thanks, Jeremy. Good afternoon, everyone, and thank you for joining us. This is our first earnings call as Covista. The name reflects what we've been building, a single platform for health care workforce development on a national scale, backed by the performance you're seeing in this quarter's results. The structural backdrop for our business hasn't changed and remains highly durable.

There are roughly 700,000 health care jobs posted every month in the U.S. and only 306,000 unemployed health care workers to fill them. That's a patient care problem, not a staffing problem, and it's exactly what we were built to solve. 5 institutions, more than 24,000 health care graduates a year, deep clinical relationships and a footprint that reaches communities most under strain.

And we're increasingly connecting our market-leading capacity to produce health care workers directly to employers through programs that fund education, deliver clinical experience and create hiring pathways. No one else does this at our scale.

Three things defined this quarter. First, we surpassed 100,000 students, achieved our 11th consecutive quarter of total enrollment growth and delivered record enrollment at both Chamberlain and Walden. Second, Chamberlain returned to positive total enrollment growth ahead of our expectations. The operating changes that we committed to are, in fact, working. Third, the strength of our results gives us the confidence to raise both revenue and adjusted EPS guidance for the year.

Total enrollment grew 6.8% in the quarter against near double-digit comparables a year ago. Walden has been compounding off an extraordinary base, and Chamberlain spent this fiscal year retooling its marketing and enrollment model.

As Chamberlain's recovery builds and Walden's persistence efforts continue to compound, the underlying earnings power of the platform is strengthening in really exciting ways. With respect to Chamberlain, last fall, we were direct with you. The market opportunity was solid, but our execution was not.

We called out 2 issues: marketing effectiveness and funnel conversion. In response, we localized our marketing in key metropolitan areas, simplified the application experience, rebuilt the scholarship process and upgraded talent in the critical roles across this activity set. We said we'd do these things, and we did. The operating signals are now telling the story. Application volumes have improved sharply. Funnel conversion is up.

Total enrollment turned positive ahead of plan, and we expect Q4 to look like Q3 with momentum building into the fall enrollment cycle. We're not declaring victory on a single quarter of 0.5% enrollment growth, but we are telling you that the operating model is working and the trajectory ahead is stronger than the trailing numbers suggest.

Looking forward, 4 things matter at Chamberlain. The first is the admission pathway expansion that we've embarked on, including fast-track options that give students more flexibility in how they earn their degree.

Second is campus expansion. Six new campuses are in active development. The first begins teaching in September and 2 have received full regulatory approval since Investor Day. Third is a new brand campaign for Chamberlain, which I expect will compound through fiscal 2027, both in enrollment growth and in the brand equity for Chamberlain.

And last but not least, is the addition of a dynamically capable new leader for the university, whom I'll speak to in a moment. Chamberlain confers more nursing degrees than any other university in the country. That's no accident, and it's not easily replicated.

At Walden, the story is one of sustained momentum on top of very strong comparables. Total enrollment grew 12.3% to over 54,000 students, a record for that institution. The work I'm proudest of is what Walden has done on student persistence. We started by focusing on first to second semester retention, and we've since pushed the same discipline deeper into the student experience.

It shows up in the retention numbers and it compounds quietly over time, which is exactly the kind of operating asset we want to build. We launched several programs heading into the 2026 academic year, including clinical psychology and behavioral analysis, and they've already enrolled over 1,400 students.

7 additional programs were approved, 3 of which are starting intake shortly in fields like palliative care and special education. The speed at which Walden brings new programs to market in high-demand fields is a competitive advantage we intend to build upon. Medical and veterinary continues its strong performance. The top line is healthy, and the operating discipline keeps converting enrollment growth into strong financial outcomes.

One operational point worth flagging. We've cut application review time by weeks through process improvements and workflow automation. Faster decisions mean a better applicant experience and a higher probability that strong candidates choose us.

Our academic outcomes remain exceptional. We're tracking at a 97% first-time residency attainment rate with AUC at over 98% in the most recent cycle. On the veterinary side, our graduates continue to earn spots in the most competitive internships and residencies in the country, and we remain among the top universities in total veterinary placements.

On our enterprise investments, our work with Google Cloud is moving forward on 2 fronts. First, we're codeveloping the AI-powered classroom of the future, built natively inside the platform our students already use. The goal is a personalized learning companion that supports each student from first course to graduation.

Initial pilots launch later this year. Second, more than 4,000 learners have already enrolled in our newly launched AI credentials across nursing, medicine and foundational AI. Additional certificates in veterinary medicine, mental health and other disciplines launch later this year. The demand validates how urgently the health care workforce wants AI fluency.

To keep this work grounded in clinical reality, we established the Covista Healthcare Readiness AI Council, with leaders, including Dr. Toby Cosgrove, former CEO of Cleveland Clinic; Dr. Selwyn Rogers of University of Chicago Medicine; and Dr. Betty Jo Rocchio, Chief Nurse Executive at Advocate Health. Building the most clinically grounded AI curriculum in health care education is our objective, and it's increasingly a differentiator that's resonating with health systems.

Before I hand off to Bob, I do want to spend a moment on capital because how we allocate it is central to how we create value for you. Trailing 12-month free cash flow grew 17% to $336 million. We refinanced our long-term debt during the quarter, cutting 50 basis points off our rate and extending maturity to 2033.

We repurchased $66 million of our stock in the quarter at prices we believe materially understate the long-term earnings power of this platform and are accretive to our intrinsic value. We ended the quarter at 0.7x net leverage. That balance sheet, combined with the cash this business generates, gives us multiple paths to create value at the same time, investment in campus expansion, employer partnerships and the AI platform, opportunistic return of capital to shareholders and the optionality to act decisively if the right strategic opportunity presents itself.

We'll be disciplined about which dollar goes where, and we'll be transparent about the choices we make. On leadership, 2 important notes. Amelia Manning will join Chamberlain as its next President, bringing the student success operating discipline she developed as COO of Southern New Hampshire University, and Michael Betz will take on an expanded role as Chief Growth and Innovation Officer, adding marketing oversight to his leadership of Walden and our digital work.

Both moves strengthen our ability to execute, and I have high conviction in both leaders. So to summarize, we delivered strong performance across every segment. Chamberlain has turned. Walden continues to compound. Med/vet is converting growth to financial outcomes. The capital structure is in great shape. The cash generation supports the investments we're making and structural demand for what we produce is durable and deepening.

As we close the fiscal year, we will complete our 3-year growth of purpose strategy in a position of strength and move into purpose at scale. That next chapter is built on 4 pillars: operational excellence, platform extension, employer integration and technology focus.

You heard the framework at Investor Day, but the point I want to leave you with today is a bit simpler. Purpose of scale is not a plan we're about to roll out for the first time. It's an extension of the operating model that's already producing this quarter's results, and you'll see that same discipline at a larger scale over the coming quarters.

As always, thank you for your continued support. And now I'll turn the call over to Bob.

Thank you, Steve. Our third quarter results reflect continued execution against our growth with purpose strategy and set the stage for our next chapter. We delivered strong financial performance, raised our revenue outlook and for the second straight quarter, raised our adjusted earnings per share guidance.

We continue to benefit from a robust financial foundation while increasing our level of profitability through scale and operational excellence, all while deploying capital in a balanced and disciplined fashion.

I'll now review our financial results and key drivers for the third quarter. Later in my remarks, I'll discuss the updated expectations and assumptions for the remainder of fiscal year 2026. Starting with the top line. Revenue in the third quarter increased 4.5% to $487 million, driven by enrollment growth across all 3 segments.

As we flagged last quarter, Walden's results were impacted by the shift of 1 academic week from the third quarter into the second quarter of this fiscal year. This resulted in $18 million of revenue being recognized in Q2 rather than Q3. Excluding this 1-week timing impact, consolidated revenue would have increased 8.4% year-over-year. So on a comp basis, the organic trajectory of the business is tracking extraordinarily well.

Consolidated adjusted EBITDA came in at $127.9 million. As with revenue, the 1-week Walden calendar shift had a meaningful impact on our third quarter margin profile as well. Excluding the timing impact, consolidated adjusted EBITDA would have increased 14.2% to $145.9 million and consolidated adjusted EBITDA margin would have been 28.9%, up 150 basis points from the prior year.

Adjusted EBITDA growth was led by Walden, adjusting for the 1-week shift with both Chamberlain and med/vet contributing as well. Adjusted operating income was $102.2 million, and excluding the 1-week Walden revenue shift, adjusted operating income would have increased 14.1% compared to the prior year to $120.3 million as revenue growth and efficiencies generated operational leverage, which is partially offset by investments in our strategic growth initiatives.

Adjusted net income for the quarter was $69 million and adjusted earnings per share was $1.98 and was also impacted by the Walden calendar shift.

Now let me turn to our third quarter financial highlights by segment. Chamberlain reported third quarter revenue of $197 million, an increase of 2.3% compared with the prior year. Total student enrollment grew 0.5% to 40,767 students, reflecting Chamberlain's return to positive total enrollment growth, an important milestone as operational improvements we put in place earlier this fiscal year continue to gain traction.

Chamberlain's return to positive total enrollment growth also coincides with the highest enrollment in university history. This was driven largely by pre-licensure, where we achieved our 15th straight quarter of total enrollment growth, reinforcing the durability of Chamberlain's positioning in that market.

While post-licensure was lower, we experienced sequential improvement in RN to BSN and continued growth in the Master's program. Adjusted EBITDA for Chamberlain increased 2.9% to $58.5 million. Adjusted EBITDA margin of 29.7% expanded 20 basis points versus the prior year.

We will continue to invest in Chamberlain's marketing and enrollment operations as well as into our new campus development as discussed at Investor Day.

Turning to Walden. As we noted last quarter, second quarter results had benefited from the 1-week academic calendar shift, and this third quarter reflects the opposite impact. Third quarter revenue was $186.6 million, an increase of 4.6% versus the prior year.

Excluding the $18 million revenue timing impact, Walden revenue would have increased 14.7% year-over-year to $204.6 million, reflecting the strong underlying enrollment growth. Total student enrollment grew 12.3% to 54,474 students joining Chamberlain and also setting a record this quarter and marking Walden's 11th consecutive quarter of total enrollment growth.

This was attributable to broad-based gains across health care and non-health care programs and continued strong persistence rates. Adjusted EBITDA was $49.7 million, excluding the 1-week revenue shift, Walden adjusted EBITDA would have increased 25.5% to $67.8 million and adjusted EBITDA margin would have been 33.1%, up 280 basis points, reflecting the powerful operational leverage inherent in Walden's model.

For the Medical and Veterinary segment, third quarter revenue was $103.5 million, an increase of 8.9% versus the prior year. Total student enrollment increased 4.1% to 5,344 students with growth in both our medical and veterinary programs. Adjusted EBITDA increased 20.1% versus the prior year to $27.5 million.

Adjusted EBITDA margin of 26.5% expanded 250 basis points versus the prior year as we remain focused on operating our institutions efficiently while making long-term growth investments and delivering strong academic outcomes. Shifting to cash flow and the balance sheet. Our trailing 12-month free cash flow was $336 million, up 17% from the comparable year-over-year 12-month period, reflecting the strength of our operating model and high cash conversion.

Net leverage declined to 0.7x as of March 31, 2026, with cash and equivalents of $147 million. During the quarter, we refinanced our long-term debt, consolidating into a $510 million Term Loan B with a 50 basis point improvement in rates while also extending the maturity to 2033. Our strong cash generation and healthy balance sheet continue to give us the flexibility to deploy capital toward high-return growth opportunities while returning excess cash to shareholders, including share repurchases of $66 million during the quarter.

Based on our year-to-date performance and our expectations for the fourth quarter, we are raising both revenue and adjusted EPS guidance for the full year. Revenue is now expected in the range of $1.93 billion to $1.945 billion, up from our prior range of $1.9 billion to $1.94 billion.

This reflects revenue growth of 8% to 9% for the full year. Adjusted earnings per share guidance is being raised to a range of $7.95 to $8.15, up from the prior range of $7.80 to $8. Our new guidance reflects growth of 19% to 22% over the prior year for earnings per share. The raised guidance reflects strong momentum across each of our segments, including our expectation for positive fourth quarter enrollment growth at Chamberlain, which we expect to look like our third quarter enrollment performance.

Our guidance also reflects an elevated level of targeted strategic growth investments in the fourth quarter across our institutions that we believe positions us well heading into fiscal year 2027. The increase in adjusted earnings per share guidance also contemplates our continued commitment to expanding our fiscal year 2026 adjusted EBITDA margin by 100 basis points, and we continue to anticipate an effective tax rate higher than fiscal year 2025.

We remain focused on executing against our strategic and financial goals, expanding access, delivering positive student outcomes, deploying capital to meet the growing demand in health care education and generating strong long-term returns for all stakeholders. And with that, I'll now turn the call over to the operator for Q&A.

[Operator Instructions]

And our first question comes from the line of Jeff Silber from BMO Capital Markets.

This is Ryan on for Jeff Silber. You've spoken about the strength of the SSM partnership at the recent Investor Day. I was just wondering if you have an update on that or any of the other employer partnerships and then how the conversations with the care providers have been going since we last spoke.

So what I can say about SSM is that the relationship continues to thrive the sort of interest, the increase in applications and inquiries around the St. Louis campus have been really encouraging.

So no specifics to share at this point, but it continues to be a great proof point of a new and differentiated way of thinking about talent acquisition for health care providers. Beyond SSM, we've got several conversations active around the country, and we hope to be able to announce new partnerships in the near term. But we're very encouraged by the outcomes that we're seeing in the early days of SSM and the interest that we're receiving from other providers.

And then just looking at the magnitude of the quarterly beat and then with your comments on the targeted investment in 4Q, I was wondering if there was any timing of expenses that you pushed out into 4Q from 3Q?

No. The way I would characterize it is we do have a dynamic resource allocation model. We look at investments on a regular basis, and we're just making incremental investments in the fourth quarter is really the way to look at it as opposed to just shifting things from the third to the fourth.

And our next question comes from the line of Jasper Bibb from Truist Securities.

Really nice to see Chamberlain returning to growth here. Can you just talk about the drivers of that and then the RN to BSN piece, what you're seeing for demand in that segment as well as your own performance in the quarter?

Yes. So again, 2 quarters ago, we let you know that we had what we thought was an underperforming enrollment cycle in Chamberlain. We thought we had identified the root causes of that, all of which that we determined were in our own control. A quarter later, we gave you a sense of how that remediation was working, talking you through some of the leading indicators of enrollment there.

And we let you know that we thought you'd see that in the results of operations as we began to exit the fiscal year. We're really pleased that, that remediation work has taken root in a way that allows us to go total enrollment positive a quarter sooner than we thought. And we're really pleased about what that means for the go-forward momentum for Chamberlain.

As you know, all year, pre-licensure nursing at Chamberlain has been a bright spot for us. We had plenty of strength there. So what we were really focused on was the trends in post-licensure nursing, the largest piece of which, as you know, is our RN to BSN program as well as our other post-graduate programs.

I'm really pleased to say that we've got great momentum in both of those categories. RN to BSN is not the growth category that it may have been 7 or 8 years ago, but we are the leader in that space. And as I indicated in prior calls, we have every intention of defending our leading position in that category. So pleased to see the early momentum show up in our reported results and look forward to seeing that momentum continue into Q4 and into the all-important fall enrollment cycle.

I noticed applications were up double digits again at Chamberlain. It seems like a nice signal ahead of the fall enrollment cycle. Have you seen the conversion from those applications normalize back toward, I guess, historical levels? Or is it maybe too early to say that?

The short answer is yes. So as you'll recall, we identified a few categories of challenges. One was at the top of the funnel related to the marketing campaign that we launched a couple of quarters ago that underperformed. And as you also know, I mentioned at the time that we had record low conversion, all of which, in our view, is an execution failure. We have fixed that.

And the fact of the matter is we are seeing conversion rates that are much more consistent with historical conversion rates, and that's really a reflection of what we've done on a personnel training and process basis at the bottom of the funnel.

Just -- I want to clarify one point I made earlier about post-licensure nursing in response to an earlier question. Just to be clear, our MSN programs in post-licensure are actually larger than RN to BSN, but RN to BSN is a really, really important category for us, and we will defend our position there.

Last one for me. I think you said Chamberlain's fiscal fourth quarter should look like the third quarter from an enrollment perspective. Just to clarify, was that saying the absolute enrollment number in the fourth quarter should be similar to the third quarter or the year-over-year growth rate in enrollment should be similar to the third quarter?

We expect the rate of growth to be directionally similar.

And our next question comes from the line of Jack Slevin with Jefferies.

Congrats on a strong quarter Maybe just to drop in on Chamberlain again, but ask it slightly differently. Obviously, performance a little better than we have expected. Leading KPIs seem to be positive. Now the incremental commentary there, Steve, on the conversion side. I guess as you look at the next, call it, 4 months here as you roll into the September enrollment cycle for 2026, like what are the key focus points that you need to sort of stay present on in order to drive that inflection that you've been talking about and sort of have a better year than you did last year?

Yes. I think it really comes down to execution. Chamberlain occupies an enviable position in nursing education. It's got incredible brand equity that resonates with both students and employers alike. It's got a fantastic mix of programs across pre-licensure and post-licensure nursing.

So it's a fantastic brand and a fantastic product to take to market. So it's really about executing in the way that we've historically been accustomed to.

The fall enrollment cycle 2 quarters ago was an anomaly for Chamberlain. Chamberlain is a high-performing organization, and we feel that from a personnel and a process perspective, we are exactly where we should be. We're also welcoming a new President to Chamberlain, who will start work in earnest next week. We're really excited about what she will bring to the momentum at Chamberlain. And so as I said back at Investor Day, Chamberlain's best days are ahead of it, and we look forward to proving that out quarter in and quarter out.

Awesome. Very helpful. And then this might be a little early and if anything goes the way that it did after the last Investor Day, then this question might come up fairly frequently. But upside in the quarter, you put out targets that are year-over-year that sort of stack on top of each other. Is it fair to say, as we look towards the '27 numbers that you still feel good about what you put out at Investor Day, even with the higher base coming through now on the raised guidance?

Yes. I mean, philosophically, our view is that we want to put out targets that represent aggressive stretch goals for the organization that represent the art of the possible for our assets and for our people. We feel good about the 3-year targets we put out directionally at Investor Day.

Obviously, as we get to fiscal '27, we'll have a full year guide for that year as we open the year, and that will reflect our best estimate of both the momentum in the business and the market opportunity in front of us. So we'll be able to provide a bit more precision on fiscal '27 at that time.

Got it. And then last one, Steve, really helpful color on sort of where things sit in the pipeline of all the campus expansion you've talked about. Is there any way to think about -- I noticed the step-up in CapEx in the quarter. Is there any way to think about as you start to roll out those 10 to 15 eventual campuses in the plan -- in a multiyear plan where CapEx levels roughly should be shaking out on a run rate basis or any way to think about maybe just the next, call it, 2 to 4 quarters as we model things out?

Sure. I'll take that one. What I would tell you is if you look at by quarter, the CapEx spend this year, you see the ramp-up. I mean, we spent $31 million in the first half of the year. We spent $20 million in the third quarter. What I would tell you is that I would expect the fourth quarter to ramp up further from where we were in the third quarter. And then if you take that into next year, that would be a good proxy for what to expect going forward.

And with that, this does now conclude our question-and-answer session. I would like to turn the floor back to Steve Beard for any closing remarks.

Thank you. We have the good fortune of coming out with earnings today in the middle of National Nurses Week. As the largest nursing educator in the United States, we just want to take a moment to salute nurses everywhere. They are a critical component of care delivery in the United States. It's a calling and a profession that we all rely upon. So a sheer thanks to all of the nurses and also a shout out to all of the aspiring nurses at Chamberlain and Walden across the country. Thank you so much.

Thank you. And with that, ladies and gentlemen, this does conclude today's teleconference. We thank you for your participation. You may disconnect your lines at this time, and have a wonderful rest of your day.

All right. Good morning, everyone. I'm Jeremy Cohen, Vice President and Head of Investor Relations, and welcome to Covista's 2026 Investor Day. To those of you in the room, thank you for grabbing your [indiscernible] and your snowshoes and joining us. And to those online, we're glad you hear with us today. So to start with the safe harbor. Today, we'll be making forward-looking statements, which are not guarantees of future performance. Actual results may differ materially from those expressed or implied in these statements due to a variety of factors. And these factors are discussed in more detail in the company's filings with the SEC, including the company's most recent Form 10-K, and such factors may be updated from time to time in the company's other SEC filings. We do not undertake any obligation to update forward-looking statements. And I urge you to read the disclaimer in full detail on the screen or in the presentation, which we'll post online at the conclusion of the event.

Additionally, we'll be discussing non-GAAP metrics and reconciliations of those historical non-GAAP metrics to their GAAP counterparts are available in the appendix. Some of our speakers today will be using abbreviated slides, but we'll still cover the same content. So again, for the comprehensive materials, please visit the Investor Relations website at the conclusion of the event. In the room today, we have many Covista executives who will take the stage, starting with our Chairman and CEO, Steve Beard. In addition, we'll be hosting a weather-induced virtual panel featuring former executives from Attorney Health and the Cleveland Clinic that Megan Noel, Chief Corporate Affairs Officer of Covista will MC. And at the end, we'll have the team take the stage for Q&A.

So as you can see, the agenda, we have a packed agenda rich with content. And so without further ado, let's get started.

[Presentation]

Please welcome Chairman and Chief Executive Officer, Covista, Steve Beard.

Good morning, everyone, and thank you for being here. I am gratified to have a pack house whether or notwithstanding. So those -- for those of you who had to go through some difficulties to get here, thank you. I know at least one of you drove here from Pittsburgh and so I'm super impressed by that. This is an important day for us for a variety of reasons. It's the first Investor Day we've done in over 3 years, and it's the first Investor Day we'll do as Covista. As many of you know, back on February 5, we rebranded the company, gave it a new name, a new visual identity, which you see on display here, thanks to the great work of the team. But I want to just point out at the outset that, that rebranding is more than cosmetic. It's a substantive pivot in how we think about the business. It's both a culmination and a commencement. It's the culmination of all the work we've done over the last 4 years to create a portfolio that we can say authentically is the leading health care educator in the United States.

And it's a commencement of where we're going to take the business going forward. We want to be clear and unambiguous and can speak to us about the fact that we intend to occupy and dominate the intersection of health care and education in ways that none of our peers or no other institution higher education can. It's a privileged place to be, and we're going to make the most of it for all of our stakeholders, including our investors. The big idea that animates the way we think about this is that the United States is facing a health care crisis that affects every community, but that crisis is addressable and can be addressed at scale.

And we believe that Covista and the 5 institutions that we take to market are a critical part of addressing that challenge, and that's the opportunity that we're going to talk about today. In addition to having what we think is tremendous social impact, we also think it's an incredible investable idea. And we think the team we have and the track record of execution we bring to this opportunity means that there's a chance to create really compelling long-term shareholder value. So thank you in advance for your attention. Thank you in advance for your questions and we've got a great story to lay out for you today.

So the place we're going to begin is to really talk about all of the attributes that make us unique in this landscape. On the one hand, we've got these durable workforce shortages in health care that create secular demand trends for us on both the consumer side and the employer side. The shortage of nurses, physicians, social workers and veterinarians is large, it's durable, and it's actually growing. In addition, we have the benefit of incredible deep clinical relationships across all 5 institutions. We've had them for decades, hundreds of clinical partners in the United States from nurses, for physicians and for veterinarians and that's an asset that we've yet to fully exploit to its fullest. We're going to introduce a new strategy today that we refer to as purpose at scale. It builds on all of the operational excellence that we had in growth with purpose and we think powers a degree of growth over the next few years that's even more impressive than what we've accomplished thus far.

And then our business by nature of the regulations that govern higher education comes with really, really high barriers to entry. We've mastered those barriers to entry, whether it's state boards of nursing, the U.S. Department of Education, a network of accreditors in such a way that we believe we can continue to grow our business in any regulatory environment faster and better than any of our peers. And we're going to get into some of that today as well. We're proud to occupy the position we have today. It's the result of a tremendous amount of work from a talented team of folks over the last 4.5 years, but our best work remains ahead of us. So before I go forward, I want to go backwards because I think the path to get to this point is really important for understanding where we're going to go in the future. It's a really important set of context. So the journey begins 4.5 years ago, really, when I had the opportunity to serve the company in this capacity, where we went about rationalizing our portfolio, getting down to a set of like-kind institutions, all in post-secondary higher education, all with the center of gravity in health care. Those lifeline institutions came with incredible opportunities for efficiencies, cost synergies and the ability to go to market in a complementary and joined up way. The catalyst for that was really the Walden acquisition, which gave us a pretext for integrating the legacy health care assets of Adtalem in a way that created durable operating leverage in the model, which shows up in the financial results we produced over the last 4 years.

So getting focus and clarity in that legacy portfolio was a foundational step for us. Then in June of 2023, we introduced growth with purpose. And this is a 3-year strategy really focused on operational excellence our commitment to drive robust organic growth of this business in ways that hadn't been done before by focusing on the 5 levers of value creation in this business: marketing, enrollment, persistence, price optimization and new programs. To say the growth of purpose was a success would be a gross understatement, it was a phenomenal success. And we're extremely proud of what that's meant for the number of students we've been able to serve across our ships.

So when you take those 2 horizons. Horizon one, focus of clarity, Horizon 2, growth with purpose, it creates the foundation that we enjoy today. And it's a platform that really is enviable. Our competitors would kill to have the attributes that we enjoy. But it sets us up for the next chapter. We've taken these assets, we've integrated them. We've grown them robustly and now I think we've earned the permission to think more ambitiously about where we go from here.

One double-click on growth with purpose because I think it bears repeating. The investor [indiscernible] targets that we came out with 3 years ago, we exceeded those in the first 2 years of the journey, an amazing accomplishment by this team. We reached record enrollment in many of our institutions. We expanded margins even as we invested in the competitiveness of our business. And we did it across a Democratic administration and a Republican administration where the regulatory priorities of the government shifted dramatically. It's really quite an accomplishment, and I don't want to understate the value of that because of what it means for what we do over the next several years.

Our success wasn't a result of luck. It was a result of discipline and focus by a highly capable team. And that seemed discipline now we're going to train on an even larger and more compelling opportunity. So the next horizon in this journey is purpose at scale. Purpose at scale is really the strategy we're going to deploy to realize our vision of being systemically important to U.S. health care.

Operational excellence remains fundamental pillar of that. It's the way we run the play now, and that's not going to change. But we believe we have the permission and the opportunities to extend that platform in a few very, very powerful ways with new programs, new geographies and what it makes sense to do so with new brands and new domains. We've earned the permission to be something we think is specific and differentiated a talent platform for U.S. health care, working hand-in-hand with employers to bring a whole new wave of clinicians to the bedside to serve all of us. In addition, in this phase of our journey, we think it's important to be viewed as a tech forward partner.

And as you know, we've invested a ton in partnerships and relationships with folks that are at the bleeding edge of artificial intelligence. We believe that unlike other technologies in education or health care, AI will really transform these industries in really powerful ways. So we're going to be a utility scale solution for health care. We're going to be significant to health care, not like Mayo or Cleveland Clinic because we don't do cutting-edge research and we don't treat highly specialized patients, but we do train the people that do that. And we do it at a scale that no one has before and no one, we believe, is positioned to catch us as we chase that ambition. I want to talk a little bit about the backdrop against which we pursue this strategy because even as we changed a ton over the last 4 years, the world around us has changed a great deal as well out. There are a couple of megatrends that are shaping education and health care that I think are worth exploring.

So first is the crisis in health care workforce. The numbers that I have on the screen here, they tell us sobering story. Our country is aging fast, care demand is rising. The existing workforce is under real strain, there's burnout. There's a looming retirement cliff among nurses and the response to that can't be temporary staffing. It can't be stop gaps and quick fixes. It needs to be scaled, repeatable and outcome driven. In addition, on the education side of the ledger, the contemporary learner has changed. The universe of well-prepared, well-resourced 18-year-olds, that could absorb the opportunity cost in stepping out of life for 4 years to pursue their education is shrinking dramatically. You've all heard about the demographic cliff moving through education.

At the same time, the folks that used to be known as the nontraditional student, the working adult, the veteran, the career changer, that population is growing at an exponential rate. Those folks need flexibility. They need speed to completion, they need affordability, and they need a clear link to career outcomes. That's what we provide. In addition, health care employers have made clear that what they want more than anything is confidence and readiness. We did some fantastic research recently with Gallup, where we went out and talked to health care executives and health care workers. One of the surprising findings was that in hiring decisions, there's really no distinction between for-profit schools or not-for-profit schools in their eyes. They just want competent professionals. And so the winning model in the future isn't one based on prestige or selectivity, it's based on outcomes and trust and scale.

In addition, if the pandemic taught us and health care, anything, it's that the spot market for talent is painfully expensive, it's unreliable and it has a tremendous amount of friction in it. As a result, health care employers want not just graduates, they want partners. Partners who can help them lower the cost of acquiring talent, raise productivity, improve the retention of their employees. And that's something we believe we are extremely well positioned to do. 97% of health care executives believe that talent partnerships with academic institutions should be part of the mix. But according to our research, only 20% of them are investing in those kinds of relationships.

That creates a tremendous business opportunity for Covista. That gap between what health care leaders say they need and what they're actually doing is something we are poised to address in a winning way.

The other trend that I think is really important. You'll hear more about it this afternoon relates to artificial intelligence. We think it's going to transform both health care and education, and I'll say more about that in a moment -- excuse me, thank you.

So health care systems are investing billions of dollars in AI technology. Imaging, ambient listening, scribes, non-diagnostic agents that support patients in post-op and non-acute areas. But the bottleneck they're experiencing relates to their workforce. The workforce is not ready to adopt this technology, and they're concerned about the extent to which this technology makes them obsolete. The data that we put together with Gallup shows that 73% of clinical executives believe that their employees need to be comfortable and fluent with AI tools. But only 10% of graduating clinicians feel prepared to do that. And since we know that most technology adoptions fail because of workforce readiness, not because of the efficacy of the technology, we think that creates a tremendous opportunity for us.

So our AI strategy, which you'll hear more about from Michael this afternoon is really focused on 2 stakeholders. On the student side, we envision a generational opportunity to personalize education in a way that allows us to scale excellence like never before. Have a student journey that is tailored at every step along the way to the specific needs of an individual student and that follows them from the beginning of their program to the end. We think that's revolutionary, particularly for a business like ours that is purpose built for scale.

On the other side of the ledger, what Michael will talk about is what we think we can do for employers. We think we can help to alleviate this bottleneck and workforce readiness by first delivering AI fluent professionals from our programs, but also by partnering with them on credentials and other training that gets existing workforce comfortable with these tools. And again, we don't think there's anyone in the market better positioned to do that than us. So when we think about AI, we think about empowering students and we think about equipping employers. And we think that's a potent and valuable mix to take to the market. And you're going to hear more about that from Michael later today.

So I want to try to pull some of these mega trends together in a way that helps you understand why we believe purpose at scale is so relevant as a strategy for us, whether it's the workforce shortage, whether it's the changing needs of students whether it's AI, whether it's the willingness of employers to embrace different models for talent acquisition. In each case, this is a challenge that requires more people, better prepared be engaged in what is an issue that affects all of us. That's a tremendous opportunity for Covista to move beyond training clinical talent to actually being a solution to keep that clinical talent, successful in ways that serve a saw. And our geographic footprint, clinical relationships and program breadth, our technology partnerships and our financial strength, our competitive advantage for us in pursuing this, and we think it's an incredibly valuable way to grow this business.

We talk a lot about scale in our business because it matters. It matters for purposes of social impact. We want to train as many aspiring clinicians as we can, but it also matters in terms of the investment thesis for Covista. Let's step through it. This year, we're going to graduate 24,000 health care professionals, 24,000 across medicine, across nursing, a class veterinary medicine, across social work. That's an incredible number. Those 24,000, they joined almost 300,000 health care alone. That doesn't include the non-health care [ ones ]. [ 300 ] health care [indiscernible], that are delivering care in every state in the United States. We're the #1 granter of nursing degrees in the United States, we educate twice as many physicians as any other medical program in the United States, and we're the #1 provider of vets in the United States. It's an incredibly powerful position to have in the market. But our impact doesn't into graduation.

There are 700 alumni who are in C-suite roles across the United States, 300 of them are Chief Nursing Officers in 42 states. Our scale isn't just relevant for education. It's extremely relevant to U.S. health care and we have the ability, if we execute correctly, if we stick to our values to not just be a partner to health care but to be essential infrastructure for that industry. And again, we don't see anyone else positioned to do that but us.

So purpose at scale as a strategy builds on growth with purpose, and there are 4 pillars to this strategy: Operational excellence. We've proven we can grow these businesses consistently profitably with fantastic student outcomes, and we're going to continue to do that for the foreseeable future.

Platform extension. We believe that we have the permission to think bold about new geographies, new programs, new domains, even new brands.

Employer integration is a reimagined way of thinking about how we partner with employers, which we've done for many, many years. But post pandemic, we're just getting so much more traction in conversations about ways we can be an enabler to those institutions.

And then the technology focus. So operational excellence fuels the engine, platform expansion reaches into new geographies and modalities, employer integration connects jobs to careers and improves retention and technology modernizes the way students learn and the way clinicians practice.

I want to spend a few minutes on capital allocation. Bob will double-click on this in his presentation. But I want you to know upfront that our approach to capital allocation is as disciplined as our approach to operational excellence. We have 4 pillars to our strategy, our philosophy, you've heard them before, but they bear repeating. The first is that we self-fund innovation through operating cash flow. We think we can widen the competitive moat invest in new programs without diluting earnings at all. And we've shown that we can do that over the last 4 years. Second, we will repurchase shares on a value-driven basis where there's dislocations in the price and intrinsic value, and we've proven that we're committed to that kind of accretive capital allocation for the last several years.

Third, we have a fantastic balance sheet. Bob and team do a wonderful job of managing debt, repricing debt in a way that gives us maximum flexibility in how we invest and how we use that free cash flow. We're going to continue to do that. And then accretive M&A. We believe that there may be opportunities in the market to extend our platform through acquisitions, but only where those acquisitions clear our internal hurdle rates and represent truly accretive strengthening of the franchise and we think the strategy purpose at scale with the disciplined capital allocation that we've outlined, produces some incredibly powerful economic outcomes.

Bob will get under the hood on these numbers later today, but we're guiding for purpose at scale over the next several years is a 7% to 10% revenue CAGR and a 10% to 14% adjusted EPS CAGR. And the goal of enrolling more than 120,000 students by fiscal '29. If we do this, and it's an aggressive goal, it puts tremendous distance between us and our nearest competitor. It's an incredibly powerful value creation story. And it's one that we, as a management team, are excited about and we hope and expect that all of you are excited about it as well. So scale outcomes and operating leverage give us a path to this double-digit earnings growth.

And each of our institutions play a critically important role in helping us realize those outcomes. We're really blessed to have probably the most attractive portfolio of brands and institutions in proprietary higher education. And we've proven that we can operate these institutions at a pace that runs far ahead of the competition. So we're going to get into the segment presentations now.

We're going to start with Walden University. Michael Betz is going to come to the stage and explain why that business, despite all the success it's enjoyed over the the last 4 years, and there were a lot of doubters on Walden. Why that institution is prepared to lead the way. So Michael, come on stage.

[Presentation]

Please welcome President Walden University, Michael Betz.

Well, good morning, and Steve, thank you so much for that great setup. As I walk through the Walden business this morning, you're going to hear me go deep on a number of the themes and a number of the structural advantages that we have that Steve mentioned. And like Steve, I would like to go back 3 years to that last Investor Day. And as Steve mentioned, we made a promise back then to take Covista to a new level of growth a new level of profitability and to maintain our strong student outcomes. And inherent in that promise was the commitment to getting Walden performing better, to getting it to reach its full potential, the potential and the success that I had joined for many years before. In short, we need to regain Walden's leadership position in graduate-focused online education. And 3 years in -- over those past 3 years, I am so pleased on the behalf of the Walden team and everybody at Covista to say, we have done exactly that. It helped become one of the catalysts for growth for our entire portfolio. So today, I'm going to talk a little bit about the comprehensive nature of the strong momentum that we have in the Walden business today, talk about the capabilities that we have built, the innovations that we have delivered that give us a competitive advantage moving forward.

And then finally, some very exciting new additive growth avenues that are already showing very strong results. But before we do that, in case you're not familiar with the history of Walden University, it's a really special place. It revolutionized education over 50 years ago. It invented the category that we're talking about today. It brought high-quality education to a broad audience and it focused on working adults.

Through this commitment and continued innovation, we have graduated over 200,000 students. So that's a little bit about the special history of Walden and our commitment not just to innovation and serving this population, but our mission focused on social change, on positive contributions that we can deliver for our students, their families and their communities. And nowhere does that show up more than in the way that our student -- than the mix of our enrollments. Steve talked about a couple of the structural advantages that we have.

Walden, we have that in 2 different ways, actually. First, what you heard about in terms of that health care focus. Over 80% of our enrollments are dead center in those critical clinical health care roles that are in such demand, both by students and by the health care workforce. But what we are able to bring to the game at Walden to complement everything else that Covista does is not just to focus on those hospital-based roles like nursing but also as the leader in preparing and addressing the massive shortage that we have in mental health professions.

As many of you know, we have shortages of social workers, of counselors, of therapists, of psychologists that is as severe and in some cases, even more severe than we do in nursing, and Walden is the leader in that space. Now that's the core of what we have in terms of our enrollment mix by discipline, but that other 20% is pretty exciting, too. For example, one of the other areas where we are helping address a massive shortage in and talent is in education. Over the past year, 1 of our strongest growing areas has been in the education field and helping address the shortage that we have in teachers across the country. And then, of course, we have our management and business programs that complement everything that we do and ensure that our students and graduates aren't just clinicians but can take the mantle and help lead in their places of work and in their communities. So firmly based in health care education with a leading position in mental health as well, gives us one big advantage.

And the other area is our mix between degree levels. Walden has always been and will always be -- have a critical mass, a center of gravity in graduate-focused education. Now I've been [ alive ] in this industry way too long, and I'll tell you, when I was at other stops, everybody was so envious of this position that we had because they know what we know. Graduate students have incredibly strong outcomes, they're successful. They provide a halo for the entire institution. And from a financial perspective, have very, very strong lifetime values. So that's the core of where we are. But again, the other 20% is really exciting, too.

Since our last Investor Day, we have doubled the number of undergraduate students at Walden. We were around 6,000, I think, students then, we're close to 12,000 today. We have been growing this part of the market in a very strong manner. All of the capabilities that we have developed are perfectly positioned to continue to do that. And I'm going to talk about that later. It's one of the most exciting growth avenues we have moving forward. So structurally advantaged in 2 very important ways.

All right. I talked about regaining our leadership position, and that starts with enrollments. At our last Investor Day, when I was fairly new to the role, we were admittedly kind of at a low point in terms of enrollments for wallet below 40,000 students. But since then, we have been growing that base incredibly strong. We are at over 52,000 students. It's continuing to grow at a very healthy rate. And that strong enrollment growth is the product of 10 straight quarters of total enrollment growth year-over-year. It is also powering the strong revenue growth that you are seeing -- that you have seen in our earnings releases over the past few years.

We're seeing that enrollment growth turn into strong top line growth which we are incredibly proud of. But I will tell you, the team is equally as proud about 2 other parts of that story in terms of growing our enrollment base in our revenue. And the first is while we've been growing the top line very well, we've been growing the bottom line even faster. In this industry, we often talk about operating leverage, the ideas that you grow, you can flow that money into the bottom line in a very attractive manner. Well, that's exactly what we've been doing, driving very strong EBITDA margin gains over the course of this strong growth and at the same time, being able, as Steve mentioned, to make important investments in future growth opportunities.

So the financials are as strong as they have ever been at Walden. But I mentioned that we are a mission-driven organization at Walden. We always have been. It's why we've been around 50 years, it's why we'll be around the next 50 years. And the thing that is most important to us that is going to sustain this is it's not just about the financials. We have never enjoyed better student success than we are today. We will graduate this fiscal year over 15,000 students. Our persistence levels at every single degree level across every single discipline level are at all-time highs. And it's not just about students graduating, it's about them succeeding in the workforce. We have the rare pleasure to be cited by Carnegie Foundation recently as an opportunity college. And what does that mean? That means we're delivering on 2 things that a lot of people say you can't do at the same time, broad access and strong social mobility. We are one of just 16% of colleges in the entire universities in the entire country that was cited by the Carnegie Foundation as an opportunity college. So very strong growth in a good position. But I think what makes us even more excited about the path ahead than what we've achieved in the past is how we've done it. We have built a set of capabilities that will serve us very well moving forward and give us a real advantage. It starts with a few kind of strategic moves and capabilities that we built.

First of all, we realized that we needed to make our programs as affordable as possible, but we needed to do it in a way that promoted our students not just starting, graduating and that protected the financial sustainability of the university. So about 3 years ago, we launched the Believe and Achieve scholarship. Before then, we had a whole host of complicated discounts that encourage people to start. And we said, we're not doing that anymore. In one day, we eliminated every single discount that we had every single scholarship that promoted students for to start, and we replaced it with believe and achieve that give students that work hard that persist a much bigger total scholarship, total discount on their cost of degree by giving it at the back of the program. Everybody wins. Our students get a more affordable degree. We have degree programs that are very price competitive in terms of a total cost of degree and we're encouraging our students to move forward, and it's helped power some of the student persistence and graduation results that we have had.

That pricing innovation doesn't stop, whether it's our competency-based programs, whether it's moves that we've made on our doctoral program that are driving growth, this is something that we will continue to use to both benefit our students and Covista. The other big bet we made that is paying off and has paid off and will continue to pay off was to build our brand. Walden was the best kept secret. We spent very little building awareness for the institution, very little to tell that story. And we had a conviction that if we did that, it would serve us in the short term and the long term, and that's exactly what happened.

We have been making consistent and big investments in building the awareness of Walden. And as a result, we're getting high-quality inbound demand, providing a halo to our paid marketing efforts with Google and Meta. And very importantly, we are building brand equity. Brand equity that is serving us today and will serve us moving forward. Now those are a couple of the kind of top-down strategic moves that we made, but if you ever have the chance to walk the halls of any one of our operating centers at Walden talk to our folks, talk to me, what they will tell you is what our real advantages is operational excellence. We made an absolute obsessive focus on ensuring that from that entire journey of a student from the time they are researching us to the enrollment process to onboarding through their program on to graduation that there would be no better place than Walden.

And the ideas that we got to power this weren't from [indiscernible], they were from our front lines. Our front lines that talk to students and prospects every single day. And we have made over 100 big and small changes to that process to delight our students, to make it frictionless and to ensure that they can move forward. Now those changes are obviously important, but again, it's about the people. We can have all the best processes and technologies in the world, if we don't have great people, it doesn't matter. I talked about our frontline staff, our enrollment teams that talk to prospects, our advisers that support them, our faculty members that teach them. We have made big investments in building their capabilities, understanding what are the skills that drive to positive outcomes, whether it's conversion rates, persistence rates, graduation rates, learning outcomes, we have invested in a large L&D team that I think is the best in the industry that are working with our operations team every day to drive that excellence so that they can live up to the very high standards that we have, and we are giving them the tools and technologies that they need to do their job even better.

And then bring it all together is the partnership that I am so lucky to enjoy with our academic team. At the end of the day, we're a university. If we want to be agile, we want to move, we want to be responsive to the market, we have to have trust across the business and academic teams, and that's exactly what we have. We have a mission-driven group of business folks that never sacrifice, never compromise student success and an academic team that has trust in that side of the business and that also understands that as we grow, as we become more efficient, we can invest back into our students, back into our staff and faculty and that is exactly what we have -- that we have done.

You put all these things together, strong strategic moves, the structural advantages that we have, the ability to operate in just a world-class manner and that partnership that we have across all parts of the organization and with the rest of the portfolio, we believe if we did nothing else, then continue to take advantage of these capabilities that we have, we would have a nice path of growth moving forward. But fortunately, that's not all we have. As Steve mentioned, we have built the foundation that gives us the opportunity and the resources to explore new additive growth avenues. We have 4 things that we're really excited about at Walden that are already showing very strong results. First of all, extending our leadership in graduate education; second, I mentioned the big opportunity that we have an undergraduate, the strong growth that we have there, huge opportunity for us. And then the ability to start doing what Walden always did best, which is roll out new programs. Powering all this, complementing all of this is innovation and technology that -- and particularly the new capabilities that AI is affording us and where we are already capturing value.

So let's start on the graduate side. As Steve mentioned, the shortages that we have are not cyclical, they're persistent. And they're persistent not just across those health care roles -- excuse me, hospital-based health care roles, but also on the mental health side and in teaching where we also have a strong program in education. Now it's not just a matter though of writing the crest of this wave. One of the things that has powered our growth over the last 3 years and will continue to power is the fact that we are winning share in a big way. Our masters of nursing program, which is our biggest program, we have outpaced the growth of the market by 3x. In social work, we are growing twice as fast as the market. Our doctoral growth over the last year is blowing the overall numbers away in terms of our doctoral growth. And the reason -- the ability that we have to -- we have the ability to continue to do that. I mentioned doctoral. We put in recently some changes to make it more career focused to put a tuition cap, so students knew how much they were going to invest and we are seeing incredibly -- the strongest doctoral growth we have ever seen in the history of Walden, we are going to continue to make innovations across all of our programs as well as tempo our competency-based program to continue to extend our lead here. But we also have this huge new opportunity and one that we are so well positioned to go after. The undergraduate market is 5x the size of the graduate market. We have 40 million working adults that have a high school degree, but no college credential. And as Steve mentioned, what used to be nontraditional was becoming traditional. Students don't just accept online as a way to learn and earn their undergraduate degree, they prefer it, particularly working adults.

In fact, we've seen a more than doubling in the number of students -- undergraduate students that are learning primary -- or excuse me, exclusively online. So that's great. It's a big market. We're well positioned for it, but it's also a really competitive market. I have a ton of respect for the Southern New Hampshire, the Western governors, others. They do a great job. I think between just those two, there's about 300,000 undergraduate enrollments. We have about 10,000 or 12,000 and we know that we're not going to continue to grow that, unless we do 3 things incredibly well: First, we are never going to sacrifice the quality expectations that we have around student outcomes and that we enjoy from our graduate programs. One of the things that we did on -- in terms of that joint partnership between academics and our business side was a relentless focus starting 3 years ago on undergraduate success and particularly in those first few terms. We know that if we get students to do the first term and second term, they're going to go on and they're going to graduate.

We have seen an over 1,500 basis point improvement in those early term persistence rates. We have undergraduate continuation rates that are approaching our master's level we are rock solid in terms of our student success on undergrad. And we were not going to do anything in this space until we were assured that is the case, and we are absolutely confident of that. But that's not enough. As I said, I got some great competitors out there. We have to come to market with a program offering that is even better. And we are -- the evidence suggests that we're doing just that. We doubled down with that career focused student, which is the biggest part of the market.

And everything we do at every step of the student journey is working backwards from making our students successful. Before they even enroll, we are advising them based on where they live, their interest and their experience, which program they should study that will lead to jobs that are plentiful, not just nationally but in their locality.

As they continue through their program, we have integrated industry-recognized credentials so that they have the skills that employers need and an extra credential to help stand out in that marketplace. And then we combine them with intensive one-on-one career coaching, where they are getting help on networking, interviewing, but frankly also a little bit of tough love when needed to make sure they're staying on course to do the hard job of finding that next career opportunity. And some of the stories that we have are just -- I wish I had more time to share some of them. They're just amazing. And then finally, we do this in an affordable manner. Believe and achieve scholarship is one thing we've done. Another thing we did 18 months ago that is just really special to us is our graduation work. Every single undergraduate that graduates from Walden gets a check for $1,500 to reward them for their hard work to help propel their career forward to help drive change in their community. It has been something that's brought down the cost of the degree, something that is a huge motivation for our students and has been something that has both been financially successful and something that is just so deeply committed to our mission.

All right. So if we get -- again, if we did nothing else other than undergraduate, we see strong growth, but we have yet another opportunity that is also showing really strong potential and strong results and that is getting back to a wallet always did best, introduce new programs. Because of the acquisition and change of control, there was a period where we couldn't do a lot of that, but those days are over. Last year, we had the opportunity to launch a number of new programs. And as of last December, over 1,000 students enrolled in programs that did not exist a year ago. And that number continues to grow in a very strong manner and even better this academic year, we will launch 7 additional new programs in high-demand fields like palliative care for nursing and special education.

So another path to grow. Bringing this all together, powering it forward is the fact that we have revived Walden's reputation for innovation. All of the numbers I've talked about, all of the student outcomes have been powered by innovative new ways to help serve our students and to support our staffing faculty. On enrollment, you'll hear more about the Build your education plan from Maurice later today, about the personalized career report that we provide to undergraduates. Not only is it the right thing for the student, when students interact and engage with these self-service tools, they convert at a higher rate and they convert faster and they retain better. We are pushing -- we are getting an enormous amount of benefit from that. On the student success side, you've heard in our earnings calls about our predictive analytics that is deeply integrated to everything we do. So we know the right student gets the right message and the right intervention at the right time or our micro grant program that has been so successful. And then on the teaching and learning side, our academics hold themselves to the same high account in terms of performance as everybody else. And the result of all of this is we are at an all-time high in NPS, we have nearly doubled it over the next 3 years, and we are so proud to say we are rated in the excellent category of NPS.

Again, another sustainable advantage that we have going forward. So to wrap it up, I want to bring it full circle. We're really proud of what we've been able to do to live up to the responsibility that the Walden heritage confers upon us. But we're even more excited about the path forward about our ability to extend our mission, to drive and help power the future of Covista, both in terms of student outcomes and financial outcomes. So thank you very much.

[Presentation]

Please welcome President, Medical and Veterinary Covista, Scott Lyles.

Thank you very much, American University of the Caribbean, fantastic institution Quintessential school, dedicated students, state-of-the-art facilities and a little bit extra that you can think about today located on the island of St. Martin. So Covista is foundational to the U.S. health care infrastructure. And as long as doctors and veterinarians continue to be at the top of that delivery chain, the medical and veterinary segment of Covista will be absolutely critical to delivering against our promise. The structural deficiency that Steve talked about that exists in U.S. health care is both on the health care delivery and on health care education. Our medical and veterinary schools sit firmly at the crossroads of solving both of those problems. The good news for us in a structural deficiency is a structural advantage. This deficiency gives us a market opportunity that's durable for our schools and for the market. We have the advantage of a marketplace that has all of the hallmarks of excess demand. So I'm going to double-click on a number of the comments that Steve made about the structural deficiency and put them in the medical and veterinary context. So the first thing, when we look at structural health care and the workforce dynamics, those extend equally to medical and veterinary. We'll do more of a double-click on that, but there's a shortage of doctors. There's a shortage of veterinarians, and there's a shortage of schools that are providing them for the U.S. marketplace.

This gives us structural advantage on where we sit. We are purpose-built to deliver against that advantage, purpose built. Now I'll show that to you in the medical context. Michael talked about it with Walden. We are no different than that. And the great news, especially for the folks in this room, is where we sit, delivering against this structural advantage delivers fantastic and advantaged financial outcomes. Now when I talk about medical and veterinary segment, what am I talking about? We're 3 institutions strong, all of them with decades of experience in the marketplace. American University of the Caribbean, you just saw on the real Roche University School of Medicine and the Roche University School of Veterinary Medicine.

Let's start with our 4-legged friends at the Roche University School of Veterinary Medicine located on the beautiful in the St. Kits. It has been in operation for over 4 decades, 1,600 current students we operate in a clinical environment in 20-plus clinical locations in the United States and internationally. And now let me give you some great news we're #1. We're #1. We're #1 in terms of the number of veterinarians that practice in the United States. We're #1 in terms of the number of veterinary residences -- residencies that are filled in the United States. That's more than UC Davis. That's more than Penn. That's more than Cornell. And the underpinning of the success is because of the structural deficiency that Steve noted in his opening.

It extends to the veterinary market. Every year, there are over 2x as many aspiring veterinarians, highly qualified aspiring veterinarians as there are seats for them to fill. This is a yawning gap and you're going to hear the same theme as we talk about our medical schools. In the veterinary market, that gap has expanded at about a 7% CAGR over the last decade. That's double, double the number of aspiring veterinarians. Now another thing that I'm going to share with you with the medical and veterinary schools is it's not just a game of quantity, this is also a game of quality. Four veterinarians, the first high-stage exam that they have to take is called The NAVLE. It's their step that is administered by the AVMA same for every veterinarian in the United States regardless of where they went to school, it's their first exam that they have to take in order to ultimately practice veterinary medicine.

Our students score first-time pass rates on the NAVLE at 89%. That is exactly the same as the average U.S. score, exactly the same. And when we look at the current cohort of students who are in our last semester who are preparing to take this test, all leading indicators are that they're going to do even better. So we're looking at investing that as we move forward. These are high-quality students who are getting high-quality education and are demonstrating that every single day that they take care of my pets and your pets, in the marketplace.

So let me move on to the medical schools. Again, 2 medical schools, Roche University School of Medicine, which is located on Barbados; American University of the Caribbean School of Medicine, Its primary campus is St. Martin, which you saw on the real, we have a secondary second location in the U.K. Both of these schools have been operating successfully for over 40 years. They have over 24,000 alumni, currently serving 4,000 students operate in a network of clinical rotations, over 150 strong across the United States and in the U.K. The driver behind the success of these schools is twofold. The first is the crossroads that Steve was talking about, simply a shortage of doctors. There's a shortage of doctors in the United States. To put some scale around that, it's a 6-digit shortage that we're looking at. And that's only going to increase over the next decade. We reckon it's going to increase about 60% over the next decade. What are the drivers behind that? Two dual drivers that I think you'll agree are pretty indelible at this stage. The first one is the march of time. Our population is going to get older, they require more health care, and that puts additional strain on a system that is already suffering from undersupply.

The second area that is really, really important is demand. There is a strong lack of supply in the marketplace. Just like the veterinary schools, there's about 2x the number of aspiring doctors every year as there are places for them to study and learn it ultimately be able to practice. That's where our schools fit in. There's about 30,000 applicant gap every single year for aspiring doctors. Our schools take in and educate about 4x the number of students as the average school 4 times. That is a big gap pillar. We are critical in helping to address the shortage of doctors and the charge of health care that you saw in that previous exhibit. The second crossroads that is really important in U.S. medicine is delivery. Now shortage of doctors, shortage delivery. It's not true everywhere. That's not true everywhere in poor rural areas, in poor urban areas, and in the practice areas that are absolutely the most important for the health and well-being of our population, internal medicine, family medicine, pediatrics to get all of our children off to a good start in life.

We are woefully under supply. This is not an even distribution of lack of capacity. I'm very proud to share with you that our graduates fill that gap, not just in terms of quantity but in where they choose to practice. We significantly over-indexed in the most starved medical geographies, and we significantly over-index in the most important practice areas for the health of our communities. Again, internal medicine, family medicine, pediatrics. Today, in many, many communities across the United States, our doctors are keeping them afloat. They're keeping the medical capability in those communities of float. We believe that as we continue to grow, we'll do the self-same for the entirety of the United States and make that medical capability thrive. So as I look forward, we'll talk about 3 things that we are focusing on. The first one is winning a well-defined, large and actionable target applicant and student. The second one is sustaining really, really strong academic outcomes that we enjoy across all of our schools.

And the last one is expanding access to innovative pathways of growth through programs and partnerships. These are themes that you've heard the medical and veterinary segment carries that standard proudly and tall. So 55,000 applicants every year to U.S. medical school, 55,000. That's been true for about a decade. 23,000 of those, less than half, will get into a U.S. school. They will be offered a seat in a U.S. school. That was true a decade ago, it was true this year. This is a yawning gap in medical education capacity.

Every year, there's about 30,000 students who won't get offered a seat in a U.S. school. A full 1/3 of those are in a strategically targeted segment that we know, we don't believe, we know are well suited for our schools and our programs produce exceptional outcomes for them, and they do ultimately become doctors. We believe we have pathways to double that target segment to be able to fill the gap of a full 2/3 of the folks who leave the application process disappointed and do have the opportunity to become absolutely outstanding doctors and serve our communities going forward. So our outcomes with our target students. Doctors have to take high-stakes exams as well.

These are administered through the AMA, but the same for every doctor no matter where you went to school and no matter where you're going to go practice ultimately. The first high stakes exam is called the USMLE step 1. And that, again, is the first step that aspiring doctors take on the road to becoming an MD. In our target segment of student, they pass the step 1, they pass the step 1 exam at a little bit over an 80% first-time pass rate. That same segment in U.S. schools passed at about a percent pass rate. Full 10-point gap, full 10-point gap on the same segment, same student, same test, better outcomes. That is because our product, our approach is purpose-built for the students who do not get a seat in U.S. schools. And there's a lot of them. There's more of them that don't than do. We are a perfect fit for those students, and we firmly believe that we can extend that to about double the size of that addressable market today.

So how are we expanding? How are we doing this? Really, 2 ways. The first one is through new programs. The second one is through partnerships. So that's starting to sound like a theme it is. in terms of our programs. We have recently launched what would be the equivalent in the United States of a post back program. This is a preparatory program for medical school that's designed for folks who either weren't in premed, as an undergrad, went and did something else for a little while and decided they wanted to go back in to medicine, that nontraditional student that Steve talked about in the medical context. What we have seen since launch of this post back for our schools is we have a matriculation rate, so folks passing out of that program and to start their first semester of medical school of over 80%. To put that in context, that's a double. That's double the average pass rate of a U.S. post back. That's a lot of students we're able to expand to programmatically, making them successful, and they continue on with a semester after semester, year after year and become doctors that serve our communities and very successful ones at that.

The second area that we're expanding into is through partnerships. And that's from a couple of different that I'll share with you. The first one is a domestic partnership with Scribe America. They're the largest medical scribe outfit in the country. They tend to be populated with folks who are recently out of their bachelor's programs are medically oriented but weren't necessarily sure where they wanted to go. And so they take some time to learn the medical profession a little bit better by getting a bird's eye view and a front row seat of what doctors and nurses ultimately do. A very large percentage of those decided to go on to medical school.

We have set up a bespoke program with scribe to introduce them, their scribes to our schools. We have bespoke scholarships with them and preparatory programs. And we've seen a lot of early demand with that partnership. The second area is international. The largest and most popular globally, medical program is not MD. It's not a medical doctor program that we have or Canada has. It's called the MBBS. And the MBBS market is about 5x the size of the MD market. And there is a significant portion of those folks who would like to practice in the United States. It's a good place to be. And they do not have the opportunity to do so. The United States does not recognize that degree. So we've created a conversion program with a number of different partners to invite folks after their second year of MBBS to be able to convert to an MD program.

Currently, we have a couple of partners in the U.K., and we have a partner in India that we are working with them on. And again, early days showing great success. So what does all this meant for our outcomes? What does all this mean for performance? In terms of new enrollment over the last year, our new enrollment grew at 4x, 4x the size of application and application enrollment growth at U.S. schools. Pure and simple, that's share gain. That share gain in the medical market share gain with our target student, share gain with students who will persist throughout the entirety of their time with us. share gain with students who will ultimately become doctors. 4x.

That new enrollment and that increased persistence has manifest itself as total enrollment gain. We had a couple of years of some pretty rocky total enrollment. We have completely turned that. And we are now looking at total enrollment increases semester-over-semester, year-over-year with the target student that is tailor-made for our programs and that we see incredible success with. They continue on.

So what does this ultimately mean financial -- for financial performance? So shared we operate in a demand advantaged environment, and that offers us all of the advantages that Economics 101 would suggest in that type of marketplace.

Total enrollment growth, we continue to have structural judicious pricing leverage. That translates into exponential revenue growth. Like the rest of Covista, the medical and veterinary management team is operationally excellent, carries that standard and we turn revenue growth into outsized operating income. We operate a platform that is at a scale to where incremental growth, incremental investment delivers outsized ROI.

And additionally, we deliver -- we, the Med/Vet segment, delivers the highest lifetime value of any segment within Covista. So what that means is when we grow the top line exponentially, that delivers outsized enterprise value to Covista overall.

So in closing, demand advantage environment, durable, defendable extendable platform. Point in scale with outsized ROI advantages and dedicated, passionate students who deliver for our healthcare system. So thank you all very much. I appreciate the time today. Look forward to engaging with you during the Q&A.

We'll invite Steve Beard back up to the stage.

Please welcome back, Steve Beard.

So I think Michael did an excellent job of letting you know why we're so excited about what's happening at Walden, a pioneer in distance learning with a fantastic opportunity to grow in undergraduate education. Scott did a fantastic job of giving you a sense of why we're so proud to run to the largest medical schools and the leading veterinary medical school serving the U.S. market. But the two of them didn't point out that I'll add is that our medical schools are also the largest producer of black positions in United States, which is quite a personal pride for me. And Walden confers more PhDs to African Americans than anyone else in the U.S., also quite a personal pride for me. It is still black history month.

So I get the privilege of talking about our flagship institution, which is Chamberlain University. And I'm going to talk about it in two frames. I'm going to talk about it first in the context of how we think about the near-term strategy for that institution. But then secondly, I'm going to talk to you about the role that Chamberlain plays in driving a new way of thinking about partnering across the entire portfolio. And along the way, I'm going to make a little bit of news. So I'm excited about that as well. But what I want to land with you at the outset is that we believe that Chamberlain is probably one of the most valuable properties in all the proprietary higher education. There's really nothing quite like it. The attributes that it enjoys are really the attributes that the enterprise enjoys. It competes in some structurally attractive markets with great secular demand trends. It has a fantastic record of student success and student outcomes, and it has growth opportunities programmatically and geographically that are also incredibly compelling. So I am thrilled to be able to offer this part of the story to you.

So as we think about the go-forward strategy for Chamberlain, it really rests on 3 big ideas. One is continuing to strengthen the value proposition of the school and its graduate by the ongoing innovation and modernization of nursing education. So that's point one, and I'm going to come back to that in a moment. Point two is really about expanding its reach. It is in 24 campuses in 17 states. That's a massive footprint, but it's only the beginning of what we envision for that institution. And the third is really partnerships, and we'll get into that as well. But coming back to the first. I think it's worth reminding everyone that Chamberlain has, for many years, the pioneer in modernizing nursing education. They introduced the accelerated BSN program. the 3-year accelerated Bachelor science and nursing program that's been replicated across the country. That's a Chamberlain innovation. They were early to the idea of using advanced emulation to train nurses. The Practice Ready. Specialty Focused program at Chamberlain, which is underwritten by a grant in the American Nursing Foundation has helped to bring down the turnover rate for new nurses and specialty practices by giving them exposure to those specialties before they graduate.

And Chamberlain Care, which is a holistic approach to student support which takes into account all of the intervening challenges that comes with educating the adult learner. As part of that, they pioneered a fantastic piece of research called the Social determent of learning. And so it's a wraparound strategy to support students with all of the intervening challenges of their lives because these are working adults that drives up even more students success. This is a long-standing, historically strong, innovative institution, and it is and will remain the flagship of Covista. So we're going to take on the recency bias around Chamberlain head on.

So let me give you an overview just as we did for the other 2 segments of how we think about the reach and the power of this platform. Chamberlain is the full stack nursing school. It serves students across the continuum of nursing education from the bachelor's degree to the master's degree to the doctoral degree. 42% of Chamberlain's students, nearly 17,000 of them are in our pre-licensure programs. These are the new nurses that are coming into the market to address these workforce challenges, net new nurses and that's a very important distinction. About 58% of the students, about 22,000 of them are post-licensure that's the RN to BSN program, that's the masters program, the doctoral program. These are practicing nurses that are advancing their careers with Chamberlain in important ways because specialization and advanced practice is critical to the quality of care we all receive. And so we covered the entire spectrum at Chamberlain in a way that few other nursing programs do. And that's a source of tremendous strength for that institution.

Here's an interesting thing that may not jump off the patient, I think it's worth noting. The 2 sides of the institution, pre-licensure, post licensure, they feed one another. 39% of the students in our master's programs and doctoral programs are Chamberlain alones. They've come back to Chamberlain for that next credential. And that says a ton about the extent to which the Chamberlain brand resonates with practicing nurses and the organizations that employ them. It's a fantastic attribute of the school. So we have this built-in pipeline pre-licensure all the way through the doctoral degrees. We are repeat providers to many of our customers who feel sufficiently good about their experience at Chamberlain that they're really ready to pursue that next credential with us. And it's a base upon which we have a tremendous amount of room to run. That breadth is really what has driven our ability to really expand our leading position. Chamberlain is #1 in pre-licensure nursing. It's #1 in post-licensure. We've grown that enrollment population from 33,000 students to almost 40,000 students over the span of a few fiscal years. It's a tremendous growth rate. And Chamberlain grew at a rate coming out of the pandemic that pace the entire portfolio. We're incredibly proud of what we're able to do, particularly given the fact that we do it in a multi-unit, multi-site system that covers so much ground.

We've graduated 74,000 nurses in the last 5 years, and we have a 9% market share in nursing. That's 9% just for Chamberlain. That's before you add in Walden, which brings to the mix, the third largest nursing school in the country. And we did it while maintaining student outcomes in various states where the level of preparation for students varies. And we did it by delivering nursing talent to communities that need it most. So Chamberlain is a fantastic story. The outcomes that our students receive, the scale of the institution and the access that we're providing to people who wouldn't otherwise have it is just really, really powerful. And it is the face of Covista in an incredibly important and valuable way. So if I zoom out a bit and look at the growth of Chamberlain from an enrollment perspective over a longer period of time, it represents a 4x trajectory over the last 14 years. Most of our [indiscernible] are too small to meet the demand in the markets where they sit. We're going to talk about St. Louis, and I'll give you an example of that in a little bit. But our scale supports the kind of reinvestment in student success and academic support and clinical infrastructure that's critical to the communities where we operate. So we have this incredible flywheel at Chamberlain that's unique to that institution. Scale enables investment improves outcomes and outcome strengthen demand and reputation for the school. It's a fantastic mix.

So let's talk about where we go in the future for Chamberlain. What I'll tell you about Chamberlain strategy is that it is remarkably straightforward. You might even say it's simple. But at the same time, it's incredibly audacious. We're going to do 2 important things at once. First, we're going to win to be in same category. We're going to own that category at Chamberlain. That's incredibly important because the BSN is the bottleneck for entry into the profession and the more we can expand that pathway to the more we can deliver to the market. So we're going to win BSN, own BSN. At the same time, we're going to defend and extend our position in post-licensure nursing. Being the leader in post-licensure is critically important because Chamberlain stands for the advancement of nursing as a profession. And so the fact that we continue to lead in areas where we are helping folks move on to advanced practice, critically important to the brand identity of Chamberlain, critically important to U.S. health care and critically important to the value proposition of Covista.

So let's dig in on BSN. Again, Chamberlain virtually invented the accelerated 3-year BSN. But we do something that I think is really, really quite fantastic. We offer the BSN in a campus-based modality. We offer it online. We also offer it on a hybrid basis. And because we're trying to serve a different kind of student, we let them pursue BSN their way. We have students at toggle back and forth from one modality to the next based on their needs. So you may start in the campus space program and maybe for work or family reasons, you need to move to a fully aligned modality or you need to take a portion of the program on campus and a portion online. The fact that we provide that flexibility means we're able to keep students in the program longer, who persist at higher rates and realize their academic and professional ambitions. It is wholly consistent with our mission and our philosophy, and it drives some incredible persistence, which, as you've heard me say many, many times before, is the most important element of the economic model of our businesses.

Persistence we get the lifetime value of the student. With persistence, we have a student that's cheaper to acquire than a new student, and we get the benefit of that student getting the benefit of their bargain by completing the program and going on to the next chapter in their career. So this flexibility, which we think is unique, by the way, relative to other BSN programs in the market is a real differentiator for Chamberlain. So the other thing you should know is that even as we do this for Chamberlain in a really innovative way we just talk about what's happening away from Chamberlain -- there are more than 170,000 students. There are more than 170,000 students looking for a seat in BSN programs they can't find one. That's an incredible opportunity, massive opportunity. These are qualified applicants. We're going to go after those students, and we're going to go after them in a big way.

So I'd like to talk a little bit about BSN Online. Relatively new in Chamberlain's program mix, huge growth engine already. But it's really about access because with the distance learning modality in BSN Online, we can actually reach students in communities that can't support a traditional campus. And what's fantastic about that, and we do it through simulation. We do it through immersion, live instruction, virtual. We have clinical opportunities in those communities. But what it means is that, that student doesn't have to leave their community to go get their degree elsewhere with the risk that they don't return to the community they're from. They can get that BSN in that community. They can do their clinical work in that community, and they can stay there to serve the people that are most important to them. And again, that's a unique attribute that is not widespread across nursing education.

And for rural employers who are grappling with severe workforce shortages, this is a good set. It is fantastic for them. And that's something also completely consistent with the mission of Covista and the mission of Chamberlain. And it's a scalable solution. So as I said, in addition to winning in BSN, owning that category, we've had a lot of fast followers, by the way, but they will not catch us. We do intend to maintain our leadership in post-licensure nursing. So we have about 22,000 students in post-licensure today on the BSN, master's degrees, doctoral programs. But here's the thing. There are 60,000 folks in the pipeline looking for an opportunity to get that BSN. And nurse practitioners, because it is a huge workforce extension in health care delivery, there are 40% increases in listings for nurse practitioners across the country. So the demand is massive. The scarcity of opportunity is punishing. But at Chamberlain, we have the scale and the reach to be able to address that at scale. So again, we're the market leader in post-licensure today. We're never going to yield that ground. We're the market leader in pre-licensure nursing. We're never going to surrender that ground at all. It seems simple, but it's complex in a way that appeals to the kind of leaders we employ at Covista. So we're going to lead the way in net new nurses and lead the way in advancing the practice of nursing.

One of the important attributes of Chamberlain that I talked about at the outset was its campus footprint. Again, 17 states currently, 24 campuses. These campuses matter. They're really important. First of all, in markets where there's a shortage of talented workforce, our campus is incredibly important because of the number of students we can push through those campuses and serve in those campuses. But also, we know from our experience, every place where we have a physical Chamberlain campus, we drive enhanced online enrollment. The physical campus is actually a beacon for the online programs. And throughout Chamberlain's history and throughout its growth, that campus expansion has been an incredibly attractive accretive investment for the institution, for the enterprise. Historically, we've only done it at 1 or 2 Chamberlain campuses a year. And again, the returns for the owners and for the students we serve have been super attractive. But as part of purpose at scale, we've fallen back and thought about the efficacy of that as a go-forward strategy for Chamberlain. And we've decided that, that's not nearly enough. That's not enough for U.S. health care. That's not enough for the students waiting for a seat in nursing school, and that's not enough for Covista. So we're going to greatly accelerate campus expansion at Chamberlain at an unprecedented rate.

Our criteria for this is also very straightforward. We're looking for markets where there's a high shortage of nurses. Very often, those are urban areas, in some cases, suburban areas. We want to ensure that we're in a place where we can also drive robust online enrollments. And so that's part of our site selection criteria. And we've come up with a map for how to grow Chamberlain geographically that we think is going to be compelling for our competitive position and competitive for the economic contribution Chamberlain makes to Covista. So it's not growth for growth's sake. It's growth targeted to where the need is and growth where we think we can get the most leverage from a performance perspective. So those of you who followed the story before understand the economics of new Chamberlain campuses, but I'm going to talk to it at a high level because I think we're actually better at doing this today than we were 5 or 6 years ago.

When we go to market today, we're looking at campuses that are about 450 to 500 students in their capacity. We're looking to open 10 to 15 of these by fiscal '29. That's at a rate that we've never done it before at Chamberlain. The average new Chamberlain campus is about 25,000 square feet. It's smaller and more efficient than some of our historical locations. We've got out of the business of building campuses. We leased them now, which is great economically for us. It keeps our capital investment down, and it limits the outlay to about $9 million to $12 million per location, which is not a big number for a company our size. And as each of those campuses reach that 450 to 500 student mark, they're EBITDA positive within 2 years. And we're already into the payback cycle by year 3, 4 and 5. So not capital intensive, high return over a very attractive time period. In the 4.5 years I've been in this job, I think I've been asked, Jay, I don't know, like 300 times, why don't you just go out and build more Chamberlain campuses. It's been such a fantastic business for you. So here's the answer. That's exactly what we're going to do, 10 to 15 new campuses over the next 2.5 years.

So beyond that, what's important to note is that we're not waiting for this new strategy. We actually have a number of these new campuses already in flight. In fact, we have 4 of them that are already in flight and the most advanced of them will begin teaching classes in September. And we're going to be excited to announce these as they come online. We're excited for what it means for the communities in which we're locating these schools. And it's another opportunity for this leadership team to demonstrate just how zealous they are about effective, disciplined execution. So we're going to bring this capacity to market in a massive way and in a way that benefits everyone who depends on nurses at the bedside across the United States. So pulling it together just for Chamberlain's go-forward strategy over the next 3 years in purpose at scale. Today, 40,000 students across the full spectrum of programs, targeting to be almost 50,000 students over the course of this strategy looking at fiscal 2029. We're doing this because it's a high-value move for Covista and its owners, but we're also doing this because it's what the country needs. And there's no better way to think about making a living than doing something where you can verifiably do well and do good. And this is a fantastic investment in all of us and a fantastic investment for Covista. So that was the first frame.

The second frame I want to talk about is Chamberlain's role in where Covista goes as an enterprise. So across all 5 institutions, we've always had robust partnerships with employers. In Scott's segment, our medical schools were at a 2x 2 model where the clinical weeks in medical school are actually done at hospitals all over the United States. Chamberlain has maintained networks of preceptors for nursing students all over the country for many, many years. Walden has worked with employers in the behavioral health space for decades. But coming out of the pandemic in our conversations with health care employers, we have detected an appetite to think more creatively about how to source talent for those institutions. And those conversations, which I have personally been involved in for a couple of years now, have given us the confidence and the conviction to reimagine how we partner with employers. And we're going to start that march with Chamberlain. And the reason we start with Chamberlain is because of all the unique attributes that institution has and because nursing is among the most acute workforce needs that health care systems are facing. So I want to talk to you a little bit about how that looks in practice.

What we believe is that if you take down some of the highest barriers to entry for students, the cost of attendance, the visibility into a career post graduation, you actually manufacture demand that doesn't already exist. Our Head of Strategy is here in the room, and he and I were in a city that's not Chicago a couple of weeks ago, talking to a major academic medical center about this very issue. And one of the questions they asked me is, how are you going to get that many nurses in this market? We've been trying to do this for years. And what I told them is that the challenge was that we typically think that talent is scarce. We operate from the premise that in a community like this city, there's just not enough nursing talent to meet their needs. But what I assured them is that talent is actually not scarce at all. Talent is abundant. What's scarce is opportunity and what our model does that other models don't is create opportunities that are not there in traditional models. And when we do that, we attract more talent and then you move from a state of scarcity to one of abundance. If you need to go to school at night, and there's no nursing program that offers a night and weekends opportunity, you're not going to go. If you need to go to nursing school online and there's not an accredited respected online program that you can enroll in, you're not going to go. If you look at the overall sticker price of going to nursing school and decide for one reason or another, maybe you've got student debt from a prior experience, you can't cover that cost, you're not going to go. And if you don't know where you're going to land on the other end of that program, that too might prove to be a deterrent for you. What we do and are going to do more of is bring those barriers down in a way that brings more and more aspiring clinicians to the party.

Case in point I want to focus on is SSM. SSM, a large not-for-profit health system, Catholic Health System operates in 4 states: Oklahoma, Missouri, Illinois and Wisconsin, extremely well-respected institution run by a fabulous leader, Laura Kaiser. We've been in discussions with SSM for a while, and we've launched something that we refer to as the Aspiring Nurse Program. What that means is that SSM helps to fund students education in exchange for a service commitment at SSM locally upon graduation. This creates a direct pipeline of talent into SSM and the service commitment gives them a stickier relationship to think about bringing down the traditional high turnover rates that you find in nurses today. The response to this in St. Louis and Oklahoma has been nothing short of remarkable. Applications at our St. Louis campus are up 117% year-over-year for the January cycle, 117% just on the basis of this program in its first year and in its first intake cycle. We don't have a campus yet in Oklahoma, but we've got an online program there. That online program has seen applications in Oklahoma driven up by 200%. First enrollment cycle, first year. We targeted at the outset with SSM delivering 400 nurses a year to them. We're falling back now with them and thinking about whether that number is far too small, just given what the market response has been.

And so you take a campus like the St. Louis campus, which has been an average performing campus for us for a long time and is now one of the top-performing campuses on an enrollment basis in the entire Chamberlain network. This is the future of Chamberlain. A future where we are partnering with employers in a way that solves their most critical challenge and provides for us contracted revenue and provides for students who didn't believe this opportunity existed before, a clear pathway to take advantage of that opportunity. It's a truly exciting way to think about the future of Chamberlain and the future of the enterprise. When you remove these barriers, you create a clear line of sight into employment, students respond.

The other thing I think you should know is that we're having conversations like the SSM conversation all over the country. And while every system is different, their needs are different, what they look for in net new nurses is different, we believe this is a model that can be adapted to suit their needs. And we expect over the coming quarters, we'll be in a position to announce more of these. And we really do think it will change the complexion of the Chamberlain model and over time, change the way Covista partners with employers. So we know this template works. We're incredibly excited about it. And we don't think that there are other market participants out there who can do this quite the way we do. One of the reasons for that is because we are committed to something that unfortunately, far too few academic institutions are. We're in the at-risk student business by choice. And our model is built to support the success of that at-risk student. We make bets on students that other institutions won't and those bets pay off huge for the student, huge for us and huge for the organizations that employ them.

So whenever anyone's come to think about Chamberlain based on the recency bias or a temporary slowdown in the pace of enrollment in a single quarter, whatever your bias happens to be, I want you to understand that Chamberlain is one of the most economically powerful, socially impactful academic institutions in the entirety of the United States and you second guess them at your peril. It's a fantastic school. So we're going to take a break now, I think, for about 10 minutes. When we come back, we're going to have 2 incredibly distinguished health care leaders talk about this market dynamic and the role that academic partnerships can play in it. Thanks so much. We've got refreshments and snacks on the other side.

[Break]

Please welcome Chief Corporate Affairs Officer, Covista, Megan Noelle.

Hello, everyone, and welcome back. I'm Megan Noelle, Chief Corporate Affairs Officer, and I am absolutely thrilled to be with you here today. I'm going to be a moderator panel with 2 very distinguished guests, Dr. Toby Cosgrove, former President and CEO of Cleveland Clinic; and Dr. Gaye Landstrom, former CNO of Trinity Health. Over the next 20 minutes, we're going to take you through the health care workforce shortage, and we're going to reframe it from just a short-term labor supply issue to a structural challenge that requires a fundamentally different approach. Specifically, we're going to focus on 3 things: the frontline clinician experience, the role of tech and AI and lastly, the workforce of the future. So let's dive in.

Dr. Cosgrove and Dr. Landstrom. Give them a minute.

Good morning. Good morning, Dr. Landstrom. Good morning, Dr. Cosgrove.

Good morning.

Thank you for being here today. So Dr. Cosgrove, I'm going to jump right in with you. We heard from the Bureau of Labor Statistics that we have about a 2 million health care workforce shortage in the U.S. alone. Can you talk to me about what this means for access to care, care quality and the economics?

Yes. Clearly, this is an enormous issue. It winds up closing facilities, particularly closing beds and hospitals if you don't have enough nurses. It turns out that the burnout of caregivers is enormous amongst nurses amazingly, it has increased with 50% to 60% of nurses showing some signs of burnout because they are overworked because of the shortage of nurses. And -- and thirdly, the shortage increases the labor cost across the entire organization. So it is a very big multifaceted issue for health care providers.

Dr. Landstrom, what is it like from your perspective? Tell me a little bit more about the access to care quality.

Sure. Well, people come to hospitals needing nursing care. And when you don't have nurses, then you can't give them access to that care. As Dr. Cosgrove said, we see hospitals closing beds, closing entire units, mothballing operating rooms because they don't have the nurses needed to provide patient care. And you asked a question about quality as well. There are a multitude of research studies that talk about the connection between the dosage of nurse staffing, the amount of care that nurses -- registered nurses can provide to patients being tied to a number of patient outcomes, including things like longer hospital stays, patients having to return to the hospital after they go home, a number of different kinds of infections and even mortality. So not having nurses has a big effect on health care, on patient outcomes. It affects patients' lives and can even lead to no access to care at all.

Dr. Cosgrove, we just talked about the U.S. system. Let's zoom out a little bit to the global system. McKinsey forecast a shortage of 10 million health care workers by 2030. Why do we should we look at this as a long-term structural challenge rather than just, again, a short-term labor supply issue?

Well, I think in 2 aspects. One is the quality of care and secondly is the economy. First is in terms of the quality of care. If you look at the shortage of nurses around the country -- around the world, I should say, it is somewhere you could -- if you had an adequate number, you'd probably save 200 million years of life across the globe. That would translate into a larger population and translates into more jobs and a huge increase in the global economy of trillions of dollars. So it is multifactorial. The third thing I think that is shortage of nurses in the rest of the world is we have been a net importer of nurses around -- from around the world, and that's no longer going to be possible. And so the shortage there is greater than it is in the United States. So we just -- that we can't depend upon importing nurse to fill our vacancies.

Dr. Landstrom, you and I have spent a lot of time talking about clinician burnout. I know it's a topic you feel strongly about. What is driving it? And what is the long-term economic cost of this?

There are a number of things that are driving the experience of burnout with not only nurses but the entire health care team. The pandemic was certainly a specific event that had a big impact across the entire country and across the globe. What happens when an organization doesn't have enough staff, the staff who are working take on a greater workload, an excessive workload. And those individuals often -- too often can't provide the care that patients need. And so then you have gilt and you have this sense of moral distress. And as that goes on, it leads to burnout. Burnout is closely tied to turnover. And that's not just leaving that organization, a nurse choosing to leave a specific hospital. Too often, they choose to leave nursing entirely. And I think that's a tragedy. When you have turnover of staff, you have those vacancies, you have day-to-day staff being overworked. It impacts the continuity of care for patients. It can vary too much day-to-day. The team becomes unstable. And when you have that, that can impact communication and patient outcomes. So it really is -- it's significant.

The other thing I would mention is that when we have turnover of experienced expert staff, you can't just recoup that with hiring early career nurses. You've really lost significant experience. And as our patients are getting sicker and sicker, those who are in hospitals are much sicker than they were in past years, you need that expertise. So it's a significant loss for the -- for our patients and their care and the entire health care team.

Very well said. Dr. Cosgrove, you and I have talked about the role of AI, and it seems like we can't wake up in today's news and not talk and think about the role of AI and technology in impacting industries. Talk to us a little bit about what you think AI will have impacts on in health care and in education, where it can help and also, frankly, where there will be shortfalls.

Well, I am incredibly enthusiastic about AI and health care. First of all, I think it can improve the efficiency of doctors because right now, 30% of physicians' time is administrative, either in the electronic medical record or for insurance. Second aspect that I think AI can help is an administrative aspect of running a hospital. It turns out that 5% of the Cleveland Clinic employees work in just putting out a bill or making an appointment, which is -- clearly could be helped with AI enormously. And probably the most important thing that we see that AI can help with is the explosion in knowledge. It turns out that last year, there was 1.8 million medical articles written and the total amount of knowledge in health care is now doubling every 73 days. Nobody can keep up with that.

But certainly, it is possible to do it with AI, which is helping enormously. It turns out that in my back pocket right now is open evidence and 50% of the doctors in the country are using this to help them get the latest information on disease process and what could be the appropriate care. And more importantly, right now, from the time as something is proven to be an effective technology until its time it's standard of care in the United States is 13 years. And hopefully, we're going to be able to shorten that so that the quality of care improves enormously. So I think that AI has great opportunities to help health care probably more than any other industry that I can think of.

Dr. Landstrom, let's stay on the topic of AI, but let's look towards the future. how do you think that the role of AI will evolve the clinician of the future?

Well, I think Dr. Cosgrove gave a great layout of how our clinicians are using AI. At the same time, we are developing new ways of caring for patients, new ways of trying to bring some of those seasoned expert nurses back into care as virtual nurses, mentoring young nurses. And so using AI to deal with this explosion of knowledge, which as it grows in medicine, it's growing in nursing. Nursing is becoming more and more subspecialized as medicine has been doing. And AI technology are helping us to deal with that amount of knowledge to be able to see the connections and what's happening with patients to have complex diseases and care needs and really helping that whole team to be able to communicate. They don't have to all be in the same room now. That technology is helping to bring them together and allowing them to coordinate care for patients.

In our Covista Care Capacity monitor, health care executives told us that talent partnerships are a big opportunity for them to think about sourcing talent differently, yet they also admitted that it was something that they felt they had room for improvement. Both of you led large organizations where sourcing talent was a big part of your role. Dr. Landstrom, let's stay with you. How should health care executives think about talent sourcing now and in the future?

Yes. This is -- it's a newer idea. As systems have grown and gotten bigger and been multistate, sometimes multi-country. This issue of needing to ensure that you have a steady pipeline of clinicians, not just tomorrow, not just in a few months or next year, but 3 years, 5 years, 10 years down the road, system leaders have to be able to plan that out and then develop multiple pipelines to meet that need. As you have systems that are in multiple states, having relationships with local academic organizations, those are important, and they're very time-consuming when you're working with many, many different organizations.

It's important to look at different ways of partnering with academic organizations that have a much broader reach who, as I led a system, I looked for organizations like Covista that could reach into multiple regions where I had hospitals and clinics and skilled nursing facilities. And that became part of that pipeline strategy to be able to yield the workforce that we need. And I urge all system leaders to really consider innovative new partnerships in addition to what they've been doing in the past, but it's going to take a lot more to ensure that we have the clinicians available to provide care in the future.

Dr. Cosgrove, same question. How should we think about talent partnerships in the future?

So I've been recently talking to a lot of hospital CEOs around the country. And I've noted that one very interesting thing about nursing supply and nursing shortages. And those who have partnered with multiple partners for their nursing supply don't seem to have anywhere near as much difficulty with shortage of nurses that those who haven't. So this seems to be clearly the right thing to do in terms of having enough nurses on board to manage the care of the patients. And so I think you have to partners have to have partnerships.

I'm going to pivot to another topic. A big theme that was coming out of today is that the American learner has changed. and that the traditional education systems while serve a very important purpose, also don't fit the needs of today's learner. So talk to us about what you're seeing around the trends in education and what needs to change in order to meet students where they need to be met today. Dr. Cosgrove, let me start with you.

Well, when I got to medical school, and it really hasn't changed very much. In order to get into medical school, you had to prove that you could memorize by getting through organic chemistry. And then you spent the rest of your time memorizing in medical school. That just can't happen now. There's just too much information to possibly memorize. And you do have technology that will help you have the data at your fingertips that you need without having memorize those capabilities. So now you have an enormous opportunity to begin to bring different types of intellects to the health care, particularly intellects that are going to have emotional intelligence and empathy. And I think that will be a great thing for health care. And so you need to figure out how you're going to educate differently and for a different model for different capabilities, and I see it as a positive.

And also, I would add that you're going to have to teach the learners how to manage in an AI environment. And interesting, Covista has done a very nice job with this with bringing on Google and Hippocratic AI to begin to help people learn how to manage in the AI environment.

Dr. Landstrom, same question. How should we be thinking about education and training for the future?

Yes. A couple of things really come to mind. I think it was about a decade ago when I first realized that the way we were educating nurses across the country, it was very traditional. And we talked a lot about there not being enough clinical education spaces in the country, and that was limiting our ability to develop nurses. But when I began working in partnership with some other academic organizations who had broader thinking about what the possibilities were that we had different students who really needed to be able to do their schooling and their clinical practice at other than Monday through Friday day shift. It really expanded out the opportunity to expand the student population, expand the number of graduates using all those clinical learning opportunities throughout all 7 days and all shifts. And it better met the needs of some of those students who needed those kinds of -- that kind of timing.

And it taught me that we have in our traditional education, I think, been far too limited by there was just one way for a student to be taught and all students should be -- we should work with them all the same. I think that is faulty thinking and it is not going to serve us in the future. So looking at -- looking at different ways, a different student and multiple ways of meeting those students' needs and educating them is one piece of it. The other piece of it is nursing education has really been limited for a number of years by the lack of faculty. And one of the opportunities when you have a partnership between a nursing school and a health care provider, there's an opportunity to bring in experienced, talented nurses to serve as faculty, but it can only be done in partnership. And so I think there's the opportunity here in the future to not be limited by clinical placements, not be limited by an inadequate number of faculty if we do it in partnership and broaden our thinking.

I love that. Okay. We've covered a ton of topics over a short amount of time. I'm going to end with the positive. what gives you hope for the future that we can solve this challenge at scale? Dr. Landstrom, let me start with you.

Thank you. It's been delightful to have this conversation, and I'm honored to do so. I think there are several things that give me great hope. First of all, there is a lot of work going on to redesign the way we deliver care, particularly within hospitals. And I think that is bringing a lot of learning and a lot of hope for the future that we can have an experience for our nurses that leads to a long and fruitful career caring for patients, retaining them in those roles. I also am seeing a historic divide between academic nursing and nursing practice that divide beginning to narrow as partnerships form. And I think that gives me great hope. And I think having new and diverse opportunities for talented people who perhaps in the past didn't have an opportunity or didn't think they had an opportunity to pursue nursing to give them those opportunities to become nurses and have a fruitful career caring for people.

Dr. Cosgrove?

Yes. I think you've hit on some very important points. And obviously, we've talked about training and how it's different. I would just also emphasize the importance of retention. And when there's partnerships and the retention is so much greater. Technology is going to help nursing, and I think hospitals have to embrace technology with the idea of helping nurses. One of the examples is you now have a little button that you can put on a patient's chest and it gives you all the vital signs continuously instead of asking a nurse to run around and take people's blood pressure every 4 hours. And we're going to have new models of health care delivery where nurses can manage large numbers of patients and reduce the work and be more thoughtful and more productive for the future. So I am -- it's going to take a multifaceted approach to deal with this shortage of health care providers around the world. But I think beginning to use all of these in concert will begin to make for a better health care for millions of more people and a productive career for lots and lots of individuals who want to come into the health care enterprise.

Dr. Cosgrove, Dr. Landstrom, thank you for a riveting and inspiring conversation. On behalf of Covista, we are so thankful for your guidance and support and for talking to us today.

I'm now going to turn it over to my I now have the pleasure to turn it over to my friend and peer, Chief Marketing Officer, Maurice Herrera.

Please welcome Chief Marketing Officer, Covista, Maurice Herrera.

Good morning, everybody. I'm really excited to be here with all of you. As a marketer, we always want to be able to market great products. And at Covista, we do that, but we do so much more. We market life-changing experiences, right? So let me say that again, we market life-changing experiences and then those enable life-changing careers, right? And so even talking to Jonathan this morning, I was sharing my background about -- I spent some time as the Chief Marketing Officer at Weight Watchers and then Avis Budget Group. And he asked me, those are very brand-forward opportunities. Why Adtalem now Covista? And the answer is because I consider it a privilege. It is a truly fulfilling privilege that I am marketing to the opportunity. You heard Steve say there is talent out there. It's just there's a scarcity of opportunities. So for me, to bring that background and all those kind of great foundations that I had in my former life to Covista over the last 5 years, to me, it's been a privilege.

And I have the privilege of leading a team that is structured and staffed to do 2 things. The first is to build brand equity, right? And what is that? That is to bring forward and assert very compelling and distinct value propositions. And you heard Michael, and this is what -- one of the reasons why I love being here at Covista as well is like I've got believers in brand with Steve and with Scott, with Michael, with Megan, like we all believe in the importance of brand. The second thing that we're built to do is to drive revenue in an ROI-accretive manner, which is why Bob and I get along really well as well as the CFO. So the next 10 minutes, I'm going to share the -- it's in 3 parts. The first is I'm going to talk about some of the results that we've achieved; the second is how we've achieved those; and thirdly, what are some of the opportunities that lie ahead.

In terms of the results, like we are -- we want to -- we have 2 overarching KPIs that we always strive to deliver. The first is inquiries. And the second is our cost of acquisition. Now not all inquiries are created equal, right? These are organic inquiries. These are organic inquiries, meaning that it's from prospects that have come directly to our site or they are looking for us and searching for us by our brand name, right? And those inquiries are up almost 20% over the last couple of years. And then our cost per acquisition is down, as you see on the right-hand side, that's down 16%. And this is as we've maintained our marketing support in terms of the dollars that we spend on marketing that's been commensurate with our revenue. Therefore, we've increased our marketing spend while achieving these results.

One of the reasons why we've been successful is that we've changed our media shift. We have gone from performance marketing, which is important, but we've increased our brand media by almost 1,500 basis points. And so that shift has been critical. So it's -- we placed that bet. But when we placed the bet in order to make it a winning bet is we did the following. We rallied around our brand strategies. We made sure that at the top of the house, as you see, we've got these brand platforms, I refer to them sometimes as the title of the book, right? This is our just do it, our think different. This is our North Star. This resolves for not just our prospects, but our existing students, our alumni, our faculty, our administrators. This is the North Star. This is why we exist, which is critically important, but then one of the critical chapters of that book is the reason why they should hire us today, why a prospect amongst all the different choices that they have. Why would they choose Walden or Chamberlain or Ross or AUC or Ross School of Veterinary Medicine. And each of these campaigns, and you've seen them throughout the day, get the W, the nurse I want to be, et cetera, we vet them before we go out in the marketplace.

We use a Fortune 500 methodology that's very predictive. So that when we're out there, we know that it's going to drive recruitment. We know that prospects are going to get inspired to take action. They're going to come to our website. And then speaking of our website, when we placed this big bet, it was really critical that we develop best-in-class websites, right, where it starts. So -- and we've overhauled every one of our websites for every one of our brands over the last 3 years. And we did this in a 4-pronged manner in terms of these 4 principles. First, it starts with user centricity. We know that these prospects that Steve talked about, like they're saddled with some feelings of self-doubt. They're saddled with some feelings of procrastination. We have to show up and meet them where they are. We have to inspire action. And it's through that user centricity of really understanding what is in their head and in their hearts that we move them through the journey. We have to be conversion focused, right? Once they come to that website, we've got to help them move through that journey. One of the ways that I'll mention -- Michael mentioned this earlier as well is we have a build your own education plan for Walden. It's a 3-minute quiz, very simple, very accessible. And as you come out of that quiz, you get a really great sense of the degree that's going to suit your needs, the cost, the time that it's going to take you. And so the level of engagement goes up, the level of confidence that you have upon visiting that website goes up. And that's just one of many, many, many things that we do because we're constantly -- to the point on the bottom right, we're constantly optimizing. We're constantly testing.

I have a group of folks that are built for conversion rate optimization where we have many, many, many tests in flight. That was one, and it was a winning one. So we've got many more at bats than we've ever had. We don't win them all. But constantly, we're trying to one up ourselves in terms of where we've been last week, last month during the past year so that we're constantly helping our prospects move through the journey. And then lastly, we're constantly data-driven. We'll look at our data and see where our prospects may be spending too much time, too little time, et cetera, and then we go back through the -- all the principles. So those are a couple of the winning ways in which we've achieved the results that I shared with you.

Now I want to pivot to a couple of things that we're going to be doing to really take advantage of the opportunities that are out there. One is in local marketing. So it's a lot more cost efficient than ever to spend our media in local markets. So approaching Chicago, different than Houston, different than Atlanta, different prospect base, different competitive set, different category dynamics, different brand development in terms of the awareness of our brand. So we're going to take a very, very specific approach to those markets, and we're going to do that across all of our segments. Just like in terms of the brand strategy, just like in localized marketing, it's one of the benefits of the operating model where we cross-pollinate these approaches across all of our segments to really leverage the power of marketing across the enterprise.

The second big bet, and I'd be remiss if I did not talk about AI, there was an article that came out from HBR yesterday about how AI is going to disrupt 2 different aspects of the prospect journey. One is in terms of how they search. The other is in terms of the role of the website. So this is what I wake up to, but we are built to win. On the left-hand side, we are -- we have a very keen understanding of the roles of content, and it starts with discovery and visibility with the LLMs that is of critical importance. It's even more important than ever then, as you saw the brand strategies, the cohesion of those brand strategies that I showed earlier, the title of the book, the chapters, that cohesion is rewarded greatly by the LLMs. The more cohesiveness there is amongst the brands, the narratives and how we show up, the LLMs reward us. We also have to be very inspiring, like we inspire action.

We also have to educate what are the exact degree types? What is right for that prospect at that journey -- at that point of their journey is critically important. And then lastly, decisioning. Like it's not over because it's a lengthy process from the time that they embark on wanting to get that degree to the time that they actually set foot at our campus or online. It's quite a lengthy process. And so we need to make sure that we show up with the right content in the right manner that moves them through the journey. On the right-hand side is -- it speaks to the process of content creation. We have 4 critical steps that we go through. Every year, we develop about 5,000 pieces of unique content. That's about 15 to 20 pieces of unique content every single day. I believe that over the next year, that's actually going to double, right? And to the point about how the role of search and the role of our websites is going through quite a lot of change, we need to show up with the right content, but we need to do it in a cost-effective manner. We need to be quicker about it, and we need to be better about it. And we have a framework, and we are structured now as a team to really meet this moment with AI. So that's what I had for you.

In close, what I would say is we feel really great about the results that we've achieved to date, and I'm confident that we're going to make the right pivots to continue to take this function of marketing across the enterprise to scale and deliver ROI accretive revenue. Before I hand it to Michael, I'm going to share with you our inaugural Covista ad campaign, and we're really proud of this of really showcasing our access mission and how that translates into 24,000. You've heard the number before, but 24,000 graduates into the health care field. And so let's take a look. Thanks, everybody.

Please welcome Chief Digital Officer, Covista, Michael Betz.

Hello. You can't get rid of -- so I am really excited to build on what you've been hearing from Steve, from our panel members, from Maurice and others about the amazing opportunity that we have in front of us to continue to drive innovation and what all the new opportunities that AI will unlock for us. In fact, about a year ago, Steve asked me to take on this role to help accelerate the innovation that we are driving and make sure that it is going across all 5 of our institutions. And so we've been hard at work bringing our technology team members, our business team members to be working hand-in-hand in cross-functional agile manner so that we can accelerate that pace of innovation.

And one of the happy byproducts of that is it also unlocked a lot of efficiency that enabled us to invest even more into our innovation agenda. And if you're talking about innovation today, you might have heard about something called AI. So that is what I'm going to be focused on today.

And it really starts with what Steve talked about, which is we are very convinced that there is a generational opportunity for new technologies, AI-powered technologies to transform higher education. And as you heard from our panel members, that is transforming health care. And that gives us an opportunity to benefit from these developments in a way that few other industries can, and I'll be speaking about that more.

Of course, that's all great in theory. The question then becomes, who is going to seize that opportunity? We're going to walk through why we are in such a special position to be the ones that are going to move forward and continue to lead the way here.

And then finally, and I think most importantly, this is not a strategy for us. This is not a plan on the paper. This is -- when we think about innovation, we think about AI-powered solutions. We already have over 20 solutions across our portfolio that are driving real value for our business and our students today. And I could geek out and talk about all of them for about 5 hours, but I will hit on just a few of the key ones and some of the exciting things that we're working on moving forward.

So why are we so convinced that this is going to be transformative? I think the first piece is that if you think about AI's impact on any industry, it's often framed as a way to drive efficiency to cut costs. And look, we're going to have some of those opportunities. We've been doing some of that at Covista. But for us, it is something much more powerful.

First, it's something that can help drive the top line as well, make our enrollment specialists even more effective, our advisers more effective. Things that when we pair up these great technologies with our great people, it's not just about cutting costs, it's about growing the institution.

And then even more importantly than that is the opportunity it has to do something that we've been talking about in education for a very long time. I actually started my career in education as a teacher for America Teacher. I had 36 kids in South Central L.A. I had in my class kids that were the smartest people I've ever met in my life, others didn't know what a letter was, and everything in between. To serve those students, I needed to be able to provide individualized education for each and every one of them.

I couldn't do it. Nobody has been able to do it. Teachers, professors, everybody struggles with this in some form or fashion. And yet we've never been able to make it work because of the economics. It would take an army of people to do that. That is changing with AI.

And then finally, as Steve talked about, as you heard from our panelists, as AI starts to transform health care education, the biggest bottleneck is going to be the talent that is not only fluent in how to use it, but can lead change. And we are out front in ensuring that our health care partners have that opportunity, and helping our students stand out by having these skills and capabilities.

So that's the opportunity. Who's going to go get it? Well, I think as you see from all of the partnerships that we've been able to secure, that one thing really stands out, our scale. We have about 100,000 students. We have the financial resources, the human resources to be able to make investments in these technologies that can power our institution and support our students. And even better, we have the unfair advantage that when we make those investments once, we can deploy them against 5 different institutions.

So our scale stands out. And I will say related to that, our ability to move fast, be market-responsive and be agile is another thing that is so important for us. And as you -- as I've mentioned, because of that, we've been able to get some industry-leading partnerships.

We know this space is moving so fast that we have to have partners in health care, in technology that can help us. And so you've probably heard about our partnership with Google, where we will be able -- where we are developing and about to roll out discipline-specific certifications co-branded by us and by Google that help teach our students how AI is impacting their discipline, be it social work, counseling, nursing, veterinary, and then be able to apply that in their workforce as they graduate and move on, giving them a real advantage over students at other institutions and, of course, making us a preferred partner for our health care providers.

Again, that's all great, but the proof is in the pudding. And as I said, this is not something that we talk about as a strategy. We already are seeing real value in terms of business value, in terms of student outcomes today in the solutions that we have been rolling out for the past few years.

So again, the way that we think about it is not -- AI is not some separate thing. It's not some program in the corner. It's not some initiative over here. It is integrated into everything we do, every step of the student journey. I'll walk you through some of the examples of that in just a minute, all leading up to students that are mastering their skills, that are successful and then have those capabilities to bring to the workforce.

But what we are doing is important, but how we are doing it, I will tell you, I think, is equally important. One of the bedrocks of our strategy is the recognition that the best ideas that, yes, we can have some great ideas from the top about how to deploy these new technologies, but many of the best ideas are going to come from our front lines: from our faculty, from our enrollment teams and from our advisers and all parts of the organization.

And so we are in a very aggressive plan to roll out, and have been doing this now for a number of months, the tools, whether it's chatbots, whether it's the ability to build agents independently, to all of our staff and providing them the training on how they can use it independently and as part of their team to support students and drive the business forward.

And then as I mentioned, because of some of the efficiencies we've been able to gain, we've been investing more and more dollars into our technical capabilities, our technical stack, so that, again, when we go build something, we have that standardized layer that we can easily move something from Walden to Chamberlain, to our medical schools, to our veterinary schools in a pretty seamless manner.

So that's how we think about it. The fun part is to kind of see how this is starting to come to life. And again, I could be here for the rest of the afternoon, I will not do that to you. But I did want to call out a few that we think are particularly exciting and illustrate the potential of what is possible here.

So one of the things that we rolled out about a year ago was an assistant for our enrollment specialists. We call it [ Wally ]. Wally is trained on all of our product program information, on our best practices, on how to engage prospects. And it is just wildly successful among our enrollment teams. They use it constantly if they get a really difficult, kind of obscure question. Our new staff love it. It helps them move up the learning curve really quickly.

And instead of telling somebody, "Hey, we'll get back to you," which is what our competitors will often have to do, we're able to keep that conversation and that momentum moving forward. And it's been something that has been even more successful than we thought and we continue to invest in.

Once we have our student, of course, the most important thing is to make sure they're successful. And you've heard, again, in our earnings calls about what we are doing in terms of predictive analytics. We have applied machine learning to understand which students will most benefit from some temporary financial help and the micro-grant program that we have that has been so successful and we continue to scale up.

But one that's a little bit more recent is, consistent with Maurice, kind of builds on what Maurice was talking about, is we have these insights into our students at an individual level and at a day-to-day, hour-to-hour level with the amount of data we have. Our bottleneck wasn't insight. Our bottleneck was the ability to literally create tens of thousands of personalized outreach to all of these students to make sure that we are supporting them how they need it and when they need it. And it was just holding us back.

But with some of the new content creation tools that are available to us, we're able to quadruple our output of those campaigns. And in fact, that's just the tip of the iceberg. We're starting to see even more.

And what's even better is the communications that we do get out, when we put our people together with these technologies, we're getting better results in terms of student engagement and student persistence. So just another area where we continue to drive forward and putting these tools into practice.

But again, the thing that we are most excited about is the opportunity to transform education. I'm old enough to remember when the online came around and what that allowed us to do in terms of expanding access. I think in the same way that Internet drove access, AI is going to drive mastery and success. You've seen study after study that show a couple of things.

One, that if you are able to individualize education, students are more successful. Full stop. There's been 100 studies on this for decades. What we're also starting to see, in fact, the study just came out the other -- a couple of -- a few days ago, which is when you are then able to pair up students, particularly struggling ones, with these technologies, they're able to close the gap, the performance gap, with other students.

So there's enormous potential. We're starting to see it with something called Coach Ally, that we use at Chamberlain that is again trained on all of our educational content, seamlessly integrated into our LMS and over half our students are using it, well over 1 million interactions. They get exactly the type of support they need in whatever language they want, by the way, at any time of day, to supplement everything that we do to support them with our tutoring and academic support resources.

And then we're also starting to see some really exciting opportunities on very life-like simulations. SimConverse is one example, where we can provide unlimited practice at any time of day using these incredibly life-like simulations.

So we're seeing it all across the journey. We're seeing the potential. We're seeing the return for us. We're seeing the return for the students. And so we are going to continue to go after this in an even bigger way. We talked about the partnerships that we had to help differentiate our students. We're also continuing to make big investments in how we power our institution and our staff and faculty.

One, of course, I talked about, is this classroom of the future. Coach Ally is early innings. Hugely powerful, but still early innings. In addition to our partnership with Google on our certificates, we are also working with them on a proof of concept to completely clean-sheet what an online digital learning experience would look like, that's either the primary way to learn or it's supplementing what is happening in real life, and turning that dream of personalized education into a reality.

It's not going to be done next month. It's not going to be done next quarter. But it is going to be something truly, truly special as we continue to push there.

Second, we talked about all of these capabilities and tools that we've delivered to our students and to our faculty, and they're having a lot of impact. But right now, there's one here, there's one there. But by building that kind of common technology platform, we are in the midst of connecting all of those. Imagine a world where a student, from the moment they're on our website researching us, get instant answers in a natural language to whatever question they want, as they progress through their program, they're getting answers on anything from billing to how to master material, all in one place and in a way that is personalized exactly to them and to their experience.

And then as I mentioned, we feel very strongly that as much as AI will power us moving forward, we also have the benefit that accreditation is not going anywhere, that the need for clinical relationships isn't going anywhere, that the jobs that we prepare people for will be augmented by AI, but not replaced by AI. And so we have a fundamental conviction that AI is not about replacing our people. It's about giving them a superpower. And so we're continuing to invest in the tools and the training that they have so that we're going to have ideas coming forward that we can't even dream of.

So thank you so much, and I will see you later in the Q&A.

[Presentation]

Please welcome Chief Financial Officer, Covista, Bob Phelan.

Good morning. As we get into the financial update, first, I wanted to share a few key points with you, things that I'll expand upon as we get further into the materials.

So first, we've got a strong track record of financial performance that gives us the confidence to deliver on our goals over the next 3 years. Second, we've got a clearly defined strategy to generate profitable growth and significant cash flow over the next 3 years. And third, we've got a balanced capital allocation philosophy that is aligned with our shareholders. So with that, let's just jump into the next phase of profitable growth.

We're going to build our next phase of growth on the foundation of operational excellence, maximizing our existing capacity while we also invest in additional capacity and health care workforce solutions. One key point about the next phase of growth is that we will continue to drive significant revenue and profit improvement while we're making these investments in long-term growth.

So let me start by going back. Several people have gone back to growth with purpose here, but that's foundational. What we've done over the past 3 years has really instilled a mindset and a discipline in the company that's going to pay dividends in the future. So we're not just jumping from one strategy to another; we're really building on a foundation as we make new strategic investments in the business. And operational excellence will remain as a core part of our DNA and a significant financial driver over the next 3 years.

So now shifting back, take a look at our top line growth over the past several years. We've grown enrollments from roughly 78,000 to over 97,000, revenue from $1.4 billion to over $1.9 billion, far exceeding the commitments that we had made at our previous Investor Day. And this was done largely with the same capacity that existed 3 years ago at our last Investor Day.

Our top line growth was driven by improved operational performance across new enrollments, persistence of our students and pricing optimization across our programs and our campuses. There's a durable demand for health care professionals. And over the past several years, we've captured more than our fair share of that demand, and we intend to continue to do this going forward.

The top line growth came with an added benefit, and that was margin expansion. So in fact, we improved EBITDA margins by 200 basis points from fiscal '23 to '25. We're on track to improve by another 100 basis points this year in fiscal '26. So 300 basis points of improvement over the course of 3-year period, bringing us to at least 26.7% margin rate this year in fiscal '26, generating over $500 million of EBITDA.

Our operating structure continues to drive margin expansion, and it will now and in the future. And while we drove the improved margins, we also improved our earnings per share over the same time, helped by reducing debt and lower shares outstanding. The combination of the revenue growth with the margin expansion, reduced interest expense, lower share count has brought us from an earnings per share of $4.21 back in fiscal '23 to now approaching $8 per share in fiscal '26.

And the improvements in profitability were very good, but it's also important to convert those profits to cash. We've done that. Our growth in cash flow mirrors what we've done from a growth in earnings. And most recently, on an LTM basis, we generated $428 million of operating cash and $368 million of free cash flow or free cash flow of about $10 per share. As I mentioned earlier, our balanced allocation of capital has resulted in us repaying $1.1 billion of debt and buying back over $900 million of shares at an average price of $54 per share.

So before I jump into our longer-term targets, I did want to reaffirm guidance for fiscal '26 for our revenue, earnings per share and for our margin growth, and we'll continue to generate strong cash flow in the back half of the year, giving us additional optionality to deploy that capital as we see fit. And just a reminder that the growth that we're experiencing in fiscal '26 in revenue, in EBITDA rate and earnings per share is on top of that very strong performance that you've seen and record levels of growth that the businesses have all talked about.

So as we're transitioning to a strategy of purpose at scale, we intend to build on a foundation of operational excellence that we've established over the past 3 years. Fiscal '27 will include a ramp-up of investments. Steve talked about new campuses, new partnerships, new technologies, everything that you just heard about, again, from all the business leaders.

As we get into fiscal '28 and '29, we'll continue to make investments, but we'll begin to see early returns on the investments we've started already and that will be made in fiscal '27. And importantly, we'll continue to generate very strong cash flow, giving us the flexibility to deploy that cash across multiple priorities at the same time, including our $750 million share repurchase authorization.

So with that strategy in mind, let's focus on enrollment for a moment. We heard the business leaders talk about drivers of enrollment growth, whether it's through Chamberlain's new campuses, new online programs, whether it's Walden's undergrad programs or Med/Vet expanding share. It's coupled with an AI-fluent graduate as well. And what it results in is significant growth across all 3 of our business segments. Getting to over 120,000 students will be very strong growth by fiscal '29, but we will also have added capacity to grow for the next horizon of years that goes beyond fiscal '29.

So we're building an infrastructure that will sustain long-term growth in a market where the demand for health care workers will continue to present opportunities for those with the foresight to invest in new capacity, new programs, new partnerships.

So moving into specific financial targets. Revenue growth in fiscal '27 will be in the range of 6% to 8%; fiscal '28, 7% to 10%; and fiscal '29 at 8% to 11%. That creates a target range of $2.35 billion to $2.53 billion for fiscal '29. And while the growth rates ramp up with the investments that we're making, it's important to note that we will only begin to utilize the new capacity that we're expanding into over the next 3 years.

Our operating model also produces leverage, generates improved margins. So we have a range of 125 basis points to 250 basis points of expansion over the course of the next 3 years. Earnings per share will grow in the low to mid-teens with growth of 9% to 13% in fiscal '27, 10% to 14% in fiscal '28 and 12% to 16% in fiscal '29. And that results in a range of $10.60 to $11.80 when you get out to fiscal '29.

As I discussed earlier, really when you stack the revenue growth with the margin expansion and add the strong cash flow model that we have in our business, plus disciplined approach to capital allocation, it creates significant EPS growth opportunities for us.

And now I'm shifting just to capital allocation. Steve has already covered our philosophy. What I'll say is we anticipate deploying capital with a balanced approach across the 4 areas that are on the page, whether it's business investments, share repurchase, debt repayment or potentially M&A. But funding the organic growth of the business is something you heard a lot about today, and that will be a priority for us.

But as I've mentioned, our cash flow profile allows us to invest across multiple areas at the same time, and we anticipate generating a substantial amount of cash. So while we invest in new campuses, new technologies, new programs, we'll have ample cash to target back to share repurchases, debt repayment and, again, potential M&A transactions. Overall, we will maintain that balanced approach to capital allocation with the goal of long-term value creation.

So as I wrap up commentary in the financial section here, there's a few key points that I want you really to take away. First is that we're focused on growth, driving our access mission at scale now and in the future. We operate in an environment with a healthy demand. Our total addressable market is substantial and it's growing. We will maintain and build on our foundation of operational excellence, continuing to drive that profit improvement over the next 3 years, while we're investing for the future beyond the next 3 years as well.

And there's far more opportunity ahead of us than behind us. This is only the beginning. Our team is focused on balancing long-term value creation while we're driving short-term proof points throughout that journey, ultimately, creating the most value for our shareholders as we go through that process.

I'm confident in our ability to achieve our goals given the foundation we've built, scalable operating model that we have and our track record for execution over the past 3 years. And now I'll turn it back over to Steve for his closing comments. Thank you.

[Presentation]

Okay. We've come to the end. We have Q&A after this. But first, I just want to thank you all for your attention and engagement today. And just want to give you a few important takeaways that I think are critical.

First, we have a compelling vision for Covista: to be systemically important to health care, to expand access to rewarding careers at a scale that's unmatched anywhere, and to be an innovative talent partner for U.S. health care, helping to solve some of these stubborn workforce challenges that you've heard so much about today.

In addition to that compelling vision, we have a credible strategy for achieving that vision with purpose at scale. And that's a strategy that comes with the benefit of operating in very, very attractive markets with fantastic secular demand trends that are durable over the long term, with differentiated brands that resonate powerfully with prospective students, with a team that is fanatical about operational excellence and believes that execution is our most important priority, with a capital allocation philosophy that is shareholder-friendly and focused on aggressive value creation over the long term, and a brand in Covista that resonates powerfully with students, with employees, with regulators and the other stakeholders who count on this business, and the economic logic, as Bob just walked through, that represents a compelling, durable ramp with multiple pathways to double-digit earnings growth. We think, taken together, that's a fantastic way to think about our business and a fantastic way for our investors to think about the journey with us going forward.

And Bob walked through all the numbers and the numbers are really fantastic, but I want you to know that each of those numbers has a person behind it. There's an individual there. It's a single mother in Oklahoma City who didn't think she could afford nursing school until SSM lowered the cost for her in partnership with us. It's the student that applied to medical school on 3 separate occasions, was denied all 3 times, but is starting at AUC as of this past January. It's a patient, perhaps somewhere here in New York, that's going to get the care they need because we graduated the right person at the right time.

That's a fantastic investment thesis as far as I'm concerned. I know you guys are tired of me saying fantastic, but it is fantastic. But it's also just a wonderful reason to get up and go to work every day. I mean we're really, really proud of what we built. We're thrilled to have you all along for the ride. And we are just super-optimistic, because for all the success we've had to date, our best work is still ahead of us.

So again, thank you for sitting through the presentation. I'm going to have the team come on up and we're going to take your questions.

Barely meaningful sort of incubation period. But where we focus our energies is on having university partnerships that we announced. We were the kind of institutions that command universal respect [indiscernible]. And we think once we do that, that will accelerate the pace of conversations as providers see some of their most admired peers in the space partner with Covista in this way.

So I can't give you an exact timeline as to when each of these partnerships will be inked and announced, but I do believe that the first few, we expect those to happen in the near term, that will accelerate the pace of conversations that we'll have across the landscape [indiscernible].

To your second question on the intersection between [indiscernible] expansion and [indiscernible] and these partnerships, as we think about we've got 3 phases of [indiscernible] as we think about those markets, each of them are markets where we believe we have attractive opportunities to partner with leading health systems in those markets. So there is a convergence in the 2 strategies that we think can be really powerful over time.

[indiscernible]

I'll start. You want to go?

Look, I think the way we think about guidance philosophically is we try to anchor on a high-integrity view of what the opportunity set for us in a given period, based on the information we have at that point.

What we do, which, depending on the day of the week [indiscernible] they love or don't love, is that once we set those goals, then the ask is go out and beat them. Right? That's the way we motivate our teams, that's the way we become accustomed to working.

And so I think what Bob laid out by way of the ramp in revenue and in profitability, we do believe that that's a credible stretched set of goals for this business even at current course and speed given all the things we're trying to accomplish. But if as we go we encounter opportunities to improve upon that, we'll absolutely do that.

But there's not an inherent conservatism baked into that. These were -- these are pretty aggressive goals in our view, just as we thought our goals 3 years ago were pretty aggressive at the time. But we want to best that wherever we can. Is that helpful? Okay.

It's Jeff Silber with BMO Capital Markets again. Thank you guys for doing this, I know how much work this takes. My first question is about the Chamberlain expansion strategy. I know in the past it's been difficult to enter new states. Can you talk about the mix between existing states and new states and what the process is like?

Yes. So look, I think the barrier to entry in nursing is pretty high everywhere. I don't think it's particularly high for us. We've done this for many, many years. We've got the largest geographic footprint in nursing. We've got lots of experience with the state boards of nursing. We've got real credibility with the Department of Education, which approves each of these programs.

So I actually think our ability to run a multistate, multi-jurisdiction, multisite model is part of our competitive moat. And so the work that has to be done to get state approval in a given location to get the clinical capacity that's necessary to keep that approval, to recruit faculty, to market to students, these are all complex activities that I think we're just more sophisticated at it than others.

And so I don't anticipate real barriers to the strategy for us. I think it may be hard for others, but this is part of the core competency of Chamberlain as an institution.

In the 4 that you're planning on ramping up, are they in existing states? Or are they new states or...

Sorry, yes. So the -- most of the states or states where we don't have a presence today. There are some states and some markets where we have presence, but we think we could support another campus, Metro Atlanta, for example, just because of the unique attributes of that market. But most of them are going to be net new. There will be a few that are in existing markets or existing states.

And my follow-up actually is for Scott. I know there's some rule changes coming on with some loan caps coming out over the summer. You guys had announced a partnership with Sallie Mae. If you can give us a little bit more color on that. And I'm just curious, are you seeing some student hesitancy because they're not -- maybe they're worried about the financial packaging in terms of enrollment coming up for this...

Yes, Jeff, thank you. So just to set the stage a little bit on Jeff's question, within OB3, there were some changes to federal government student financing. So all of the stuff we'll be talking about refers to U.S.-based students.

There were some good guys and some bad guys in that one for our -- for Med/Vet in particular, which is the highest user of graduate level loans given our formation. On the good side, for professional degrees like medical and veterinary degrees, the Stafford cap was raised from $150,000 to $200,000. That's a lifetime value, not per year. The bad guy was that Grad PLUS was eliminated starting on July 1. It's still in effect until June 30. And let me add to that, anyone who is already enrolled in a Grad PLUS eligible program will continue to have access to Grad PLUS loans.

So that's kind of the -- that's the put and take that Jeff is talking about and does significantly change the financing landscape, in particular, for medical and veterinary schools. We are in the process of still finalizing some of our relationship with Sallie Mae. I'll let Steve talk more about that. On the medical and veterinary side, they do have an already established facility that they have launched. Our students have access to those. We are marketing that actively. It is specifically dedicated to medical and veterinary students. And we will have very, very broad coverage within their underwriting guidelines.

In fact, we work very closely, Jeff, with Sallie Mae to -- in their initial development of that program. And it's favorable to our student base.

To your second question on how are applicants and students looking at it, it's kind of a mixed bag. And in some ways, it's been a little surprising to me. I think what we have really done since about October, November have been educating students on that financial pathway. They candidly haven't been that aware of it. That's what we're hearing. So we've been helping them to navigate. We do see some acceleration in students wanting to start in May. That's a real advantage that we have in both of our medical and veterinary schools, is that students can still start their education and be grandfathered in to Grad PLUS. And we have also started marketing to our students who are looking to start in September and beyond on the Sallie Mae opportunity, which they're embracing as you can well imagine.

Does that answer the Med/Vet part? Steve, I'll pass...

Let me double-click on 2 parts of that. So headline, we haven't seen any slackening in demand for the programs related to the change in the federal lending programs. None whatsoever. It hasn't shown up inquiries. It hasn't shown up in applications. So that has not proven to be an issue for us.

The Sallie Mae partnership that we've been talking about is an enterprise-level partnership. Med/Vet has had a long-standing existing partnership with Sallie Mae. So that solution is already in place and available to students now.

And the third piece is, of all of our programs, I would argue that the medical and veterinary programs are probably the least price-sensitive of all because those students have aspired to these careers, in many cases, since they were very small, right? And they also know that they're going to enjoy the kind of earnings power on the other side of that program that will allow them to comfortably service any debt they incur to go to school. And that's why the credit underwriting profile of our Med/Vet students is the most attractive profile for any lender we work with outside of the federal government. And we're using that attractiveness in Med/Vet as a basis for getting an enterprise-wide arrangement with Sallie Mae for other programs at Walden and at Chamberlain.

Jasper Bibb with Truist. Showed a lot of good stats about the number of qualified applicants for med school that get rejected. I guess how do you think about the opportunity to fill the remaining capacity in the medical schools? Is that maybe changing the geographies that you're marketing in? Is that doing more education for the qualified applicants in the U.S. that are getting rejected? And then as you scale up that capacity, what might that unlock from a margin perspective for that segment?

Steve, do you want to -- I'll...

Go for it.

So on the existing demand, you're absolutely right, it is extremely strong, as we shared with you, over 2x demand for every seat. And as Steve just noted, talking about the Sallie Mae stuff, these are professions of passion for these folks. These are long-term dreams and desires that they've had. Those aren't going away. You grew up wanting to be a doctor, you continue that.

For us in our existing schools, we do have some headroom. So we can continue to grow in our existing footprint, which is great. And we are seeing very strong growth, both in application and enrollment. So that's the good sign. We have made some operational changes recently that are accelerating that even more. So already strong demand, operational ability to capitalize on that. So within our existing footprint, still absolutely have some headroom in a demand advantaged marketplace. I'll let Steve address any question about potential expansion.

Yes. So 2 things you should know about the medical schools in particular. What you're seeing in the accelerating performance at the 2 schools is that we are going to market different in a different way. Historically, we've marketed our medical schools to anyone and everyone who would like to go to medical school, as opposed to marketing to that portion of the applicant pool that is going to be most likely to want the kind of option that we're providing. So that's the first difference.

The second difference is that we had marketed them fairly generically, without focusing on the unique attributes that exist at the 2 medical schools. And so like the AUC ad that you saw earlier today, we're now marketing these institutions on the unique attributes they have that distinguish them from other schools and that appeal to the right profile of student. And that's why we've got real confidence in what the enrollment ramp looks like over time at the 2 medical schools.

As Scott said, a ton of headroom and capacity to exploit there, and we absolutely intend to do that. But we believe that even beyond that capacity, there may be opportunities for us to further extend the medical education franchise since it is such a financially attractive model, and it brings with it some really, really powerful brand attributes for the enterprise. So obviously, utilizing the existing capacity is a higher return proposition than going out and getting new capacity, but we believe we will do that at a sufficiently steady clip that we can do both. So utilize what we have in the 2 schools today, even as we look for additional capacity to take advantage of that incredibly large market of students that don't have a home for med school.

And then maybe one on Walden. You mentioned the ambitions to grow the undergraduate business. Can you just talk about what that's going to look like from a program mix perspective? What's been growing fastest so far? And I guess, where you think you're most differentiated versus the other online competitors?

Yes. So first of all, I just want to make it clear one more time, we are always going to be a predominantly graduate institution. We are growing our graduate programs. We have a ton of headroom there. We just think that there is an additional opportunity on undergraduate. All of our brand equity, all of our operations, we've been able to seamlessly, with almost no incremental investment, double the number of undergrads. And so we're going to continue to go through that -- down that path in an even bigger way with a great new campaign kicking off for undergraduate in a couple of months.

But to your question about program mix, in some ways, it's very similar to what we have in the graduate, in some ways different. So the advantage we have is we're very strong in the social and behavioral sciences at the undergrad level. Psychology, we have very attractive programs to go straight from your bachelor's into your licensed masters programs that perform very well.

I talked about education. That has been a pleasant surprise for us. You know that's kind of -- that's been traditionally a little cyclical. That's really coming back strong for us, seeing very strong growth in education. And then yes, we're doing a lot on the business front there. But on the business front, we are very focused on not generic business degrees, but highly specialized concentrations that line up directly to areas where there are strong growth in jobs. And so you put those together, the business programs that we have, the specialized, basic programs, the health care-related ones, and we got a strong package from a program offering.

But what I will tell you differentiates is that focus on career preparation, planning and placement. This -- for too long, we've talked about that in this space and not delivered on it. And we completely clean-sheeted everything that we do to integrate career success at every step of the journey. And the early results that we are seeing, not in just in terms of persistence, but in terms of career and social mobility, are really impressive. It's the right thing for our students, but also I think that's going to really separate us from the crowd.

Perfect. So I'm going to ask some questions coming on through online to you guys.

So Steve, you talked about the physical investments at Chamberlain. How should we think about that flowing through from an earnings per share perspective? And is it factored in the 10% to 14% growth projections you guys gave today?

Is the campus expansion -- yes, it is. The campus expansion is built into the go-forward forecast.

Your earlier question was about earnings?

Yes. Is the campus expansion factored into the earnings? How does that impact your profile going forward?

Bob, do you want to start and I'll pick it up?

Yes. So I mean, answering the question, it is factored into the guidance, the earnings guidance that we've provided. We will provide some separate information on that so that you understand what the investments are that we're making over the next couple of years so that you can understand both the underlying margin profitability that we've got on the Chamberlain side as well as what it looks like with those investments.

Having said that, it does take a little while to ramp. So we will be separating that out. It will ramp up over time. But as Steve mentioned earlier, you get to an EBITDA profit 2 years after you start to teach. So it's a pretty quick turn. But again, all those investments are included in what we have in terms of guidance right now.

Yes. So we believe we can execute a step-change growth in Chamberlain without diluting earnings at the enterprise level, right, because of the power of the balance of the portfolio. There will obviously be some impact on Chamberlain's P&L, and Bob mentioned the way we'll talk about that. But on an enterprise level, we can still deliver the kind of attractive earnings growth even as we invest in what we think is going to be a powerful accelerant for Chamberlain's leadership in the marketplace.

And I would just add one last part to this, is that we've been investing a bit this year already. So it's not that we're just going to start in fiscal '27. Steve mentioned, there's things in progress already. So we've got investments that we're making that are already a part of what you're seeing in our margin profile. And overall, again, we're growing those margins by 100 basis points this year.

And not that we need another incentive to outperform, but because of the durable operating leverage in the model, the better we can do in driving that top line revenue, the more flexibility we have to fund these sort of investments while still expanding margins and growing the earnings profile of the business. So it's a fantastic -- once again, fantastic economic model to run.

Perfect. I'll pause, if anyone else in the room before I ask another online one?

I'm [ Patrick Connor ] with [ Sand River ]. I just had a follow-up on the student financial loan situation and just whether the situation at Walden is different than Med/Vet, and how lending to a Walden student is different than Med/Vet? And then on just the arrangement with Sallie Mae, how you guys kind of envision that going and how the arrangement with Sallie Mae might be different than with the government previously in terms of risk sharing and credit and that kind of thing?

You want to start? Yes. So let me start by saying, while historically, we have had students that have taken advantage of Grad PLUS, we don't see it impacting us going forward. And if we get something -- when we get something with Sallie Mae, it will be helpful.

But the reason why we're not worried about it going forward is 2 reasons. One, a lot of times, the dollars that were getting -- they were getting there were for refunds. And so yes, I have students that might be less refunds, but it doesn't impact their ability to pay for their degrees. So if you look degree by degree and you look at the limits, I think every one of our programs come in below the limits going forward without a need for Grad PLUS dollars.

The other thing is why we're in a much better position is with all of the improvements we've made on doctoral, that is where a lot of our Grad PLUS dollars were, but we have improved our -- the speed through that program. We have put on tuition caps on just about every one of those programs. And so while historically, there were some students that took advantage of that going forward and even over the last couple of years, it's just not going to be needed for our doctoral students.

Yes. A little bit on the fact, I was a graduate assistant in the Office of Student Financial Aid at Indiana University when I was in law school. One of the reasons this administration wanted to eliminate the Grad PLUS program is because it is primarily used to borrow amounts above and beyond the cost of attendance and the proceeds are often used for purposes that aren't directly related to the academic journey, and then that's debt that the student has to deal with after graduation.

So I'm not going to comment on whether it's good policy or bad policy, but there is a rationale for eliminating the program. We saw that when I was in financial aid in Indiana. As Michael said, he probably mentioned affordability of programs more than anyone else today. Walden is laser-focused on that, and we believe that our program mix is such that folks will be able to finance it through available private or federal loans without a problem.

As it relates to Sallie Mae, what I would tell you is that students as a general matter, won't see a tremendous difference in the private loans versus the federal loans with one exception. These are commercial lenders. And when it comes to the repayment of these loans, they're going to take a commercial approach to that. And rightly or wrongly, there's lots of views that the federal programs did not take that approach on the back end and created something of a moral hazard for students to borrow more than they needed to borrow.

But again, we don't anticipate any headwind in either demand for our programs at Walden or persistence through those programs at Walden in connection with these loan programs. And actually, I don't think many of our peers anticipate any headwind either, but I can speak for us and say we feel good about it.

Perfect. All right. Steve, I'm going to go back online real quick. We're going to go into capital allocation. So really a 2-part question here. First and foremost, you mentioned some M&A today. You also mentioned some share repurchases potentially. What is factored in going forward? So both like what's your focus on M&A? And then, Bob, maybe for you on a share repurchase perspective, is that factored into your financials?

Yes. I mean I'll start off and say, first off, that we have no M&A factored into the projections that we provided. So M&A is not included in that. That would be something that would be in addition to what we've got at this point. From a share repurchase perspective, we pulled in everything in terms of what we've done in the second quarter. For all of you saw that, we had a significant repurchase during the second quarter. And then we've also modeled in some level of normalized, I'd call it, share repurchases throughout the balance of the 3-year period.

The other thing I'll say about M&A, the reason we wouldn't bake that into a 3-year forecast is twofold. First, it's entirely dependent on the opportunity set, which we don't fully control. But secondly, unlike some of our peers in the space, we don't have to do anything.

The portfolio we have today is fit for purpose in our view. We will get opportunities to look at things just because of our scale and our performance. But we can be discerning buyers. We don't need to commit any unnatural acts or overpay for assets unnecessarily. We can be thoughtful and prudent and ensure that if we do something inorganic, we do it at a price that's attractive to our owners and in a way that we think meaningfully and thoughtfully augments the portfolio.

Okay. One last one unless...

Jack Slevin from Jefferies. Just to throw one more in here. I think the 39% number stood out to me in terms of students in MSN or doctors' programs at Chamberlain that were previous BSN students. You also talked about an emphasis on winning in BSN, right? So I guess the operative question for me is, how long does that take to pull through? And does winning in BSN mean future winning in some of the, I'll say, less growthy areas in the portfolio for Chamberlain presently?

Yes, it's a great question. So if you ever come to a Chamberlain graduation, they do this thing at every graduation, where they say, "Stand up if your first degree from Chamberlain." And "Stand up if this is your second degree from Chamberlain." And then, "Stand up if this is your second degree from Chamberlain." It's always astonishing how many folks are there for their third credential.

Growing BSN at Chamberlain creates a community of alumni that are going to look to Chamberlain first for that next credential and which is fantastic. So that bodes well for post-licensure programs down the road. And if they don't look to Chamberlain, we hope they look to Walden, because it's a fantastic post-licensure nursing program as well.

So I would expect that 39% of our post-licensure students being alumni to go up over time as we grow pre-licensure nursing consistent with our strategy.

All right, Steve, I'll do maybe one last one here. You guys chatted about AI today. Obviously, it's a topic de jure. What gives your business a durable moat against the AI disruption? We hear about you talking about deploying AI technology. But can you kind of go into the durable moat that your business has against AI?

Yes. Look, I don't -- Michael is the expert, so I will get out of his way in a moment. I don't think we've seen any evidence that generative AI is going to disintermediate education, particularly clinical education. We just don't see that happening. I'd hate to be a content business right now, that's a tough place to be. But in a clinical instructional business, I don't see any real disintermediation risk.

I see a ton of augmentation opportunity, though. And this idea, we sat with Google in Chicago a month ago at this point, and I sort of waxed on about the idea of giving a new student that comes into our program a wearable that's an agent, that follows them through the entirety of their program, listens to all their lectures, monitor how they're interacting with content on the LMS, knows the questions they're asking their professors, has some anonymized data of what else is happening in the class. I just think we could power so many more students successfully through that model than we do today. And that bodes well for our ability to continue to scale in a way that expands access at just enormous proportions.

Yes. No, look, I'll be honest, I wouldn't want to be a nondegree granting institution, because I do think there is real disruption that's possible there. But it is a categorically different story for accredited degree-granting programs, particularly in clinical fields. And I say that for a couple of reasons.

Trust me, we know the challenges to get accredited. They are significant. They are multiyear. And they are -- and accreditations, we don't see going anywhere anytime soon. Second, the clinical -- because we are clinically focused, the networks we've built to provide field placements, you're always going to need that going forward.

And then the jobs that we're preparing people for, you've all seen the recent labor reports, right, where health care is powering the entire labor market. And these are not jobs. We are not going to, Elon-Musk-withstanding, have the robot nurses and doctors anytime soon. So we feel really protected both in terms of kind of the regulatory moat, the facility moat we have, where we're preparing students to move into.

And as Steve said, of all the different things where we have a huge upside from it, I think the biggest thing is that what we're seeing is the power to support that nontraditional student. And that's exactly who we serve. And by being able to do that even more at scale, that is just going to further create our ability to deliver more opportunity and bring more talent into the health care workforce.

And just to double-click on the accreditation point. During the pandemic, we had to take every program online, including the medical schools. And we had great success in the basic sciences programs, teaching medical students in that modality. In addition, because it was an online modality, we got a ton of data on how students engage with the content. When the pandemic was over, lots of medical schools asked, could we do more of this basic instruction online? And the answer was, "Absolutely not. We're doctors, we don't learn that way."

So that is a real barrier to how some of these innovations show up. And again, to Michael's point, augmentation, but not substitution.

All right. Thank you. We've got lunch for you, if you're hungry. Management is available to chat if you're interested. But thank you so much for being with us today. We really, really appreciate it.

Greetings, and welcome to the Adtelem Global Education Second Quarter 2026 Earnings. [Operator Instructions]. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Jay Spitzer, VP of IR. Thank you, Jay. You may begin.

Good afternoon, and welcome to our earnings call for the second quarter fiscal year 2026 results. On the call with me today are Steve Beard, Chairman and Chief Executive Officer of Adtalem Global Education; and Bob Fallon, Chief Financial Officer. Before I hand you over to Steve, I will as usual take you through legal safe harbor and cautionary declarations. Certain statements and projections of future results made in this presentation constitute as forward-looking statements that are based on current market, competitive and regulatory expectations and are subject to risks and uncertainties that could cause actual results to vary materially.

We undertake no obligation to update publicly any forward-looking statement after this presentation, whether a result of new information, future events, changes in assumptions or otherwise. Please hear latest Form 10-K and Form 10-Q for discussions of risk factors as it relate to forward-looking statements. In today's presentation, we have certain non-GAAP financial measures, and we refer you to the appendix of the presentation materials available on our Investor Relations website for reconciliations to the most directly comparable GAAP financial measures and related information.

You will find a link to the webcast on our Investor Relations website at investors.adtalem.com. After this call, the presentation and webcast will be archived on the website for 30 days. I will now hand you over to Steve.

Thanks, Jay. Good afternoon, everyone, and thank you for joining us. This quarter marks our tenth consecutive quarter of enrollment growth. We remain on track to achieve our full year revenue guidance of 6% to 8.5% growth and we're raising our adjusted earnings per share guidance to 17% to 20% growth. As we enter 2026, we continue to execute against our strategic road map. Our strong second quarter results reflect that execution. The momentum we've built over the last several years is proving sustainable demonstrating the power of our differentiated business model.

Our consistent performance, strong balance sheet and robust cash generation, power of value-creating capital allocation philosophy. This quarter, we deployed $165 million to share repurchases, and we have approximately $728 million remaining on our current authorization. We'll continue to take a disciplined, returns-focused approach to capital allocation. Our focus on students and investments in modern, innovative learning continue to yield strong academic, operational and financial outcomes. Walden has achieved record total enrollment. More than 52,000 students now generate industry-leading scale and operating leverage. Chamberlain expanded its reach as the national leader in nursing growing enrollment by 6,000 students in just 3 years to reach a record of 40,000 students. Ross Vet continues to graduate more veterinarians than any other school -- and AUC and Ross Med together graduate twice as many physicians as any MD granting school in the United States.

Simply put, we've established the quality and scale to be a trusted leader in health care talent development, and in a central component in tackling America's health care workforce shortage. Now let me zoom out. We all read the headlines. The health care workforce crisis isn't easing. It's intensifying. America's health care system begins 2026 substantially understaffed with workforce gaps expected to deepen. The challenge is everywhere, but is particularly acute in rural communities and underserved urban areas where continuity of care and access are already fragile.

The stakes for the entire health care system couldn't be higher. Tackling a crisis of this magnitude requires workforce infrastructure that operates at a different scale than traditional academic institutions. And that's precisely where our opportunity lies. At our Investor Day on February 24, we'll lay out our multiyear growth framework, including capacity expansion plans and new revenue streams that position us to meet these societal needs while delivering sustainable earnings growth. Now let me walk through our second quarter performance. Total enrollment grew over 6% to 97,000 students. Revenue grew 12% to $503 million.

We delivered further efficiencies as adjusted EBITDA grew to $155 million. Our solid profitability, together with disciplined capital allocation, has yielded adjusted earnings per share of $2.43, an increase of 34% versus last year. Growth with purpose remains our durable operational framework, yielding clear academic, operational and financial returns. Our strategy to optimize existing capacity has yielded record or near record enrollments at Walden and Chamberlain and has positioned the Med Vet segment for sustainable growth.

More importantly, we believe the success of growth with purpose has earned us the permission to expand our leading position and invest in solutions that address U.S. health care workforce shortages, while sustainably growing earnings for years to come. With that context, let me turn to our segment results. At Chamberlain, we're confident in our trajectory. Q3 total enrollment will remain soft as recent improvements work their way through the student journey but the real proof point is the fall enrollment cycle. Let me explain why we like what we're seeing. Chamberlain's fundamentals remain exceptionally strong. Over the past 2 years, Chamberlain added 5,600 new students and grew revenue by $155 million, a 27% increase.

We had record enrollment 9 months ago. This quarter's negative 1% total enrollment and the relatively flat growth we expect over the balance of the year represents a temporary pause in that trajectory, not a reversal of it. Over the last 3 years, we successfully launched new campuses in Atlanta and Kansas City. We relocated our Phoenix campus, and we built our national online BSN program to more than 4,200 students across 38 states in just 4 years.

Together, these moves have maintained or grown our market-leading positions. We're #1 in BSN, #3 in RNBSN, #1 in Masters and #1 in the doctoral category. This is a testament to the performance and scale foundation that sets Chamberlain apart. Last quarter, I identified 2 execution gaps, marketing effectiveness and enrollment funnel conversion. We moved swiftly to address both and early indications are encouraging.

Application volumes for both pre-licensure and post-licensure nursing programs are up double digits during the second quarter, running ahead of where we were at this point last year. On marketing, we optimize spend and we improved our website. We streamlined scholarship offerings so students can research programs with a clear picture of net cost of attendance. And our focus on a more seamless prospective student experience has increased funnel conversion. We're moving forward with precision and operational accountability.

But here's what matters. We expect this application momentum will translate into new enrollment growth and position us well heading into the critical fall cycle. At Walden, we delivered our tenth consecutive quarter of enrollment growth, up 13% in the second quarter. As a result, we achieved record total enrollments of 52,400 students. Similar to prior quarters, Walden's digital learning platform and flexible offerings continue to demonstrate strength as we innovate and deliver an increasingly seamless experience for working adults.

Building on this momentum, we launched several new programs heading into this academic year. Programs such as the master and applied behavioral analysis and the Masters degree in clinical psychology are attracting working professionals who want to make meaningful societal contributions. Overall, our new programs have already enrolled more than 1,200 students in less than 1 year with additional programs in the development pipeline that we expect to roll out soon. Last quarter, I highlighted that we streamlined our professional doctoral programs, creating a more seamless student experience with a simplified tuition structure.

Building on that, we recently launched the Walden University PhD completion program designed for doctoral students who left their original program before finishing their dissitation. We're now providing a channel for them to reach the finish line and earn their degree with us. These enhancements showcase our commitment to drive meaningful impact for thousands of students. Turning to our medical and veterinary segment. The second quarter isn't an enrollment period, but we're seeing momentum in leading enrollment indicators. At our medical schools, we're executing on 2 fronts creating innovative pathways that expand access and remove barriers to the MD program and driving operational excellence in our enrollment funnel.

This sets us on a sustainable trajectory of enrollment growth leveraging technology and artificial intelligence in our basic sciences curriculum enables a higher precision learning environment. Combined with our Capstone program, this has yielded enhanced student outcomes through increases to our USMLE Step 1 pass rates. Ross Pet continues to operate at near capacity, maintaining its position as a leader in veterinary education with a one-of-a-kind experiential learning model and Ross Vet has also increased its naval pass rate.

In closing, let me come back to where I began. As America's largest health care educator, we're uniquely well positioned to address substantial and growing health care workforce shortages at scale. Our combination of program breadth, geographic reach and proven outcomes is unparalleled. Finally, I want to acknowledge the unwavering commitment of our 10,000 colleagues, 97,000 students, and 385,000 alumni. They make all of this possible. And with that, I'll turn the call over to Bob Falun, our CFO.

Thank you, Steve, and hello, everyone. Halfway through fiscal year 2026, we are executing against our growth with purpose strategy, putting us on track to meet our full year financial goals. Importantly, we continue to enhance our financial foundation and increase our level of profitability by generating efficiencies through scale and operational excellence. This, in turn, is delivering significant cash flow and a more flexible balance sheet. Our robust financial performance is also allowing us to deploy capital in a balanced fashion, whether through share repurchases, debt repayment or through investments in high ROI additional growth opportunities, including bringing new capacity to market and providing innovative student-facing technology.

Taken together, we continue to build strategic momentum that supports long-term value creation. I'll now review the financial results and key drivers for our second quarter performance. Later in my remarks, I'll discuss our expectations and assumptions for the remainder of fiscal year 2026. Starting with the top line. Revenue in the second quarter increased by 12.4% to $503.4 million, driven by all 3 segments.

Walden continues to be a source of strength and in particular, was aided by a 1-week economic calendar shift from the third quarter into the second quarter of this fiscal year, resulting in an incremental $18 million in revenue recognized in Q2 rather than in Q3. Excluding the 1-week shift, revenue was up 8.4% versus last year for ad talent.

Consolidated adjusted EBITDA came in at $154.9 million, up 23.9% compared to the prior year. This growth was led by Walden, which again includes the incremental week with Med Vet contributing partially offset by Chamberlain. Adjusted EBITDA margin of 30.8% expanded 290 basis points from last year.

Excluding the incremental 1 week Consolidated adjusted EBITDA margin was up 30 basis points year-over-year. Adjusted operating income was $126.1 million, up 24.3% compared to the prior year as revenue growth and efficiencies generated operational leverage, which was partially offset by investments in our strategic growth initiatives.

We continue to balance our strategic growth investments with a more efficient, integrated and scaled operational foundation. Adjusted net income for the quarter was $87.9 million, up 26.7% compared to last year, attributed to adjusted operating income growth, lower interest expense resulting from our actions to reduce outstanding debt and our borrowing costs and partially offset by a higher provision for income taxes. Adjusted earnings per share was $2.43 or a 34.3% increase compared with the prior year. We repurchased 1.7 million shares of our common stock at an average price of $95 within the quarter resulting in an average diluted shares outstanding of $36.2 million or approximately $2.2 million lower than last year.

This completed our prior $150 million authorization and we subsequently announced a new $750 million board authorization through December 2028, which has $728 million available as of December 31. Our strong operational and financial discipline, coupled with our high cash conversion rate, resulted in a trailing 12 months operating cash flow generation of $428 million, up $146 million from the comparable year-over-year last 12-month period.

Our strong cash flow and healthy balance sheet is affording us the ability to deploy capital to invest in the long-term profitable growth of our business as well as returning capital back to our owners. We believe these actions have and will continue to increase long-term intrinsic value for the benefit of our shareholders.

Next, I'll discuss the second quarter financial highlights by segment. Chamberlain reported second quarter revenue of $183.8 million, an increase of 1.6% compared with the prior year, driven by pricing optimization. Total student enrollment during the quarter declined by 1% as growth in pre-licensure programs was offset by declines in post-licensure programs. Our pre-licensure BSN programs have grown for 14 consecutive quarters as investments to grow our BSN online offering are yielding promising returns. Post-licensure nursing was lower from declines in the RN to BSN program, partially offset by growth in our master's programs.

As Steve noted, Chamberlain applications during the quarter improved significantly an encouraging trend that we expect to position us well for future enrollment. Adjusted EBITDA for Chamberlain decreased by 14% to $45.2 million for the quarter, adjusted EBITDA margin of 24.6% was lower compared to the prior year as we make investments focusing on bringing new capacity to market and continue to invest in our students, to support enrollment growth and academic outcomes.

Turning to Walden. Second quarter revenue of $217.6 million, an increase of 27% versus the prior year was driven primarily by strong growth in enrollments, aided by the aforementioned 1 additional week of revenue during the second quarter. Excluding the additional $18 million from the 1-week shift, Walden revenue was up 16.5% versus last year. Total student enrollment was up 13% compared to the prior year, the tenth consecutive quarter of growth. This was driven by robust enrollment growth across all degree levels, particularly in masters and undergraduate and continued high persistence rates. Growth in our health care programs was led by both social and behavioral health and nursing. Our non-health care programs also grew in the quarter. Adjusted EBITDA increased by 66.5% to $86.7 million. Adjusted EBITDA margin expanded by 940 basis points versus the prior year to 39.8%. Excluding the 1-week revenue shift, Waldman's adjusted EBITDA margin expanded approximately 400 basis points as our operational excellence generated efficiencies and leverage that outpaced increased brand and student-facing digital investments, and additional student support commensurate with the high level of new enrollment. For the medical and veterinary segment, second quarter revenue was $102 million, an increase of 6.9% versus prior year.

As Steve mentioned, there is no change in the student enrollment for the second quarter compared with the first quarter, given term starts. Adjusted EBITDA increased by 17.6% versus the prior year to $31.4 million. Adjusted EBITDA margin increased 280 basis points versus the prior year to 30.8% as we remain focused on operating our institutions efficiently while making long-term growth investments that leverage our existing capacity, creating new enrollment pathways and delivering academic outcomes.

Based on the year-to-date performance and our expectations for the balance of the year, we are maintaining our annual revenue guidance as we continue to grow our business on top of strong enrollment levels. Revenue is expected in the range of $1.9 billion to $1.94 billion, or approximately 6% to 8.5% growth year-over-year. As I mentioned earlier in my remarks, we had a 1-week shift in the academic calendar, resulting in Walden, recording 1 additional week of revenue in the second quarter and 1 less week in the third quarter. The $18 million shift between the quarters benefited the second quarter, while it will reduce the third quarter, but overall has no net impact on our annual performance.

In addition, the revenue guidance also continues to reflect our prior comments related to enrollment and revenue growth being higher in the first half of the year as we lap double-digit comps from last year particularly the strong comps from last third quarter. Our reiterated revenue guidance contemplates Chamberlain's top line impact and while operational improvements are resulting in application volumes growing year-over-year in the second quarter at Chamberlain, the financial impact is not immediate, but we do expect application growth to translate to future quarters new enrollment growth.

And finally, strength in Walden's top line is anticipated to continue to deliver robust growth. We are raising our adjusted EPS guidance from the previous range of $7.60 to $7.90, or growth of 14% to 18.5% to a range of $7.80 to $8 or growth of 17% to 20%. At the midpoint, our adjusted EPS range is increasing by $0.15. The increase in adjusted EPS guidance contemplates our continued commitment to expanding our fiscal year 2026 adjusted EBITDA margin by approximately 100 basis points.

We expect quarter-to-quarter margins will fluctuate with a higher level of targeted investments being made in the third quarter and less investment in the fourth quarter. Further, the 1-week Walden revenue shift into the second quarter will have a pronounced impact on our third quarter margin profile. The raised adjusted EPS guidance also incorporates our capital allocation actions and continued strong cash flow generation and we continue to anticipate an effective tax rate to be higher than fiscal year 2025. Overall, we will continue to execute on expanding access and delivering positive student outcomes deploying capital to meet the health care education market's growing demand, maximizing long-term value and ultimately generating high returns for all stakeholders.

As Steve noted, I look forward to discussing our longer-term targets at our upcoming Investor Day. And with that, I'll now turn the call over to the operator for Q&A.

Thank you. We will now be conducting a question-and-answer session. [Operator Instructions]. Our first question comes from the line of Jeff Seibert with BMO Capital Markets.

I'm actually going to start with Walt and I'll let some other folks focus on Chamberlain. Even excluding the calendar shift, the Walden numbers continue to impress, can we just double-click on that? What exactly is going on? Where are you seeing the growth? Do you think you're taking share from other schools in this market?

Yes. So the Walden growth is consistent across the board, but we see it most pronounced in the areas that we've consistently been most excited about. That's in the behavioral sciences programs and also in the nursing program and the MSN credential. To a lesser extent, we're seeing great returns on our investments in the education programs at Walden. .

And as we increasingly look to expand that institution's presence and undergraduate enrollments, we're having great traction there as well. So really pleased with the balanced growth across the program mix at Walden.

Okay. and then maybe shifting to 1 of the regulatory issues. We're expecting some changes in the loan caps this July. I know you had announced an earlier partnership with Salt. Can we get an update in terms of what's going on there?

Yes. We're working with Sallie Mae on definitive documentation for that partnership. Sallie Mae has also been working to pull together the syndicate of capital sources that will actually provide the loan dollars. But we continue to be excited about that partnership and what it means for the entire portfolio, including the medical and veterinary segment where obviously we expect to have to utilize supplemental lending sources the most.

So more to come on that, but we continue to move at pace with them, and we'll be excited to announce definitive documentation once it's complete.

Our next question comes from the line of Jack Stephens with Sebree.

I am going to decide to dig in on chamber a little bit a bit. So if we just look at a really encouraging sign on the double-digit growth, I guess the immediate question becomes sort of if you could remind us of what that typical lead time is, and I'm hearing the emphasis in the fall cycle, but maybe just walking through a little more detail on sort of what exactly is going right as you're -- you've enacted some of those changes you called out last quarter? And then whether or not that sort of lags through the second half and then see the rebound or sort of an inflection around the fall cycle tracks to what you typically would expect.

Yes, happy to speak to it. As we said before, we identified a couple of gaps, marketing effectiveness and enrollment funnel conversion. We took a number of steps to address processes on both dimensions. And as you'll note, we also took a number of steps to make changes in personnel across the Camlin organization. .

We feel really good about the implications of those moves. As I said in the prepared remarks, some of the leading indicators of enrollment have been really positive. Application volumes up for both pre-licensure and post-licensure nursing programs. You have to remember that fall cycle is the biggest cycle of the Chamberlain fiscal year, and it creates a big hole to dig out of. But we are confident in the trajectory of the recovery.

So while we expect -- the total enrollment story on a quarter-over-quarter basis to be flat over the balance of the fiscal year, we do expect as we approach that fall enrollment cycle to be in a position to go back to positive total enrollment year-over-year and get back to a total enrollment trajectory consistent with what we've enjoyed in the last few cycles.

So we think we have the situation well in hand. We feel good about the early signals we're seeing and we're confident that we exit the fiscal year moving towards a positive total enrollment growth in Chamberlain with the benefit of a robust trajectory in pre-licensure and a return to form in post-licensure nursing.

Got it. Okay. Really helpful, Steve. And 1 more for me here. I guess, running some quick numbers. The last few years, you've seen roughly $60 million of improvement in revenues second half versus first half, the timing of that 1 week impact. But even adjusting for that, it looks like the high end of the guide at about $45 million. I guess I'd just be curious to sort of describe what the scenario would play out that would see you sort of meet or exceed the high end of that guide? Is it simply Chamberlin coming in a little ahead or really where you could envision that upside potentially coming from if it were to materialize?

Yes, I think it would come from a quicker-than-anticipated return to form at Chamberlain and potentially some additional acceleration in the trajectory of the Med bed segment. We think we're moving at sort of an optimal clip at Walden, and so it would come from the other 2 segments. .

Okay. Got it. Super helpful. Can you rats again on the quarter and looking forward to seeing you at Investor Day.

Thank you. I appreciate it.

Thank you. There are no further questions at this time. I'd like to pass the call back over to Steve for any closing remarks.

Yes, I want to do 2 things. First, thank all of our colleagues across the ad talent portfolio for all of their incredible work over the course of the last quarter. We've come back from the break in the calendar year to hit the ground running aggressively. I also just want to put out a plug for our upcoming Investor Day on February 24. We've got a lot of news that we're prepared to share. We're really excited about it, and we look forward to having you all participate virtually or in person -- thank you so much. .

Thank you. This concludes today's teleconference. You may disconnect your lines at this time. Thank you for your participation.

Greetings, and welcome to the Adtalem Global Education First Quarter 2026 Earnings. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Jay Spitzer, VP of Investor Relations. Thank you, Jay. You may begin.

Good afternoon, and welcome to our earnings call for the first quarter fiscal year 2026 results. On the call with me today are Stephen Beard, Chairman and Chief Executive Officer of Adtalem Global Education; and Bob Phelan, Chief Financial Officer.

Before I hand you over to Steve, I will, as usual, take you through the legal safe harbor and cautionary declarations. Certain statements and projections of future results made in this presentation constitute as forward-looking statements that are based on current market, competitive and regulatory expectations and are subject to risks and uncertainties that could cause actual results to vary materially.

We undertake no obligation to update publicly any forward-looking statement after this presentation whether a result of new information, future events, changes in assumptions or otherwise. Please see our latest Form 10-K, Form 10-Q for a discussion of risk factors that relate to forward-looking statements. In today's presentation, we use certain non-GAAP financial measures. We refer you to the appendix in the presentation material available on our Investor Relations website for reconciliations to the most directly comparable GAAP financial measures and related information.

You will find a link to the webcast on our Investor Relations website at investors.adtalem.com. After this call, the presentation will be webcasted and archived on the website for 30 days. I will now hand you over to Steve.

Thanks, Jay, and good afternoon, everyone. Thanks for joining us today. We delivered an outstanding start to fiscal year 2026. This marks our ninth consecutive quarter of enrollment growth. Total enrollment is up 8% year-over-year to 97,000 students. Revenue grew nearly 11% to $462 million, and we expanded our adjusted EBITDA margins by 100 basis points while delivering adjusted earnings per share of $1.75. That's growth of nearly 36% year-over-year.

This performance demonstrates the power of our growth of purpose strategy and the operational excellence we've embedded across the enterprise. Walden grew enrollment for the ninth straight quarter and achieved record total enrollment. Our Medical and Veterinary segment posted its third consecutive enrollment cycle of growth. Chamberlain grew enrollment for the 11th straight quarter, and we're continuing to generate strong free cash flow while maintaining attractively low net leverage.

Before I dive into the quarter, let me place our performance in the context of what's happening in health care. The health care workforce crisis continues to intensify. It's being driven by our aging population and accelerating retirements among practicing clinicians. This challenge is particularly acute in rural settings where nursing shortages alone are projected to triple by 2027 according to the National Center for Health Workforce Analysis. The shortage spans the entire health care workforce from physicians to technicians and represents a defining characteristic of health care for the foreseeable future.

The industry is working to accelerate modernization through AI to augment practitioner efficiency, but these innovations don't solve the structural workforce challenge, and that's precisely where our opportunity lies. As the largest provider of health care-focused education in the country, we're well positioned to play a vital role as essential talent infrastructure. That opportunity has never been clearer or more compelling.

Now, let me address Chamberlain's performance in the quarter directly. Chamberlain grew total enrollment by just over 2% in the first quarter to nearly 40,000 students, but that growth fell short of our standards. The primary driver was execution failures within our marketing and enrollment operations. We've completed a rigorous diagnostic, so let me be specific about what we found.

First, we underperformed in local marketing effectiveness during our critical September intake cycle. Our local market campaigns didn't resonate as effectively as they could have in key metropolitan areas. And we failed to optimize our marketing mix quickly enough when we saw early warning signs.

Second, we failed to convert inquiry volume at historical rates. Our enrollment funnel conversion rates fell below our benchmarks, which means we generated strong interest, but didn't close enrollments efficiently. That's an operational issue, and it's fixable. To be clear, this quarter's variance is driven by execution. The fundamentals of our Chamberlain platform remain attractively robust.

Nursing demand has never been stronger. Chamberlain has a powerful brand that resonates with students and employers, significant capacity, a full breadth of nursing programs across multiple modalities. We have everything we need to serve this market effectively. We simply need to execute better at converting that demand into enrollment. Put another way, we're execution constrained, but not capacity constrained. So we've taken decisive action to strengthen performance.

First, we've made operational improvements to our marketing mix with enhanced local market focus. We're reallocating resources to the channels and geography that drive the highest quality enrollments, and we're moving faster to optimize underperforming campaigns. Second, we streamlined our enrollment processes to reduce friction in the student journey. Every unnecessary step in our enrollment funnel is an opportunity to lose a student. So we're eliminating those barriers. Third, we've made key leadership changes at Chamberlain.

Following the recently announced retirement of our current President, we're conducting a national search for Chamberlain's next leader. We've also restructured the senior leadership team to accelerate decision-making and sharpen accountability. These changes reflect our commitment to accountability. When we don't execute to our standards, we address it decisively.

Looking ahead, we anticipate continued softness in post-licensure enrollment through the second and third quarters as we implement these changes. That's a realistic assessment based on enrollment cycle dynamics and the time required for our operational improvements to gain traction. However, we expect to return to stronger new enrollment in the back half of the year. We're already seeing early positive signals from our adjusted marketing approach and our restructured leadership team is moving with urgency and precision. To be clear, we believe this is fixable. We're leaning in to correct it with speed and discipline.

And most importantly, this doesn't change our conviction in Chamberlain's long-term trajectory, its strength as a brand or our full year guidance as an enterprise. I also don't want to focus on this quarter's challenge to obscure Chamberlain's fundamental strengths and strategic progress. Our pre-licensure BSN programs continue robust enrollment. In just its fourth year, our online offering added nearly 750 students sequentially, now serving over 4,000 students in aggregate.

Our second Atlanta campus in Stockbridge, which opened just 2 years ago, now has 600 students and our 24th location in Kansas City is now enrolling its first cohort starting this January. Taken together, that's all a testament to how quickly we can meet the market's demand for flexible, high-quality nursing education. We recently expanded our practice-ready specialty focused model through a partnership with the American Association of Post-acute Care Nursing. This addresses the critical shortage of post-acute care nurses.

This new specialization joins existing tracks in critical care, emergency care, home health care, nephrology, oncology and perioperative nursing. Taken together, it further positions Chamberlain to meet the evolving needs of the health care workforce. Again, our fundamentals are strong, the market opportunity is massive, and we're addressing the execution gaps with rigor and accountability.

Turning to Walden University. We delivered our ninth consecutive quarter of enrollment growth at nearly 14%, achieving record total enrollment of over 52,000 students. Walden's digital learning platform and flexible offerings continue to demonstrate strength as we innovate and deliver an increasingly seamless experience for working adult learners. We're optimizing our marketing mix, curating content for large language model recognition and building upon Walden's strong brand recognition.

Our investments in program enhancements, the Believe & Achieve Scholarship offering and AI-enabled technology are translating directly into enrollment growth. We recently streamlined our professional doctoral programs, creating a more intuitive student experience with a simplified tuition structure, integrated scholarship support and a redesigned capstone process that enables students to build toward degree completion throughout their studies.

Technology is enabling our faculty and advisers to spend less time on administrative tasks and more time on student-facing support. Walden's value proposition is clear and it is reflected in total enrollment growth across all degree levels and very, very strong persistence rates.

In our Medical and Veterinary segment, we're showing consistent progress. Total enrollment grew 2.4% to approximately 5,300 students and key leading indicators across our medical schools are pointing to sustainable long-term growth. Notably, Ross Med had its largest September new student start in the last 5 years. And Ross Vet continues to operate near capacity, maintaining its position as a leader in veterinary education with a one-of-a-kind experiential learning model.

Our partnership philosophy extends across all of our institutions as we create innovative ways to enhance educational access and remove learning barriers. AUC's partnership with the University of Lancashire in the U.K. remains our international hub. And we've established a new direct admittance partnership with the University of Wolverhampton, creating an additional pipeline for prospective students. We're expanding our global reach through a partnership with Sage in India, offering a pathway for Indian students to attend Ross Med upon completion of an advanced medical preparation program.

And here in the States, we announced a partnership with ScribeAmerica, creating the MedPath program designed specifically for existing frontline health care workers to advance into medical school. This is an excellent pathway for experienced U.S. health care professionals to step up and help fill the physician gap. These partnerships aren't opportunistic. They're strategic investments in expanding access to in-demand health care education while strengthening our long-term enrollment pipelines.

I also want to highlight our continued leadership in preparing students for technology-enabled careers. We recently launched a strategic partnership with Google Cloud to prepare health care workers for an AI-enabled future. This is the first partnership of its scale designed specifically for health care students and practicing clinicians, and it's fully complementary to our partnership with Hippocratic AI. We'll codevelop customized AI credentials for our students, including a foundational AI fluency course for every Adtalem student, plus specialized courses tailored for each career pathway, including nursing, physicians assistance, counseling and other disciplines.

This partnership directly addresses one of health care's most pressing challenges while differentiating our institutions for prospective students and practicing clinicians. It's exactly the kind of forward-thinking investment that positions us as the leader in health care education. Our financial position remains exceptionally strong, giving us significant flexibility to execute our strategy and return value to shareholders.

We're generating trailing 12-month free cash flow of $319 million. We have cash and equivalents of $265 million as of September 30. We increased our revolving credit facility by $100 million to $500 million, and we extended the maturity to August 2030. In addition, we repaid over $50 million of outstanding Term Loan B balance on October 29. We repurchased $8 million of shares in the first quarter with $142 million remaining on our $150 million Board-authorized share repurchase program through May of 2028.

We're executing our capital allocation philosophy with discipline, investing first in student growth and then in strategic initiatives. We're maintaining financial strength and flexibility. We're returning excess cash to shareholders, and we're thoughtfully pursuing strategic M&A where we can find attractively valued assets that extend our capabilities or expand our presence in in-demand health care education markets.

This brings me to our upcoming Investor Day on Tuesday, February 24, 2026. We're going to use that forum to provide much deeper visibility into our strategic road map, our capacity expansion plans, our long-term value creation framework and our capital allocation philosophy. You'll hear directly from our institutional leaders about how we're executing at the operational level. You'll see the operational discipline that allows us to invest in growth while expanding margins, and you'll gain a comprehensive understanding of how we're positioned to serve as the essential talent infrastructure for America's health care workforce.

I encourage you all to join us either in person or virtually. Let me close with 3 clear statements. First, we're maintaining our full year fiscal 2026 guidance. That's revenue of $1.9 billion to $1.94 billion and adjusted earnings per share of $7.60 to $7.90. Second, our strategic opportunity has never been greater. The structural health care workforce shortage isn't going away. It's actually intensifying.

We have the scale, the brand strength, the program breadth, the technology leadership and the financial resources to serve as the essential talent infrastructure for America's health care system. Third, we're going to continue to allocate capital with discipline, return value to shareholders and hold ourselves accountable to the highest standards of execution. That's our commitment to you, and we'll deliver on it.

As I've said before, my objective above all else is creating category-leading long-term value for shareholders through operational excellence and strategic discipline. This quarter demonstrates that commitment. Our strong enterprise results show the power of operational discipline. We started the year with momentum. We're addressing challenges with clarity, speed and accountability. We're positioned to deliver on our commitments, and we're building a health care education platform that will create sustainable long-term shareholder value.

I look forward to discussing all of this with you in greater detail at our Investor Day in February. And with that, I'll turn it over to Bob to walk through the financials in more detail.

Thank you, Steve, and hello, everyone. We started the fiscal year with financial strength in line with our expectations as we continue to sustain our momentum. We are generating significant cash flow and have taken proactive actions to strengthen our balance sheet while also increasing our financial flexibility.

We are well positioned to continue to execute our growth with purpose strategy and we will continue to be disciplined capital allocators. We are deploying capital to high ROI growth opportunities, focusing on maximizing our existing capacity. Further, our robust financials uniquely provide us with the ability to optimally invest in additional growth opportunities, bringing new capacity to market and providing innovative student-facing technology while continuing to increase our level of profitability.

I'll now review our financial results and key drivers for our first quarter performance. Later in my remarks, I'll discuss our expectations and assumptions for the remainder of fiscal year 2026. Starting with the top line. Revenue in the first quarter increased by 10.8% to $462.3 million, driven by all 3 segments, in particular at Walden.

Consolidated adjusted EBITDA came in at $112 million, up 15.8% compared to the prior year. This growth was led by Walden with Med/Vet contributing, partially offset by Chamberlain. Adjusted EBITDA margin of 24.2% expanded 100 basis points from last year. Adjusted operating income was $90.3 million, up 19% compared to the prior year as revenue growth and efficiencies generated operational leverage, which was partially offset by investments in our strategic growth initiatives.

We continue to balance our strategic growth investments with our more efficient, integrated and scaled operational foundation. Our margin can fluctuate quarter-to-quarter as we remain flexible on how we deploy capital to generate the highest long-term return. Adjusted net income for the quarter was $64.9 million, up 28.5% compared to last year, attributed to adjusted operating income growth and lower interest expense resulting from our actions to reduce outstanding debt and our borrowing costs, partially offset by a higher provision for income taxes.

Adjusted earnings per share was $1.75 or a 35.7% increase compared with the prior year. We repurchased 57,000 shares of our common stock at an average price of $134 within the quarter, resulting in first quarter diluted shares outstanding of 37.1 million or $2.1 million lower than last year.

Next, I'll discuss the first quarter financial highlights by segment. Chamberlain reported first quarter revenue of $179.2 million, an increase of 6.7% compared with the prior year, driven primarily by growth in enrollments and pricing optimization. Total student enrollment during the quarter increased 2.2%, the 11th consecutive quarter of growth and our investments to grow our pre-licensure BSN online offering are yielding returns.

Total enrollment growth in pre-licensure programs, along with high continued persistence rates was partially offset by post-licensure programs. Adjusted EBITDA decreased by 5.1% to $35.1 million for the quarter. Adjusted EBITDA margin of 19.6% was 240 basis points lower compared to the prior year as we reinvested revenue growth, focusing on bringing new capacity to market and continuing to invest in our students to support enrollment growth and academic outcomes.

Turning to Walden. First quarter revenue of $190 million, an increase of 17.6% versus the prior year was driven primarily by strong growth in enrollments. Total student enrollment was up 13.6% compared to the prior year, the ninth consecutive quarter of growth from robust enrollment growth across all degree levels, particularly in master’s and undergraduate and continued high persistence rates.

Growth in our health care programs was led by social and behavioral health and nursing. Our non-health care programs also grew in the quarter. Adjusted EBITDA increased by 29.5% to $61.9 million. Adjusted EBITDA margin expanded by 300 basis points versus the prior year to 32.6% as our operational excellence generated efficiencies and leverage that outpaced increased brand, student-facing digital investments and additional student support commensurate with the high level of new enrollment.

For the Medical and Veterinary segment, first quarter revenue was $93.1 million, an increase of 5.9% versus prior year. Total student enrollment was up 2.4% as a result of our execution against our long-term strategic growth initiatives at our medical schools, and vet continues to operate near capacity.

Adjusted EBITDA increased by 11.6% versus the prior year to $21.4 million. Adjusted EBITDA margin increased 120 basis points versus the prior year to 23% as we remain focused on operating our institutions efficiently while making long-term growth investments, leveraging our existing capacity and delivering academic outcomes.

We started the third year of our growth with purpose strategy with strong results. Our operational excellence continues to fuel increased investments in future growth off of record levels of enrollment. We are sustaining momentum and in turn, we are maintaining our fiscal year 2026 guidance as we continue to execute our strategic and financial goals. Revenue in the range of $1.9 billion to $1.94 billion, approximately 6% to 8.5% growth year-over-year, with adjusted earnings per share in the range of $7.60 to $7.90, approximately 14% to 18.5% growth year-over-year.

Looking forward to the remainder of the year, we continue to anticipate revenue growth to be higher in the first half of the year than in the second half. As Steve mentioned in his prepared comments, our maintained guidance contemplates softness in Chamberlain's top line in the second and third quarters. And as a reminder, for Walden, one academic week shifts from the third quarter into the second quarter this fiscal year.

Our top priority remains to reinvest into our institutions and deliver positive student outcomes through our financial strength and dynamic capital allocation approach. And while we plan to make targeted investments during the second quarter, we remain committed to expanding our fiscal year 2026 adjusted EBITDA margin by approximately 100 basis points. Included within our guidance are the recent capital allocation actions as well as our continued strong cash flow generation.

Finally, we continue to anticipate an effective tax rate to be higher than fiscal year 2025. We started the fiscal year with strength in line with our expectations. We will continue to execute on expanding access and delivering positive student outcomes, deploying capital to meet the health care education market's growing demand, maximizing long-term value and ultimately generating high returns for all stakeholders. And with that, I'll now turn the call over to the operator for Q&A.

[Operator Instructions] Our first question comes from the line of Jack Slevin with Jefferies.

Nice work on the quarter guys. I want to start the commentary on Chamberlain and all the color you gave. But maybe just to get a little bit more granular there. I just want to understand sort of the range of outcomes that you're thinking about moving forward here given the really strong ramp you've had the last 2 years in enrollment.

And sort of are we thinking this is something where we might see sequential declines in enrollment as you sort of get new starts back online? Or I'd just love to think through sort of the range of outcomes that you're thinking about in that second and third quarter guidance as you look at the Chamberlain volumes.

Yes. So I'd encourage you to put the deceleration in post-licensure nursing into a discrete box. We don't believe this represents a go-forward trend in that part of the Chamberlain portfolio. We believe that our market position in post-licensure nursing remains strong. We've historically taken share in RN to BSN and expect to continue to do that.

This is really, I think, a misstep on our part in relation to how we thought about marketing in advance of the September enrollment cycle. And so we've taken a hard look at where we went wrong, what we can do to remedy that. And we expect that while we'll see a tail on that deceleration flow through the balance of the year, we will recover, and we will continue to defend our position in post-licensure nursing at the same time, growing really, really attractively what we're doing in pre-licensure nursing, particularly with our BSN online program.

So again, this is not a trend that has legs in our view. This is a onetime dislocation that's a result of our execution miss. But because it's within our control, we feel very confident about what that means for purposes of the out periods in post-licensure nursing, and that's why we're confident enough to maintain our guide for the full year.

Okay. Got it. Super helpful. One follow-up on that front. So just to maybe look at the margin in the quarter pulls back a little bit in Chamberlain. Should I think about that as a reaction to some of the trends you were seeing intra-quarter? Or can you sort of spell out what you think about sort of that trajectory going forward on the cost side?

Yes. Look, I think as we begin to recover the top line at Chamberlain to something consistent with what we would expect ordinarily, you'll see the margin expansion over the course of a full year period. So that, too, is a reflection of the temporary pressure on the top line from the performance miss in September. We expect to recover that as we approach the end of the fiscal year.

Got it. Okay. Super helpful. Last one for me and more just sort of out of an abundance of caution given your stock traded off 5% yesterday. Just want to sort of clarify that you feel comfortable with where your systems, backbone and platforms from a technology standpoint are across your business, but probably in Walden would be the most relevant one.

Just want to clarify the question. Just our technology infrastructure generally.

Yes. I guess you had a peer yesterday or someone in the peer set that had sort of large issues around -- yes, do you get the question now?

Yes, perfect. Thank you for the clarification. No, we feel great about the tech stack that we use to support the operations, both on the front end of the funnel as well as everything we deploy in support of the student journey. And in fact, we are really excited about some of the innovations that we're rolling out to both enhance and differentiate that student journey. So certainly sympathetic with what happened with one of our peers, but no analogous dynamic in our model to be concerned about.

Our next question comes from the line of Jeff Silber with BMO Capital Markets.

Sorry to go back to the Chamberlain issue. How do you know that this is not a competitive issue where you're losing share?

Because as recently as 2 quarters ago, we were taking share in RN to BSN. We know -- you know and we know that's not a growth area in the way that it was many years ago, but we believe we still have one of the most attractive brands in RN to BSN. We believe that employers, in particular, are keen to see their RNs make the leap to BSN through Chamberlain's program.

So there's nothing we're seeing in the competitive landscape that gives us any concern that we've lost our positioning relative to the alternatives. I just think as we've looked to move from an historical national-based marketing campaign to one that's more market specific, we had a misstep along the way.

I think we've diagnosed that well. And I think you'll see the product of that correction over the course of the fiscal year. We intend to defend our position to RN to BSN given our legendary strength there, even as we grow our pre-licensure presence through BSN Online. So I don't believe we are suffering from any adverse competitive dynamics in post-licensure nursing.

Okay. That's really helpful. Last quarter, you announced a partnership with Sallie Mae, and I was just wondering if we can get an update on how that's progressing and when we may see some announcement in terms of the specifics.

Yes. We're working to finalize definitive documentation with Sallie Mae. My hope is that we'll be able to close that relatively soon, and I expect we'll be able to announce that. We're really encouraged by what that means for all the students we have across the portfolio and Sallie Mae's willingness to step up and support the broad program mix we have. But that work continues to be in flight, and we're certain we'll get it locked down soon.

Our next question comes from the line of Alex Paris with Barrington Research.

Add my congrats on the strong quarter. I have a couple of questions that are more industry-oriented. Earlier this year, the Department of Education announced increased verification efforts to root out fraud across all of higher education. I've talked with a couple of other companies in this space, one notably that had some issues with friction because of the fraudsters crowding out well-intentioned students, and that had an impact on new student enrollment.

I'm wondering what your thoughts are there and maybe just some additional color about what you have to do now that you didn't have to do before? And are you seeing a spike in increased fraudulent activity in the enrollment process?

Yes. So I'll answer the second part of the question first. We're not seeing any spike in go students or fraudulent enrollments or anything like that. We obviously are subject to the same administrative burdens associated with the department's focus on that as everyone else. But as we sit here today, we don't have any concerns that that's an issue across our program set. But obviously, we continue to monitor it closely.

Yes, I was wondering if that might have been a contributing factor with the new student enrollment challenges at Chamberlain, but [indiscernible].

No. Really, at Chamberlain, 2 issues. One, the marketing mix we deployed in advance of the September cycle wasn't effective as hoped and wasn't executed as well as hoped. And then also at the conversion level, even where we were seeing strong demand with a number of missteps at the conversion level, which resulted in the diminished enrollment growth for that cycle. But I don't believe the verification issue had anything to do with the deceleration in enrollment at Chamberlain.

Okay. Good. And then kind of shifting gears a little bit. I got 2 more. The Google Cloud partnership and these AI credentials that you're talking about for health care professionals, this would be both existing students as well as noncurrent students at Chamberlain and the other brands within the portfolio. Are these 4 credit courses? And as such, are they Title IV eligible given the increased coverage proposed in the Big Beautiful Bill for shorter-term credentials?

Yes. As an initial matter, these are programs that will run alongside our existing degree programs. We're ways away from thinking about how to embed them comprehensively in our programs. Obviously, there are accreditation issues that come with that, but we think that's an opportunity down the road. We view this as a way both to provide a differentiated student experience by creating baseline fluency and AI tools across our student populations and to create stackable credentials that have real currency in the clinical marketplace.

So Google has been in the certification and stackable credentials business for a while. It's really exciting to be able to partner with them in a way that brings what we do best together with what they do best. So not wholesale modifications to existing degree programs, but ancillary complementary certificate programs that run alongside our degree programs.

Got you. Is there an additional cost for existing students? And likewise, is there a cost for non-existing students?

No incremental additional cost for students.

Got you. Okay. And then my last question is, again, industry-related. Given one of your competitors made an announcement about the impact of military, active duty, tuition assistance, I'm wondering what your institutional, your enterprise exposure is to military. And I suspect that's primarily GI Bill and VA.

Yes. So active duty military exposure is pretty low, very low actually. Obviously, the platform you're referring to, that's a very large part of their model. So we've not really seen any problems with student disbursements, whether that's veterans benefits or traditional Title IV benefits. Obviously, it's something we continue to monitor as the shutdown drags on. But for the moment, that has not been an issue for our programs.

Yes. That was my related question, government shutdown related. And then last question, kind of just a silly one. The February Investor Day, is that going to be held at your Chicago headquarters or elsewhere?

It won't be in Chicago, TBD. I suspect it will be out East, but we'll have details for you pretty soon here. Stay tuned.

Our next question comes from the line of Steven Pawlak with Baird.

On the marketing missteps at Chamberlain, I guess just kind of maybe piggyback off an earlier question, what gives the confidence that the marketing mix or marketing message in your other programs is appropriate that there isn't -- or that this is sort of contained and now addressed problem?

Yes. So we deploy a central marketing center of excellence that then localizes our marketing programs for each of our institutions. So even though our institutions are like in the sense that they're all postsecondary, the unique marketing strategies across the portfolio do vary quite a bit.

So we have every reason to believe that the root causes of the misstep in September with Chamberlain are Chamberlain-specific. And no reason to believe that they present any issue for any of the 4 institutions, and that's obviously borne out by what you see in the enrollment trends across those institutions.

So it's a Chamberlain-specific issue. We have a tremendous amount of confidence in the steps we've taken to address it, and we're confident that, that will flow through results of operations over the course of the fiscal year.

Okay. And then on the sort of conversion challenges, is there a particular part of the funnel that students were sort of falling out of? Or was it maybe more the number of steps and sort of the increased friction points that you referenced?

Yes. So any time there's a handoff of a student from one part of the enrollment journey to another, that's an opportunity for leakage. And at Chamberlain, we determined that there are opportunities to simplify and reduce the number of handoffs in a way that diminishes the risk of that kind of leakage.

When our students are considering our programs, they're also considering other programs and our ability to stay in front of them to ensure they're getting the information they need to make an informed decision about enrollment. It is critical to preserve the kind of high conversion rates that make all the difference in our model. That just didn't happen in September, but we believe we know what needs to happen for the upcoming enrollment cycles at Chamberlain to change that outcome starting with January.

There are no further questions at this time. I'd like to pass the call back over to Steve Beard for any closing remarks.

I just want to thank the team across the Adtalem family for a really strong and robust start to the fiscal year. This is year 3 of growth with purpose for us. We've been incredibly pleased with the strategy, and we look forward to a strong third year of that strategy, but that is entirely down to the folks that support our students across our 5 institutions. So a sincere thanks to our teams.

That concludes today's teleconference. You may disconnect your lines at this time. Thank you for your participation.